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   Abstract 
 
Aqueous dispersions of gold nanoparticles are efficiently labelled with low-spin d6 transition 
metal lumiphores, creating monodisperse luminescent nanoparticles with a plethora of 
potential imaging applications. 13 nm and 100 nm citrate-stabilised gold nanoparticles are 
used as inert scaffolds for the assembly of multiple transition metal lumiphores, and thiol-
appended ruthenium(II) and iridium(III) polypyridyl complexes have been synthesised for 
surface-attachment. The direct attachment of cationic lumiphores to citrate-stabilised gold 
colloids with negative zeta potentials, affords nanoparticle aggregation, due to loss of 
electrostatic stabilisation. In order to circumvent this problem, a surfactant pre-coating step 
has been implemented, and the following commercial surfactants have been evaluated: 
Triton™ X-100, TWEEN® 20, and Zonyl® 7950. Gold nanoparticles coated with 
Zonyl® 7950 fluorosurfactant can be functionalised with cationic lumiphores and colloidal 
stability is maintained even at high nanoparticle concentrations, i.e. 9 nM. The 
fluorosurfactant not only ensures colloidal stability, but also enhances the emission of the 
ruthenium(II) and iridium(III) complexes investigated. Importantly, the complexes attached 
on the resultant luminescent nanoprobes do not exhibit luminescence quenching from the gold 
nanoparticles. Imaging applications of the resultant luminescent nanoparticles have been 
demonstrated in in vitro cellular uptake studies and in blood flow particle tracking within the 
microvasculature.  
 
Furthermore, gold nanoparticles have been co-coated with lumiphores and both functional 
peptides, for targeted delivery in cells, and gadolinium(III) complexes, in order to realise 
imaging probes for both luminescence and MRI detection. 
Preface 
 
Three years of doctoral training have taught me a host of skills that will stay with me for the 
rest of my career, from chemical techniques to a myriad of interpersonal skills. I believe that 
thorough scientific practice is paramount for good research, and should be thought of as one’s 
legacy to science; however our understanding and interpretation of the world develops and 
changes with progression, the absolute data will never change. 
 
This PhD experience has developed my communication skills tremendously, and I have 
learned to exploit opportunities beyond my own expertise whenever possible.  Although my 
research project has focussed on the chemistry behind luminescent particle development for 
imaging applications, I have been very fortunate to work alongside experts in biosciences, 
biomedical research and chemical engineering, with significant involvement in the application 
developments. This has given me exposure to a wealth of different scientific fields, which I 
have found incredibly interesting and fulfilling.  
 
Research by nature has its ebbs and flows, and it has taken me quite some time to recognise 
this; I feel that learning to accept the lows with the highs is the first step in climbing the steep 
learning curve of self-directed research. This transition, from directed study to independent 
research, can be quite daunting, and can lead to a lot of external resistance. It can be all too 
easy to fall into the trap of accepting theories and ‘seeing’ what other people ‘see’ without 
actually opening one’s own eyes, but as Galileo once said: 
 
“for in the sciences the authority of thousands of opinions is not worth as much as one tiny spark 
of reason in an individual man”  —  Galileo Galilei, 1610 
 
Research in any field has a creative element to it, and many artists will tell you that it is very 
difficult to be creative on demand. My Grandmother (Nan, aged 86) read my patent 
publication, and she is neither a chemist, nor a scientist, in fact she left school at 15 and 
committed her life to bringing up her family. However, she is one of the wisest and most lucid 
people I know, thus I was intrigued by her thoughts on my work. 
 
“Chemistry was not my forte at school. Periodic tables were not within my brushstroke but being 
able to reproduce by surface loading makes artistic sense, and will not alter the bulk, or should I 
say span, of the finished canvas.”  —   Nan, Phyllis Buckle, 2013 
 
Highly specialised skills only give you the toolbox and the in vogue jargon to work within the 
confinements of a close-knit community, whereas being able to step back from the intricacies 
and appreciate the purpose and significance of research developments is crucial for 
progression; if I was not able to express what I was trying to achieve to my grandmother, then 
I would fear that I did not understand quite why I was doing it myself. I also believe that it is 
incredibly important to incorporate a great deal of candour when disseminating research to the 
wider community; it can be all too easy for the scientist to get carried away with hubristic 
experiments and lose touch with the bigger picture.  
 
One of the greatest lessons I have learned about working closely with other people who share 
the passion of discovery, is that the collective achievement can far surpass the product of the 
individual efforts. It is my opinion that breaking down some of the political barriers in the 
academic environment, so that there is more openness in collaborative research, would lead to 
a more fruitful future for scientific research.  
Nicola Rogers 2014 
  
 
 
 
 
Gold nano-footprints and silver linings; making the most of failed experiments. 
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1.1 Luminescent Nanoparticles for Imaging 
Luminescence imaging is a powerful tool that can achieve high sensitivity and quantitative 
detection using commercial optical microscopes. Developing probes for detection is a means 
of improving the diagnostic tools, which can be applied in a variety of very different scientific 
disciplines to advance fundamental research and clinical practice. Luminescence labelling 
offers improved resolution with optical microscopy over colorimetric staining techniques that 
exploit absorption/transmission and reflection of light; such techniques are often limited by 
scattering artifacts and relatively low contrast. Electron microscopy is another technique 
readily used to image biological structures, but this is a high-vacuum destructive technique 
and thus, sample preparation renders the imaged specimen in a state far removed from that of 
interest. Although electron microscopy can achieve nanometre imaging resolution, an 
additional disadvantage for biologically relevant applications is that it takes an incredibly long 
time to obtain quantitative data in respect of optical techniques: it takes >500 times as long to 
obtain useful data via electron microscopy than confocal optical microscopy, taking into 
consideration the full experimental pipeline.
1
   
 
Molecular probes are useful as gross staining agents but lack the high spatial and temporal 
resolution required in many applications because it is difficult to image individual probes, as 
opposed to accumulations of stain. The design of luminescent nanoparticles can exploit the 
incorporation of multiple probe molecules localised on a single nanodevice, in order to ensure 
brightness. Nanoparticles can provide a flexible platform which can be modified to address 
many problems of the 21st century. Optical imaging at the nanoscale may lead to 
breakthroughs in biomolecular sciences, providing information on the monitoring of specific 
cellular processes, such as protein trafficking, and the targeting of cell organelles with high 
spatial resolution.
2-6
 Optical nanoprobes for luminescence imaging present powerful tools for 
diagnostics in flow, such as in lab-on-a-chip devices,
7
 or within biological systems,
2,8
 and can 
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achieve high sensitivity in detection. Noble metal nanoparticles
9
 and quantum dots
10,11
 
provide good candidates as optical nanoscale probes for detection by different imaging 
modalities.
12
 The potential to target specific biochemicals, tissues or diseases, by modifying 
the particle surface with targeting vectors,
13
 opens up new pathways towards diagnosis and 
treatment of disease, which is crucial for the progression of the medical sciences.
11,14-16
 The 
emerging field of ‘theranostics’, a term used that is a portmanteau of therapeutic and 
diagnostic, not only seeks to image where disease occurs, but also to treat the disease, 
immediately upon localisation.
17 Nanotheranostics is applicable for the evergrowing field of 
‘personalised medicine’, in which therapy can be adapted to a patient’s specific biomolecules 
using genetic information.18 Personalised medicine may be the future for biomedicine, 
especially for cancer therapies, where effective treatment is far from a one-size-fits-all 
solution.  
 
Luminescent tracer particles can also be used in rheological applications. The miniaturisation 
of technology has made microfluidic flow devices a popular area of research due to the 
advantages they offer: green, continuous chemistry with improved yields19 and, in the case of 
the production of nanoparticles, improved monodispersities.20 Luminescent tracer particles 
have been produced which faithfully follow flow in microchannels and can be imaged by 
techniques such as particle tracking velocimetry (PTV) as well as micro particle imaging 
velocimetry (μ-PIV), to give spatial and temporal data respectively regarding the flow 
dynamics within a device.7 Hence the ability to design nanoscale probes, which can give 
temporal and spatial information in one package, is desirable to assess the efficiency of new 
micro-devices.21,22 
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1.2 Photoluminescence Imaging: A Move Towards Transition Metal 
Complexes 
Photoluminescence is the emission of light from matter following absorption of photons at a 
different wavelength. The last decade has seen the emergence of transition metal complexes 
as attractive candidates for luminescent imaging probes,23 but until recently such stains have 
relied heavily on organic dyes, typically fused aromatic ring structures.24 Organic 
fluorophores offer a good point-of-entry as molecular probes because they can offer 
substantial absorption cross-sections and high photoluminescence quantum yields. In 
addition, fluorescent proteins have revolutionised biological imaging, particularly green 
fluorescent protein (GFP). Such proteins can be expressed in a number of genetically 
modified cell lines, and even in animals, advancing the design of biosensors to study protein 
interactions.25 Organic fluorophores can offer brightness and are relatively cheap to purchase, 
hence their ubiquitous usage for luminescence measurements in many different fields of 
research. However, the energy difference between excitation and emission peak maxima is 
relatively small (tens of nm) because the electronic transitions associated with the excitation 
and emission are to and from the same excited state and the ground state. A substantial energy 
difference between excitation and emission peak maxima (hundreds of nm) is desirable for 
three reasons: firstly, to prevent self-quenching (i.e. the re-absorption of emitted light by 
another proximate lumiphore of the same type); secondly to reduce the risk of detecting 
scattering excitation light from the excitation source, or attenuating a lot of the emission 
signal with filters; thirdly to distinguish the emission of the target probe from background 
autofluorescence (which is the fluorescence from endogenous fluorophores, e.g. DNA, that 
have small Stokes shifts). Organic fluorophores also have very short lifetimes (ca. 1 ns), 
which eliminates the possibility of image time-gating to remove autofluorescence signal,26 
and also a tendency to photobleach over time. Photobleaching is usually irreversible with 
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fluorophores because the dye accumulates permanent chemical damage due to the reactivity 
of the excited singlet state. This limits the time period over which experiments can be done.  
 
Lanthanide chelates are also exploited for biological imaging as they have high photostability, 
large energy differences (>100 nm) between the excitation and emission peak maxima, and 
extremely long lifetimes (into the millisecond range) which can be used in time-resolved 
imaging techniques27 and time-gated luminescence microscopy.28 The highly shielded f 
orbitals lead to atomic-like spectral characteristics of the f–f transitions, which ensure 
unambiguous identification and sharp spectra. Distinct narrow spectral lines are imperative 
for multiplex labelling and detection, in which different probes are used to label different 
targets within the same sample. Clean detection channels at different wavelengths are 
necessary to identify each label exclusively, without signal cross-over. The relative intensities 
of each transition can also report on the local environment, and in some cases (e.g. Nd3+) 
lanthanides emit in the near-infra red (NIR) region, which is desirable for tissue penetration. 
In principle the trivalent lanthanides ions are ideal lumiphores for imaging because the 
emission is sharp and distinct, and delay-gated measurements can be implemented to remove 
autofluorescence in biological samples.29-31 However, lanthanide ions are very toxic due to 
their similarity in behaviour and size to biologically ubiquitous metal ions such as Ca2+, and 
formation of stable complexes is paramount for biological applications to avoid 
transmetallation.32 An additional problem is the almost zero efficiency of the direct excitation 
of the lanthanide ion itself (ε ~ 1–10 M−1 cm−1), due to the Laporte forbidden f–f (and often 
spin-forbidden) transitions.33 This is usually circumvented by the use of organic antenna 
ligands, which present much greater absorption cross-sections as well as being able to transfer 
the absorbed energy from light, usually via a triplet state, to the lanthanide ion, thus 
populating the luminescent state indirectly.  The net result of the cascade of energy through a 
series of concomitant energy levels ensures that the difference between the excitation and 
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emission wavelengths of antenna-sensitised lanthanide complexes is large (up to 400 nm). 
This is highly beneficial for the facile separation of excitation and emission light but can have 
one significant drawback; the excitation wavelength has to be pushed to a short wavelength 
with respect to the emission, i.e. most europium complexes require sensitisers which are 
excited in the UV range of electromagnetic spectrum.34,35 This is disadvantageous because 
UV radiation is damaging to biological tissue, and in addition, short-wavelength radiation 
(<330 nm) and is incompatible with the glass optics of most conventional microscopes. Also, 
the multiple energy transfer steps involved in the luminescence of lanthanide complexes, 
some with efficiencies far below unity, can result in photoluminescence quantum yields that 
are inadequate for imaging.23 Regardless of these difficulties, lanthanide imaging agents are 
being developed to address and overcome some of these issues, so that they can be used for 
biomedical analysis and cellular imaging.29 
 
Transition metal complexes including the d6 metal centres Re(II),36 Ru(II),37 Os(II),38 and 
Ir(III),39 coordinated to high ligand-field polypyridyl ligands, are attractive imaging probe 
candidates for several reasons: these low-spin d6 complexes are closed-shell and kinetically 
inert because the exchange of ligands is very slow,23 which is crucial to ensure low toxicity 
with heavy metal ions. Typically such complexes have attractive intrinsic photophysical 
properties in the visible region on the electromagnetic spectrum.23,24,40 The lifetimes of the 
luminescent states are usually long (>100 ns) because de-excitation pathways arise from 
formally forbidden triplet electronic transitions, allowing time-gated emission techniques and 
luminescence lifetime imaging40,41 to be employed. Transition metal lumiphores also exhibit 
large differences between the excitation and peak emission wavelengths because the singlet 
excited state (often a metal-to-ligand charge-transfer (MLCT) band) rapidly decays into the 
triplet state via spin-orbit coupling induced inter-system crossing.37 Transition metal 
lumiphores thus luminescence from a lower energy state than the initially excited state. It is 
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also possible to tune the emission properties of transition metal complexes using a wide range 
of ligands because the emissive states emanate, at least in part, from ligand-centred 
transitions, and are thus sensitive to the electronic structure of the ligands.37 An important 
criterion for the rational design of emissive d6 transition metal complexes is the position of 
the d–d metal-centred (MC) state; MC transitions are formally forbidden and thus have 
extremely long radiative lifetimes with high susceptibility to environmental quenching, and 
therefore have negligible luminescence quantum yields.38 For this reason, Fe(II) tris(2,2’-
bipyridine) is not emissive, even at 77K, because the 3MC state quenches the emission.38 In 
addition, the d–d states of d6 transition metals are reactive with respect to decomposition by 
ligand displacement, and thus large crystal field splitting and hence high energy MC states are 
also required to prevent photochemical instability.38 
1.3 Gold Nanoparticle Imaging Probes 
Molecular lumiphores are useful labelling agents but the move towards the design of 
luminescent nanoparticles affords brightness by integrating multiple labels onto a single 
nanodevice. It is important to note that although attaching multiple lumiphores to a single 
reporter group may indeed produce highly luminescent imaging probes, the local high-
concentrations of lumiphore complexes at the particle surface could induce self-quenching, 
and this lumiphore-lumiphore interactions are incredibly important when considering 
functionalised nanoparticles, even at low nanoparticle concentrations.42,43 
 
The optical properties of metal nanoparticles have been of interest for centuries44 and 
scientific research on colloidal metals dates back, at least, to the work of Michael Faraday.45  
Metal nanoparticles have become popular over the last few decades with the advent of 
nanotechnology and the desire to develop devices on scales beyond the molecule. The unique 
electronic band structures of these mesoscopic constructs result in their physical properties 
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lying somewhere between the macroscopic bulk properties of a solid and the atomic scale, 
whilst the large surface:bulk ratio of atoms permits many analogies between the chemical and 
physical properties of nanoparticles and 2D solid surfaces. The key to the popularity of  gold 
nanoparticles lies in their ease of synthesis, as compared with traditional wet synthetic 
chemistry strategies; wet colloidal synthesis offers an elegant means by which to access 
thermodynamically stable edifices on this scale in a controlled manner.46 Gold nanoparticles 
are regularly used in biology and medicine2,16,47 due to their easily tuneable size, water-
solubility, low toxicity and high surface area for drug and/or probe loading.   Furthermore, the 
significant molecular weight of gold ensures high contrast for electron and x-ray based 
measurements.  
 
Gold nanoparticles exhibit strong interactions with visible light because the conduction 
electrons on the metal surface undergo a collective and quantised oscillation when they are 
excited at a specific wavelength. This affords a highly absorptive surface plasmon resonance 
(SPR) peak in the UV-Vis absorption spectrum. The SPR scattering frequency and intensity 
are sensitive to particle size, shape and surface environment, and can be quantified by Mie 
theory48 for spherical particles of arbitrary size.49 The SPR scattering property can be 
exploited in optical imaging of particles44,50 by both reflection microscopy techniques51,52 and 
by dark field microscopy.53,54  However, such techniques produce scattering artifacts in 
biological tissue, and therefore luminescence-based imaging techniques are advantageous. 
Over the last ten years there have been reports in the literature of gold nanoparticles 
exhibiting intrinsic luminescence properties,55 although this phenomenon is much less well 
understood than the absorption properties of metal nanoparticles. The luminescence is 
attributed to the electron and hole interband recombinations within the metals. The 
luminescent particles reported tend to be small (sub-5 nm) and the quantum yields are low 
(ca. 10−5). Nevertheless, some glutathione-capped particles have been reported to exhibit 
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quantum yields in the 10−2 order of magnitude.56 Although much progress in the development 
of these intrinsically luminescent nanoparticles has been made over the last ten years, the 
mechanisms of emission are not fully understood, and the emissive properties are very 
sensitive to particle size, surface functionalisation57 and surface roughness.56 This makes the 
design of multimodal imaging probes very difficult with such unpredictable luminescent 
properties, and the quantum yields are usually too low for imaging. However, recently the 
group of Vo-Dinh have synthesised gold ‘nanostars’,58 which exhibit plasmon-enhanced two-
photon luminescence, and have been used for imaging in vitro and in vivo.59,60 
 
The development of luminescent nanoparticles by the functionalisation of nanoscale gold 
scaffolds with multiple luminescent reporter groups, as shown in the schematic of Figure 1.1, 
is therefore a more attractive approach for developing bright optical imaging probes. This 
strategy also allows the optical tagging of multimodal nanovehicles that can lead to 
theranostic devices.17 
. 
 
Figure 1.1 Schematic of luminescent nanoparticle synthesis; functionalising gold nanoparticles with 
tailor-made surface-active lumiphores. 
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To consider such nanoparticles as platforms for imaging in biological environments, it is 
important to understand how complex nanomaterials will behave in complex environments. 
Several biomedical studies of gold nanoparticle uptake in tissues and tumours have been 
reported, both in vivo61,62 and in vitro4,16,63,64 mostly by destructive techniques such as electron 
microscopy and inductively coupled plasma mass spectrometry (ICPMS), or by imaging 
techniques that utilise the scattering optics of the particles alone (dark field microscopy or 
confocal reflection microscopy). However, luminescent probes can be assembled covalently 
on the surface of gold nanoparticles,65-67 which provide a distinct optical signature 
independent of the particle properties and can be imaged both in vitro and in vivo in live tissue 
samples using conventional microscopy, and can also be imaged temporally in dynamic 
systems such as microfluidic devices. Quantum dots (i.e. semi-conductor nanocrystals which 
exhibit highly tuneable intrinsic luminescence following excitation and radiative relaxation 
across the size-dependent band gap) are often used as nanoscale luminescent probes due to 
their superior brightness,68-70 but their luminescence properties are size dependent, they often 
suffer high toxicity, the surface modification is non-trivial, and the quantum dots tend to 
‘blink’ upon irradiation. These limitations hinder their development as biological probes. 
Quantum dots also tend to be small (< 5nm), which usually leads to rapid renal clearance 
from circulation in vivo,71 and they are thought to accumulate in organs over time.8 Therefore, 
gold nanoparticles offer many advantages over quantum dots. Upconversion nanoparticles are 
another class of luminescent nanoprobes, which exploit non-linear optics that convert two or 
more low-energy photons into a higher-energy output photon, by doping nanocrystals with 
lanthanides. Such particles are of interest as they can be excited in the optically transparent 
NIR window for biological tissue.72 However, upconversion particles are often difficult to 
synthesise, requiring high temperatures for prolonged periods of time and under hazardous 
reaction conditions. Furthermore, it is quite difficult to control the size and optical properties 
of the crystals formed, and the synthesis of sub-10 nm particles is challenging. In contrast, the 
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principle of using the gold nanoparticle as a scaffold for multifunctionalisation with 
luminescent tracers unearths a myriad of design options for the resultant nanodevice using 
straightforward synthetic techniques, whilst allowing control of both the particle size and 
luminescent properties in simple stages. Therefore the surface-functionalisation of gold 
nanoparticles is a flourishing area of research,65,66 with applications not only in imaging 
probes,51,52,73,74 but also nanomedicine47,75,76 and catalysis.77,78   
1.4 Thesis Outline 
This thesis details the development of a novel labelling strategy to functionalise aqueous 
dispersions of 13 nm and 100 nm gold nanoparticles with luminescent transition metal 
complexes. Chapter Two focuses on the attachment of a previously developed surface-active 
ruthenium complex79 to 13 nm gold nanoparticles. A surfactant-mediated coating process of 
the nanoparticles has been studied and optimised for imaging, and the resultant luminescent 
nanoparticles have been characterised.74 Due to the success of this strategy, the luminescent 
nanoparticles are developed further in Chapter Three, following the synthesis of larger, 
100 nm gold nanoparticles, and their subsequent functionalisation with the ruthenium(II) 
lumiphore. The cellular imaging applications of these 13 nm and 100 nm luminescent 
particles have also been explored in Chapter Three, in collaboration with Dr Nikolas Hodges, 
and Dr Robert Harris (School of Biosciences, University of Birmingham), with the help of Mr 
Sunil Claire (EPSRC Doctoral Training Centre in Physical Science for Imaging in the 
Biomedical Sciences – ‘PSIBS’, The University of Birmingham).  
 
Further expansion of the nanoparticle work for biological imaging probes has been executed 
by the design and realisation of nanoparticles for targeted delivery. The attachment of 
targeting peptide probes to the luminescent nanoparticles has been investigated in Chapter 
Four, in an attempt to achieve actively targeted delivery of particles within living cells. 
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In Chapter Five, Ruthenium(II)-based luminescent probes have been replaced by 
cyclometallated iridium(III) complexes to produce brighter nanoparticles for imaging flow 
dynamics in microchannels. Successful tracer particles for particle tracking velocimetry 
(PTV) techniques have been investigated as tracers in blood flows, in collaboration with 
Professor Gerard Nash, Professor Stuart Egginton and Dr Hannah Jeffery (School of Clinical 
and Experimental Medicine, University of Birmingham), and with support from Dr David 
Lewis (School of Chemistry, University of Birmingham). Preliminary in vivo investigations 
have been performed to explore the possibility of imaging luminescent nanoparticles in 
biological tissue, following intravenous injection. In addition to these studies, the synthesis of 
bimodal imaging particles has been explored by attaching MRI-active gadolinium complexes 
with luminescent complexes to gold nanoparticles, with the help of Ms Lindsey van Gemeren 
(PSIBS, University of Birmingham), and her supervisors: Professor Michael Hannon (School 
of Chemistry), Professor Zoe Pikramenou, Professor David Adams, and Dr Nigel Davies 
(School of Clinical and Experimental Medicine, University of Birmingham).  
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Plapper, R.; Seidel, M.; Niessner, R.; Knöll, J.; Seubert, A.; Parak, W. J. Anal. Chem. 2011, 83, 2877. 
(13)  Gu, F. X.; Karnik, R.; Wang, A. Z.; Alexis, F.; Levy-Nissenbaum, E.; Hong, S.; Langer, R. S.; Farokhzad, 
O. C. Nano Today 2007, 2, 14. 
(14)  Kotov, N. A.; Winter, J. O.; Clements, I. P.; Jan, E.; Timko, B. P.; Campidelli, S.; Pathak, S.; Mazzatenta, 
A.; Lieber, C. M.; Prato, M.; Bellamkonda, R. V.; Silva, G. A.; Kam, N. W. S.; Patolsky, F.; Ballerini, L. Adv. 
Mater. 2009, 21, 3970. 
(15)  Chithrani, B. D.; Ghazani, A. A.; Chan, W. C. W. Nano Lett. 2006, 6, 662. 
(16)  Giljohann, D. A.; Seferos, D. S.; Daniel, W. L.; Massich, M. D.; Patel, P. C.; Mirkin, C. A. Angew. Chem. 
Int. Ed. 2010, 49, 3280. 
(17)  Lammers, T.; Aime, S.; Hennink, W. E.; Storm, G.; Kiessling, F. Acc. Chem. Res. 2011, 44, 1029. 
(18)  Kim, T. H.; Lee, S.; Chen, X. Expert Rev. Mol. Diagn. 2013, 13, 257. 
(19)  Oelgemoeller, M. Chem. Eng. Technol. 2012, 35, 1144. 
(20)  Wagner, J.; Köhler, J. M. Nano Lett. 2005, 5, 685. 
(21)  Lewis, D. J.; Dore, V. D.; Goodwin, M. J.; Savage, A. C.; Nash, G. B.; Angeli, P.; Pikramenou, Z. Meas. 
Sci. Technol. 2012, 23, 084004  
(22)  Lewis, D. J.; Dore, V.; Rogers, N. J.; Mole, T. K.; Nash, G. B.; Angeli, P.; Pikramenou, Z. Langmuir 2013, 
29, 14701. 
(23)  Fernandez-Moreira, V.; Thorp-Greenwood, F. L.; Coogan, M. P. Chem. Commun. 2010, 46, 186. 
(24)  Lo, K. K.-W.; Choi, A. W.-T.; Law, W. H.-T. Dalton Trans. 2012, 41, 6021. 
  Chapter One 
14 
 
(25)  Tsien, R. Y. Angew. Chem., Int. Ed. 2009, 48, 5612. 
(26)  Jin, D.; Piper, J. A. Anal. Chem. 2011, 83, 2294. 
(27)  Bünzli, J.-C. G.; Eliseeva, S. V. Chem. Sci. 2013, 4, 1939. 
(28)  Connally, R. E.; Piper, J. A. Ann. N. Y. Acad. Sci. 2008, 1130, 106. 
(29)  Bünzli, J.-C. G. Chem. Rev. 2010, 110, 2729. 
(30)  Eliseeva, S. V.; Bünzli, J.-C. G. Chem. Soc. Rev. 2010, 39, 189. 
(31)  Faulkner, S.; Pope, S. J. A.; Burton-Pye, B. P. Appl. Spectrosc. Rev. 2005, 40, 1. 
(32)  Idée, J.-M.; Port, M.; Raynal, I.; Schaefer, M.; Le Greneur, S.; Corot, C. Fundam. Clin. Pharmacol. 2006, 
20, 563. 
(33)  Montgomery, C. P.; Murray, B. S.; New, E. J.; Pal, R.; Parker, D. Acc. Chem. Res. 2009, 42, 925. 
(34)  Lewis, D. J.; Day, T. M.; MacPherson, J. V.; Pikramenou, Z. Chem. Commun. 2006, 1433. 
(35)  Lewis, D. J.; Moretta, F.; Holloway, A. T.; Pikramenou, Z. Dalton Trans. 2012, 41, 13138. 
(36)  Stufkens, D. J.; Vlček Jr, A. Coord. Chem. Rev. 1998, 177, 127. 
(37)  Juris, A.; Balzani, V.; Barigelletti, F.; Campagna, S.; Belser, P.; Von Zelewsky, A. Coord. Chem. Rev. 
1988, 84, 85. 
(38)  Demas, J. N.; DeGraff, Β. A. Anal. Chem. 1991, 63, 829A. 
(39)  Lowry, M. S.; Hudson, W. R.; Pascal, R. A.; Bernhard, S. J. Am. Chem. Soc. 2004, 126, 14129. 
(40)  Baggaley, E.; Weinstein, J. A.; Williams, J. A. G. Coord. Chem. Rev. 2012, 256, 1762. 
(41)  Kuil, J.; Steunenberg, P.; Chin, P. T. K.; Oldenburg, J.; Jalink, K.; Velders, A. H.; van Leeuwen, F. W. B. 
ChemBioChem 2011, 12, 1897. 
(42)  Pramod, P.; Sudeep, P. K.; Thomas, K. G.; Kamat, P. V. J. Phys. Chem. B 2006, 110, 20737. 
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2.1	Introduction	
It is desirable to synthesise luminescent nanoparticles for imaging purposes; this chapter 
explores different procedures for attaching a tailor-made luminescent ruthenium polypyridyl 
complex to gold nanoparticles, in order to produce a brightly luminescent nanodevice. 
However, the attachment of a cationic transition metal complex to citrate-stabilised gold 
nanoparticles with a negative zeta potential has proved to be a challenge, and this chapter 
explores the development of a method to circumvent the difficulties faced, which has recently 
been published as a patent application.1  
 
2.1.1	Methods	of	Gold	Nanoparticle	Synthesis	
Top-down lithographic methods can be employed to produce well-defined sizes and often 
non-spherical shapes of noble metal nanoparticles without aggregation, either by 
photolithography or electron lithography, but commercial instrumentation is expensive and 
both techniques can only produce 2D structures in one step.2 There are many bottom-up 
synthetic methods for the production of metal nanoparticles in the literature, from nanosphere 
lithography3 to wet chemical synthesis, whereby the latter usually proceeds by the reduction 
of the metal ion from its salt in the presence of a suitable stabilising agent. A popular 
technique employed to produce aqueous gold nanoparticles is the citrate reduction of 
HAuCl4, introduced by Turkevitch in 1951,4,5 in which the gold nanoparticles are surrounded 
by an electrical double layer of citrate ions, chloride ions, and their associated cations; the 
Coulombic repulsions between capping layers override van der Waals attraction between 
metal centres, stabilising the nanoparticles from aggregation. Although the citrate reduction 
has been used for over fifty years, it is only within the last ten years that studies have been 
undertaken to infer more detail about the synthetic mechanism.6,7 The reduction of the 
gold(III) salt using trisodium citrate is highly reproducible and the diameter of the particles 
produced can be controlled by the gold-to-citrate ratio; this effect was later investigated and 
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quantified by Frens,8 where definite size control of the gold cores in the range 10 – 150 nm 
was reported. Perrault et al.9 and Ziegler et al.10 have recently extended this range to up to 
diameters of 300 nm, by the innovative use of seed-mediated synthesis in combination with 
various mild reducing agents, with monodisperse products as a result.  
 
Electrostatically stabilised colloids can aggregate relatively easily,11 and therefore the 
development of thiol-stabilised gold nanoparticle synthesis12 has had a considerable impact on 
the bottom-up field because these nanoparticles are protected by steric repulsion. Using the 
paradigm of Whitesides’ modification of gold surfaces by ω-alkanethiol self-assembled 
monolayers,13,14 Brust, Schiffrin and co-workers have translated these principles into the 
synthesis of nanoparticles.12  The now universally utilised Brust synthesis involves transfer of 
a gold(III) salt (usually HAuCl4) to an organic phase, containing dodecanethiol and the 
reducing agent sodium borohydride.  The phase transfer of the gold salt is mediated by a 
quaternary amine phase transfer catalyst. Thus, the gold(III) salt is reduced to gold(0) in the 
organic phase and nanoparticles are formed, which can be handled like a chemical compound. 
These nanoparticles tend to be < 5 nm in diameter and soluble in organic solvents; re-
dispersion of the particles into various solvents can also be achieved, and the chemistry of the 
nanoparticles mimics that of the capping ligands exposed to the bulk solvent. The sterically 
stabilised particles produced by the Brust synthesis are often referred to as ‘monolayer-
protected clusters’ (MPCs).15   
 
2.1.2	Ruthenium	Polypyridyl	Complexes	
Ru(II) polypyridyl complexes are arguably the most studied inorganic chromophores, and 
lend themselves to luminescent labelling for biological applications due to their intrinsic 
photophysical properties, including relatively long lifetimes (hundreds of ns) compared with 
biological background fluorescence, large differences in the excitation and emission 
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wavelengths, and good photostability. Ru(II) polypyridyl complexes can be excited and are 
emissive in the visible region of the electromagnetic spectrum. Therefore, the excitation and 
emission wavelengths involved are compatible with biological systems and glass microscopy 
optics, making this inorganic complex and its derivatives ideal for cellular imaging. As 
microscopy techniques continue to develop and push the boundaries of temporal and spatial 
resolution, there is an increasing demand for luminescent imaging labels that are resistant to 
photobleaching. Therefore, much work has been carried out recently with ruthenium 
complexes in the field of biological probes, including the development of protein 
labelling,16,17 DNA-sensory work with intercalating ruthenium complexes,18,19 and cellular 
staining agents.20,21  
 
Taking the archetypal complex [Ru(bpy)3]2+, Ru2+ is a low-spin d6 metal ion, and the 2,2’-
bipyridine ligands (bpy) are -donors through the orbitals localised on the nitrogen atoms, 
and have -donating and -accepting orbitals on the aromatic rings.22 Low-spin  d6 metal 
systems have low rates of ligand exchange and are thus relatively stable and unreactive, which 
is incredibly important when considering an imaging agent.22 A simplification of the 
[Ru(bpy)3]2+ coordination geometry to octahedral symmetry, i.e. in the Oh point group 
(although it is in fact in the D3 point group), gives the molecular orbital diagram and energy 
states in Figure 2.1. 
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Figure 2.1 Molecular orbital diagram (left) and energy state diagram (right) of Ru(bpy)32+, assuming 
Oh symmetry. 
 
 
The [Ru(bpy)3]2+ complex absorbs light across the electromagnetic spectrum, from the blue to 
the UV regions, due to excitation of the singlet metal-to-ligand charge transfer (MLCT) band, 
or higher energy metal centred (MC) and ligand centred (LC) bands. The complex is highly 
absorptive, with molar absorption extinction coefficients in the order of 104 mol−1 dm3 cm−1.22  
 
Excitation of [Ru(bpy)3]2+ in any of its absorption bands gives rise to photoluminescence from 
the triplet MLCT state. The relativistic heavy-atom effect (due to the presence of the 
ruthenium centre) allows efficient inter-system (ISC) crossing to occur, which facilitates the 
luminescence from the triplet MLCT state. However, despite the spin-orbit coupling induced 
by the heavy ruthenium centre (and thus the likelihood of the states actually being strong 
admixtures of singlet and triplet character), the electronic states are formally assigned as 
singlet or triplet.22,23 Ultrafast LASER spectroscopy techniques have been employed to 
establish that upon excitation into the intense singlet MLCT band, ISC to the corresponding 
triplet MLCT band occurs within ca. 50 fs,24 followed by vibrational relaxation on the 5–
ground
state
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10 ps time scale.25,26 The energy position, lifetime and intensity of the photoluminescence are 
sensitive to solvent, due to the charge-transfer nature of the transition.  
 
The luminescent excited state of [Ru(bpy)3]2+ can interact strongly with molecular oxygen, 
due to its long lifetime and its triplet character, resulting in luminescence quenching; the 
luminescence signal decreases as the non-radiative decay rate, knr, increases. The relationship 
between the rates of decay from the excited state, and both the observed lifetime of the 
luminescent state, obs, and the quantum yield of luminescence, , are shown below in 
Equations 2.1 and 2.2, where kr is the radiative rate of decay from the excited state. ( kx are 
first order rate constants for generic unimolecular processes that induce the disappearance of 
the luminescent excited state.) 
 
       ߬௢௕௦ ൌ 	 ଵ௞ೝା௞೙ೝ      Equation 2.1 
    
   Φ ൌ	 ௞ೝ௞ೝା௞೙ೝ         Equation 2.2  
 
Ground-state molecular oxygen (O2 (3g−)) can give rise to a collision-dependent decrease in 
the luminescence of the triplet MLCT state, by both energy transfer and electron transfer.27 
This effect may be regarded as an unwanted interaction for luminescence imaging, but it can 
be exploited for diagnosis of oxygen concentration and/or photodynamic therapy, by 
production of highly reactive and toxic singlet oxygen (i.e. O2 (1g) or O2 (1g)) via energy 
transfer or superoxide radicals (O2•¯) via electron transfer.27,28  
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2.1.3	 Current	 Strategies	 for	 Labelling	 Gold	Nanoparticles	with	 Transition	
Metal	Complexes	
Several different strategies have been reported in the literature for the assembly of 
luminescent probe molecules onto gold nanoparticles,29,30 as summarised in Figure 2.2., most 
of which use small (<10 nm) nanoparticles synthesised by the Brust-type two phase synthesis 
(Section 2.1.1).   
 
 
Figure 2.2 Schematic of the different strategies available for attaching lumiphores onto gold 
nanoparticles. a) electrostatic attachment of probe molecules to charged nanoparticle surfaces, b) 
ligand displacement of alkylthiol ligands from MPCs with thiolated probe molecules, c) ligand 
displacement of citrate anions with thiolated probe molecules, d) direct reduction of Au(III) in the 
presence of thiolated probe molecules, e) direct reduction of Au(III) in the presence of thiolated 
coordination ligands, followed by the coordination of a metal to form surface-attached metal 
complexes on the nanoparticle. 
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The simplest way to construct lumiphore-labelled gold nanoparticles is to use electrostatic 
interactions between negatively-charged nanoparticle surfaces and cationic complexes (Figure 
2.2a). In 2002 Huang and Murray31 reported pH-dependent electrostatic binding of 
[Ru(bpy)3]2+ as its chloride salt to ca. 2 nm tiopronin-capped gold nanoparticles, which are 
negatively charged at a pH of 4.7 (Figure 2.3). 
 
 
Figure 2.3 Electrostatic binding of [Ru(bpy)3]2+ to tiopronin-capped gold nanoparticles, as reported 
by Huang and Murray.31 
 
 
Upon adsorption to the negatively charged gold nanoparticles, steady-state 
photoluminescence studies of the [Ru(bpy)3]2+ complex showed a reduction in the emission 
intensity, and Huang and Murray report the triplet MLCT state to be quenched. Notably, 
substantial quenching was also reported in a control experiment with cationic 
N,N-trimethyl(undecylmercapto) ammonium protected nanoparticles, with which the 
[Ru(bpy)3]2+  cannot electrostatically bind. It was therefore concluded that both static and 
collisional quenching occurs in these physisorbed structures.  Size-dependent nanoparticle 
quenching of [Ru(bpy)3]2+ has further been studied by the group, with particles in the 1–4 nm 
size range. 32 
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There are disadvantages with electrostatic binding for probe attachment: the binding is likely 
to suffer from high salt concentrations due to electrostatic displacements, and electrostatic 
binding can reduce the colloidal stability of the nanoparticles, removing the integrity of an 
imaging probe. A strong covalent bond between the particle and the luminescent probe is 
desirable to ensure that dye leaching off the nanoparticle does not occur. 
 
 The covalent attachment of a probe molecule to gold nanoparticles can be achieved easily 
using well-established S-Au chemistry; tailor-made bifunctional metal complexes can be 
designed to incorporate a lumiphore centre with a thiolated moiety that is available for 
binding to gold, thus anchoring the complex on the nanoparticle surface. Brust-type thiolated 
gold nanoparticles (MPCs) can be functionalised post-synthesis by place-exchange reactions 
(Figure 2.2b), in which the thiol capping ligands are exchanged by thiolated probe 
molecules.33-35 The ligand exchange process has been investigated extensively by Murray, and 
is reported to be an associative mechanism, with a rate and equilibrium stoichiometry 
dependent on the reaction feed ratio, and the relative steric bulk chain length.15,36,37 In systems 
where the terminal groups of the thiols are quite different, often a large excess of the 
functionalising thiol moiety is necessary to drive the ligand exchange to achieve, for instance, 
a 1:1 binary self-assembled monolayer.38 There are many examples in the literature whereby 
lumiphores have been attached to gold nanoparticles by place-exchange.  In 2006, Pramod et 
al.39 successfully attached thiol-derivatised Ru(bpy)32+ complexes to gold nanoparticles by 
place-exchange, as shown in Figure 2.4. 
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 Figure 2.4 Ru(bpy)32+ functionalised triethylene glycol-stabilised gold nanoparticles. n=1 and n=5.39  
 
The monothiol derivative of triethylene glycol was used as the initial capping agent to 
stabilise the gold nanoparticles, because the attachment of the Ru(II) complex to 
octanethiolate-protected gold nanoparticles was unsuccessful. This was thought to be due to 
the incompatibility of the polar dicationic Ru(II) complex and the nonpolar nature of 
alkanethiolated particles. The same group has, however, successfully attached a similar Ru(II) 
complex to photochemically produced dodecanethiol-capped gold nanorods by place-
exchange.40 Mixed monolayers were yielded in the exchange reactions of both complexes. 
Transient absorption spectroscopy studies of the nanohybrid systems illustrated photoinduced 
charge-transfer between the anchored [Ru(bpy)3]2+ chromophores, rendering [Ru(bpy)3]+ and 
[Ru(bpy)3]3+ products that persisted for several nanoseconds before undergoing charge 
recombination. Charge-transfer was only observed at high Ru(II) complex concentrations on 
the nanoparticles and blank experiments using saturated solutions of the unattached Ru(II) 
complexes did not produce redox products. This confirms the necessity of the nanoparticle 
scaffold to anchor the Ru(II) complexes close enough together for this process.39 It is 
noteworthy that these functionalised nanoparticles were only soluble in organic solvents, and 
thus not suitable for biological imaging.  
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Gunnlaugsson and co-workers41 recently attached ruthenium polypyridyl complexes (shown 
in Figure 2.5) to ca. 3 nm gold nanoparticles coated in tetraoctyl ammonium bromide, by 
ligand-exchange, and resuspended them in aqueous buffer. Three different complexes were 
synthesised using the same surface-active ligand, by varying the auxiliary ligands of the 
complex, to compare the DNA intercalating interactions of the resulting nanoparticles.  
 
Figure 2.5 Ru(II) complexes attached to tetraoctylammoniumbromide-stabilised gold nanoparticles, 
as reported by Gunnlaugsson and co-workers.41 
 
 
The resulting particles were found to be readily uptaken by HeLa cells (human cervical cancer 
cells), and evidence of DNA-binding in vitro was reported for nanoparticles coated in all three 
ruthenium complexes by examination of circular dichroism experiments and co-localisation of 
nanoparticle emission with fluorescently-labelled DNA in cell microscopy studies. 
 
Pope and co-workers42 have reported another example of place-exchange, in which they have 
attached a luminescent thioester-funtionalised rhenium complex to poly(ethylene glycol)-
coated gold nanoparticles. Unreacted rhenium was removed by extraction of the aqueous 
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particles with dichloromethane, and the complex attachment was confirmed by Energy 
Dispersive X-Ray (EDX) spectroscopy and steady-state photoluminescence. Time-resolved 
liftetime studies of the particles showed retention of the triplet MLCT emission lifetime upon 
surface attachment to the nanoparticles, in contradiction to preceding literature.  
 
The functionalisation of citrate-stabilised metal nanoparticles can also be achieved by ligand-
exchange, (Figure 2.2c) as the citrate anions are readily replaced by thiols.43-45  However, this 
strategy is often problematic for cationic transition metal complexes, and is discussed in 
Section 2.1.4. 
 
A different methodology sometimes used to synthesise functionalised gold nanoparticles is by 
the direct reduction of Au(III) by NaBH4 in the presence of either a  transition metal complex 
containing a gold-anchoring group (Figure 2.2d),  or an anchoring ligand which is 
coordinately active (Figure 2.2e) and can complex to a metal in a second step.46 This method 
has been explored by Mayer, in the formation of 3–4 nm gold and silver nanoparticles with 
fully conjugated ruthenium complexes, to facilitate potential electron transfer between 
ruthenium centres and silver nanoparticle cores.47 Unlike most other work, Mayer’s group has 
anchored the ruthenium complexes to the metal nanoparticles with pyridyl nitrogen atoms and 
thiophenyl sulphur atoms, as shown in Figure 2.6.48  
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Figure 2.6 Functionalisation of gold nanoparticles with fully conjugated Ru(II) complexes, by direct 
reduction of Au(III) in the presence of the stabilisation complex.47 
 
 
The complex, the solvent system, and the ratio of Au(III)/Ru(II) chosen in each synthesis 
were all found to influence the stability, the size and the shape of the resultant nanoparticles. 
A 33 % decrease in the steady-state luminescence was reported on the stable particles, in 
respect of the free complex. This is attributed to the quenching by the gold nanoparticles. 
Direct reduction of Au(III) salts in the presence of  ruthenium(II) bipyridyl dithiocarbamate 
complexes has also been reported by Beer et al.,49 as shown in Figure 2.7. The resultant 
Ru(II)-coated nanoparticles were 3–4 nm in diameter,  and luminescence quenching was also 
reported; almost complete quenching of the photoluminescence was observed upon formation 
of the functionalised nanoparticles. 
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Figure 2.7 Functionalisation of gold nanoparticles by direct reduction of Au(III) in the presence of 
ruthenium (II) bipyridyl diothiocarbamate complexes, as reported by Beer and co-workers49  
 
 
It was also reported that displacement of the dithiocarbamate complex with dodecanthiol was 
not possible, even with stirring over five days, thus verifying the robustness of the system. 
 
A similar strategy of direct reduction was also employed in 2011 by Yu et al.50 (Figure 2.8) to 
produce ca. 7 nm ruthenium(II) labelled gold nanoparticles with electrochemiluminescence 
activity, using an amine group to bind to the gold. 
 
Figure 2.8 Schematic for the one-pot synthesis of ruthenium functionalised gold nanoparticles by Yu 
et al.50 
 
 
Photoluminescence was also observed on the resultant nanoparticles, although the 
luminescence intensity of the ruthenium complex reduced fifteen-fold upon attachment to the 
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gold nanoparticles, in respect of the free complex, due to luminescence quenching by the 
nanoparticle core. 
 
When employing this one-pot direct reduction synthetic strategy to functionalise metal 
nanoparticles, the probe group has to be designed with two integral functions; not only must 
the probe be designed to optimise its luminescence, the stabilising properties must also be 
maximised so that it can provide a capping agent for the particles. The complex is introduced 
in situ during particle formation and caps the particle as it forms, and therefore has to be tuned 
to the size of the particle desired as well as its secondary function. Therefore, the particle size 
and coating cannot be varied independently from one another with ease, and the coating 
density or bimodal coating of the surface is difficult to control. This technique tends to yield 
small, relatively polydisperse nanoparticles, which are not ideal for biomedical theranostic 
devices.  
 
Examples of gold nanoparticles functionalised with non-luminescent transition metal 
complexes, for alternative applications to imaging, have been synthesised by place-exchange 
with thiolated ferrocene complexes for redox sensing51 and by direct reduction of Au(III) in 
the presence of thiolated carbonyl ligands, followed by coordination with Ru(II) for catalytic 
applications52,53 and by direct reduction in the presence of soft-donor appended complexes for 
materials synthesis by Wilton-Ely and co-workers.54,55  
 
2.1.4	 Photophysical	 Effects	 Upon	 the	 Attachment	 of	 Lumiphores	 to	 Gold	
Nanoparticles	
Upon attaching luminescent dye molecules to gold nanoparticles, the localised SPR of the 
gold nanoparticles can have a dramatic influence on the luminescence of the dye due  to the 
strong electromagnetic field generated at the particle surface.2 Upon excitation of the SPR, the 
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electromagnetic near-field is enhanced in the vicinity of the particle, which in turn interacts 
with the excited states of nearby lumiphores. Both enhancement and deactivation of the 
excited luminescent state can manifest from the proximity of the gold core, and to date, there 
are numerous reports on the effects of nanoparticles on the photophysics of organic dyes.29,56-
59 Luminescence deactivation of the excited state can occur by energy transfer to the gold 
nanoparticles in a similar manner to Förster resonance energy transfer (FRET) between 
lumiphores, due to their high absorption extinction coefficients across the whole of the 
UV-Vis spectrum. Conversely, quenching can occur by electron transfer from the excited 
state to the continuum of energy levels in the metallic core. Both of these effects increase the 
non-radiative rates of decay from the excited state. However, the luminescence properties can 
equally be enhanced by the SPR; the light intensity enhancement by the near-field 
amplification at the resonant frequency of the SPR can either increase the excitation of the 
lumiphore by amplifying the field of the absorption light, if the excitation wavelength 
overlaps with the SPR, or increase the radiative rate and thus the quantum yield of the 
lumiphore by amplifying the electromagnetic field of the emission radiation, if the emission 
wavelengths overlap with SPR.2 In addition to these particle-lumiphore interactions, any 
electronic molecule-molecule interactions are likely to occur due to the high local 
concentrations of the lumiphores on the nanoparticle surface. At increased distances up to ca. 
10 nm the nanoparticle is not able to interact electronically with the excited state, but the 
enhanced electromagnetic field is still strong enough to increase the radiative rate and 
enhance the luminescence up to 100-fold.2,59  
 
In general, it is proposed that lumiphores in very close proximity to the surface (<5 nm) 
interact strongly with the electronics of the particle, and tend to have quenched emission. The 
quenching of ruthenium(II) complexes upon attachment to gold nanoparticles has been 
reported in several studies, as discussed above, and  is summarised in Table 2.1. 
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Table 2.1 Summary of literature on luminescent ruthenium(II)complexes on gold nanoparticles
author/ 
publication year labelling strategy size 
quenching upon 
binding to gold 
nanoparticles
Murray31 2002 electrostatic binding ~ 2 nm 
 
70% reduction in the 
emission intensity 
 
Beer and 
Thiebaut49 
 
2006 direct reduction ~3 nm 
emission band almost 
completely quenched 
 
Thomas and 
Kamat39 
 
2006 ligand exchange 5 nm 
20% of signal had a 
much reduced 
lifetime component 
 
Mayer48 2006 direct reduction 2–30 nm 
33% reduction in the 
emission intensity 
 
Cui50 2011 direct reduction 7 nm 
luminescence intensity 
reduced fifteen-fold 
 
Gunnlaugsson41 2011 ligand exchange ~4 nm significant quenching 
Dietzek60 2012 ligand exchange 30 and 60 nm 
luminescence not 
measured 
 
     
 
2.1.5	 Functionalising	 Citrate‐stabilised	 Gold	 Nanoparticles	 with	 Cationic	
Lumiphores	
For the purpose of optical tracking of individual reporter groups, larger nanoparticle centres 
are desired, which can be synthesised by the citrate-reduction method.5,9,10 The citrate-
stabilised particles are particularly attractive for biomedical applications because the sols are 
aqueous and preparations afford repeatable sizes with good monodispersity. The 
functionalisation of citrate-stabilised gold nanoparticles can also be achieved by ligand 
exchange (Figure 2.2c), and in previous studies within the Pikramenou research group neutral 
luminescent europium complexes have been successfully attached to citrate gold 
nanoparticles to make luminescent imaging probes.43,45,61 The pre-eminence of the neutral 
complex designs for enabling attachment and steric stability of the particles in these studies, 
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without losing stability of the particles in the partially-coated states, was integral to the probe 
formation. Dietzek et al. coated 60 nm citrate-stabilised nanoparticles in anionic Ru(II) 
isothiocyanato complexes and maintained the nanoparticle integrity.60 Similarly, Toma and 
co-workers62 have previously coated citrate gold nanoparticles with pentacyanoferrate 
complexes without losing particle stability, but the transition metal complexes in this study 
were tri-anionic. However, if cationic complexes are added to citrate gold nanoparticles, the 
surface-functionalisation can initiate particle aggregation because the surface charge 
neutralisation upon functionalisation sacrifices electrostatic stability.63,64 This can make their 
functionalisation difficult as electrostatic stability is often lost in the coating procedure, and 
thus there are few reports in the literature of such systems.  
 
To circumvent the problem of nanoparticle aggregation upon functionalisation, Chen and co-
workers65 proposed a two-step functionalisation strategy of citrate nanoparticles to coat with 
both neutral and positively charged thiols, by first functionalising the surface with lipoic acid, 
in order to slow down the removal of the negative charge during displacement with the 
modifying thiol. A similar approach has been reported using the commercial polysorbate 
surfactant TWEEN®.66,67 It is proposed that the initial coating of citrate-stabilised gold 
nanoparticles with TWEEN® allows the subsequent coating of the particles with thiols 
because the weakly adsorbed oligo(ethylene glycol) moieties of the TWEEN® surfactant 
protects the gold nanoparticle surfaces sterically from aggregation. However, they can be 
displaced easily by thiolated species, and once completely displaced are stabilised by the 
coating thiols.  TWEEN® surfactants have since been used to mediate peptide nucleic acid 
conjugated gold nanoparticles68 and to coat nanoparticles and subsequently detect Cr3+ 
chelation to citrate anions on the particle surface by surface-enhanced Raman spectroscopy 
(SERS), whilst resisting aggregation.69 Poly(ethyene glycol) units are frequently added to 
gold nanoparticles in the literature to increase their stability, especially within biological 
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media.70-72 Fluorosurfactant-capped nanoparticles have also been reported to exhibit high 
stability in the presence of salt for selective colorimetric detection of homocysteine via 
induced aggregation.73,74  
	
2.1.6	Chapter	Outline	
In this chapter, the interaction of three commercially available surfactants (Triton™ X-100, 
TWEEN® 20 and Zonyl® 7950) with 13 nm citrate-stabilised gold nanoparticles is reported. 
The structures of these three commercial surfactants are presented in Figure 2.9 below. 
 
Figure 2.9 Structures of the following surfactants: (a) TWEEN® 20; (b) Triton™ X-100; and (c) 
Zonyl® 7950. 
 
 
TWEEN® 20 and Triton™ X-100 are supplied as viscous liquids and used without 
purification. Zonyl® 7950 is supplied as a formulation in isopropanol, and has been analysed 
by GC-MS, 1H and 13C{1H} PENDANT NMR, to approximate that 1 mg mL−1 of the Zonyl® 
7950 formulation is ca. 1 mM fluorosurfactant (see Chapter Two experimental, Section 
2.12.1). 13 nm gold nanoparticles have been coated with these surfactants, and the surface-
interactions with the particles have been characterised. A schematic of the particles is shown 
in Figure 2.10. 
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Figure 2.10 Schematics of 13 nm gold nanoparticles coated in (a) Triton™ X-100, (b) TWEEN® 20, 
and (c) Zonyl® 7950. 
 
 
The expediency of each surfactant to facilitate the luminescent labelling of the particles with a 
dicationic surface-active ruthenium polypyridyl complex, RuSH, without losing colloidal 
stability, is evaluated and discussed herein. The structure of RuSH, which is made in situ 
from the oxidatively stable RuSAc thioester analogue complex,  is shown in Figure 2.11, and 
a schematic of the isolated nanoparticles coated in TWEEN® 20 and RuSH, i.e. 
Ru-T20•AuNP13, and coated in Zonyl® 7950 and RuSH, i.e. Ru-Z•AuNP13, is presented in 
Figure 2.12. 
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Figure 2.11 Structures of RuSAc and RuSH complexes discussed in this chapter. 
 
 
 
 
 
 
Figure 2.12 Schematic of (a) Ru-T20•AuNP13 and (b) Ru-Z•AuNP13 nanoparticles, as discussed in 
this chapter. 
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2.2	The	 Preparation	 of	 a	 Surface‐binding	Ruthenium(II)	 Polypyridyl	
Complex:	RuSH	
2.2.1	Synthesis	of	RuSH	
The tailor-made ruthenium complex RuSH was first prepared in the Pikramenou research 
group by Dr Shiva Farabi,75,76 based on the parent archetypal ruthenium tris(bipyridine) 
lumiphore. RuSH incorporates two surface-binding thiols groups attached to the 
functionalised bipyridine ligand, separated by a hexyl spacer to prevent previously reported 
luminescence quenching of the chromophore by the gold surface.77 In brief, the ancilliary 
ligand was synthesised by the Williamson reaction of 6-bromohexene with 4,4’-dihydroxy-
2,2’-bipyridine, and complexed to Ru(bpy)2Cl2 by refluxing in ethanol. The complex was 
purified by precipitation as the hexafluorophosphate salt in ethanol, and the terminal olefin 
groups were finally converted into thioesters by free-radical mediated nucleophilic addition of 
thioacetic acid, to give RuSAc.76 This protected thiol analogue was isolated and fully 
characterised, and the active thiol groups were unmasked by thioester hydrolysis with aqueous 
ammonia to produce RuSH, as shown in Figure 2.13, immediately prior to addition to gold 
nanoparticles.1,76  
 
The BpyHex ligand formation was confirmed by electrospray mass spectrometry, with a peak 
observed for the protonated ligand at m/z 353.2, i.e. [M+H]+., and for the sodium adduct at m/z 
375.2, i.e. [M+Na]+.. 1H NMR reveals all the expected protons for BpyHex, integrating to the 
correct expected signal intensities, and the loss of the broad H-bonded O-H frequency 
(centred at 2760 cm−1 for 4,4’-dihydroxy-2,2’-bipyridine) in the powder Fourier transform 
infrared spectroscopy (FT-IR) absorption spectrum of BpyHex corroborates the ether 
formation. 1H and 13C NMR assignments were made by analysis of 2D COSY and HSQC 
spectra (Appendix 9) and agree with previously reported data,75 as published by the author.76 
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Figure 2.13 Synthesis of the surface-binding Ru(II) complex RuSH. 
 
 
Successful complexation of of the BpyHex ligand to give RuHex is evident from electrospray 
mass spectrometry, with peaks observed for the cationic species following loss of counter 
ions, at m/z 911.1, corresponding to [M−PF6]+., and at m/z 383.2, corresponding to 
[M−2PF6]2+.. The BpyHex ligand protons exhibit significant chemical shifts upon 
complexation to Ru2+: H6 shifts upfield from 8.45 ppm in the free BpyHex ligand to 7.41 ppm 
in RuHex, as this proton experiences electron shielding due to the proximity of the Ru(II) d-
electrons. H3 and H5, however, shift downfield slightly, from 7.94 ppm and 6.82 ppm in the 
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free ligand, to 7.97 ppm and 6.90 ppm respectively in the complex: these protons face away 
from the metal centre and experience a slight overall deshielding effect upon complexation, 
due to the donation of electrons from the ligand towards the metal centre. 1H and 13C NMR 
assignments were made by analysis of 2D COSY and HSQC spectra (Appendix 9) and agree 
with previously reported data,75 as published by the author.76 The purity of the RuHex 
compound can only be estimated as ca. 95% by inspection of the NMR data, and was carried 
forward to the next step of the synthesis. 
  
Successful thioesterification of the RuHex complex was confirmed by 1H and 
13C{1H}PENDANT NMR spectroscopy and mass spectrometry. Elecrospray mass 
spectrometry of RuSAc revealed peaks at m/z 1063.2, corresponding to the loss of one 
counterion, i.e. [M−PF6]+., and at m/z 459.1  for [M−2PF6]2+., due to the loss of two counter 
ions. It was possible to obtain CHN elemental analysis of RuSAc within 0.2% of the 
theoretical percentage mass of each element, confirming the purity of this final isolated 
product, and the carbonyl bond of each thioester is evident from the peak observed at 1683 
cm−1 in the FT-IR absorption spectrum. Notably, this is absent from the FT-IR absorption 
spectrum of RuHex. The successful thioesterification reaction was confirmed unequivocally 
by 1H NMR spectra, with loss of the olefin protons at ca. 5.8 ppm and 5.0 ppm, and the 
appearance of the triplet at 2.85 ppm (H12) and the terminal methyl group of each thioester at 
2.27 ppm. 1H and 13C NMR assignments were made by analysis of 2D COSY and HSQC 
spectra (Appendix 9) and agree with previously reported data,75 as published by the author.76 
The thiol groups were finally unmasked in situ by thioester hydrolysis with aqueous ammonia 
directly prior to addition to the nanoparticles, to give RuSH, which was confirmed by 
MALDI mass spectrometry using a gentisic acid matrix, with a peak at m/z 829.7, 
corresponding to [M−2PF6]1+., i.e. the monocationic molecular parent ion (similar 1+ 
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molecular parent ions are observed in MALDI for [Ru(bpy)3](PF6)2 at m/z 570.01, 
corresponding to [Ru(bpy)3]1+. using a sinapinic acid matrix)78. 
	
2.2.2	Photophysical	Characterisation	of	RuSH	
The solution-based photophysical properties of RuSAc have been studied in the Pikramenou 
research group previously in CH3CN,75 and the UV-Vis absorption spectrum in Figure 2.14 
agrees with this work.75 However, upon attachment to citrate-stabilised gold nanoparticles, the 
complex is exposed to an aqueous system, and thus the photophysical properties of the free 
complex in a 1% (v/v) CH3CN in water solution, have also been measured (Figure 2.14).  
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Figure 2.14 UV-Vis absorption spectra of aerated 15 M RuSAc in CH3CN (black solid line) and in 
1 % CH3CN, water (blue solid line), and steady-state luminescence emission spectra in CH3CN (black 
dashed line) and in 1 % CH3CN, water (blue dashed line), exc = 450nm. Spectra corrected for 
instrument response. 
 
 
The RuSAc complex is insoluble in water as the hexafluorophosphate salt, and thus 1% 
CH3CN is required for solubility. Both absorption spectra exhibit the same bands at the same 
energies; the singlet MLCT state is observable at 410–480 nm and the sharp LC state (–*) 
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is present at 289 nm. Weak absorptions are also seen between 300–380 nm, and are thought to 
be MC (d–d) transitions.22 The spectra in Figure 2.14 are very similar to that of  
[Ru(bpy)3](PF6)279,80 however, the singlet MLCT state experiences a ca. 10 nm bathochromic 
shift in the absorption max upon the ether fuctionalisation of one of the bipyridine ligands in 
the 4,4’ positions, in RuSAc, with respect to [Ru(bpy)3](PF6)2.79,80 This shift is expected due 
to the electron donating effect of the oxygen lone pairs to the pyridine -ring. Electron-rich 
-systems increase the energy of the M orbitals by increasing the formal crystal field 
splitting, and although the L* orbitals will also increase in energy, there will still be L* 
orbitals at the original energy position from the remaining unsubstituted bpy ligands. Thus, 
the energy gap of the MLCT transition decreases from [Ru(bpy)3](PF6)2 to RuSAc. The 
excitation spectra of RuSAc in solutions of both CH3CN and water (1% CH3CN) are shown 
below in Figure 2.15. 
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Figure 2.15 Excitation Spectra of RuSAc in CH3CN (black) and water (1% CH3CN) (blue), em = 
630 nm. Spectra corrected for instrument response. 
 
 
The complex emits from the triplet MLCT state (at em = 630 nm) following excitation into 
any of the singlet excited states between 250–500 nm, i.e. the LC, MC and the MLCT states, 
as can be seen in Figure 2.15. The excitation spectra in both aqueous and CH3CN solvent 
systems resemble the photoabsorption spectra in Figure 2.14. 
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The steady-state luminescence spectra (Figure 2.13) display solvent dependency; aerated 
solutions are more emissive in 1% CH3CN/water than CH3CN solutions, per unit 
concentration, and exhibit a 5 nm red shift in λmax positions. Similarly, a 10 nm red-shift is 
observed when the parent complex Ru(bpy)3Cl2 is dissolved in water, with respect to CH3CN; 
the chloride salt was used for comparison due to availability. The photophysical properties are 
summarised in Table 2.2.  
 
Table 2.2 Summary of the photophysical properties of RuSAc and the parent complex Ru(bpy)3Cl2 for 
comparison in aqueous and CH3CN solutions.
 Φ / %a τ / nsb λmax / nmc
 
Ru(bpy)3Cl2 
in H2O 
2.8d 
[5.5]e 
405 
[700]
625 
 
 
Ru(bpy)3Cl2 
in CH3CN 
1.6f 
[7.8]e
155 
[870] 
615 
 
 
RuSAc 
in 1% CH3CN/H2O
2.0±0.5 
[2.5±0.5]
260 
[325]
650 
 
 
RuSAc 
in CH3CN 
 
1.0±0.5 
[7.0±1.0] 
 
130 
[775] 
 
645 
 
 
a aerated Φs measured using an integrating sphere, deaerated values in square brackets. (systems degassed with 
nitrogen for 20 min). 
b lifetimes measured in aerated solutions, deaerated measurements shown in square brackets. Errors estimated as 
±6 %. 
c error estimated as ±3 nm.   
d data taken from Nakamaru.81 
e data taken from Harriman.82 
f data taken from Balzani and co-workers.83 
 
 
The red-shift in the emission is expected because charge-transfer bands are sensitive to 
solvent polarity. Spectroscopic studies provide significant evidence that the MLCT states are 
localised on one bipyridine unit, and therefore possess appreciable intramolecular charge 
separation.22 This charge localisation is stabilised by polar solvent systems and thus state red-
shifts. 
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Both the ruthenium(II) complexes (RuSAc and Ru(bpy)3Cl2) in Table 2.2 display oxygen 
sensitivity, in both solvent systems studied, although much greater quenching of the 
luminescence is observed in solutions of CH3CN, than in aqueous systems: a ca. 80% 
decrease in the observed lifetime is observed for both RuSAc and Ru(bpy)3Cl2 in aerated 
CH3CN solutions, with respect to deaerated systems, whereas a 20% decrease for RuSAc and 
a 40% decrease for Ru(bpy)3Cl2 are observed in an aqueous environment. Similar trends are 
observed in the luminescence Φs of each system. The  of triplet MLCT luminescence 
(measured at λexc = 450 nm) of RuSAc is 1.0±0.5% in CH3CN, whereas it increases to 
2.0±0.5% in 1% CH3CN/water (See Table 2.2).The of RuSAc in water is marginally lower 
than that of Ru(bpy)3Cl2 in all of the studied systems, which may be due to the reduction in 
symmetry following functionalisation of one of the ligands, which opens up more non-
radiative vibrational decay paths.  
	
2.3	Synthesis	of	13	nm	Gold	Nanoparticles	
13 nm sodium citrate gold nanoparticles were chosen due to their highly reproducible 
preparation and narrow size distribution, i.e. 13±1.7 nm, by analysis of 100 nanoparticles by 
TEM.5 This nanoparticle preparation, initially developed by Turkevitch in 1951,4 and later 
refined by Frens,8 is the most commonly employed to synthesis aqueous sols of gold 
nanoparticles in the 10-20 nm size-range, with root-mean-square deviations in the size 
distribution of 12.5%,4 and has been utilised several times in the Pikramenou research group 
over the last decade for nanoparticle studies, owing to the facile and repeatable 
preparation.1,45,61,76,84  
 
13 nm citrate-stabilised gold nanoparticles were synthesised according to Grabar et al.5 by 
reduction of the Au3+ salt, HAuCl4, in water, with trisodium citrate. The trisodium citrate salt 
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not only reduces the gold(III) ions, it also caps the resulting nanoparticles, along with the 
spectator chloride ions, and presumably oxidation products of the citrate anions. These 
capping ions stabilise the nanoparticles electrostatically, with respect to aggregation 
(discussed in Section 2.1.1)6,7 as shown in the schematic below, Figure 2.16.  
 
Figure 2.16 Synthesis of 13 nm citrate-stabilised gold nanoparticles. 
 
 
The resulting 9 nM aqueous colloid (concentration estimated from the size of the 
nanoparticles and the concentration of Au3+ ions used, assuming all ions form nanoparticles.43 
See Appendix 1.1) was characterised by UV-Vis absorption spectroscopy, dynamic light 
scattering (DLS), electrophoretic light scattering (to measure the zeta potential) and 
transmission electron microscopy (TEM), which are presented in Figure 2.17. 
 
  Chapter Two  
45 
 
 
Figure 2.17 (a) UV-Vis absorption spectrum (measured at 9 nM particle concentration), (b)TEM 
image, (c) DLS intensity distribution, (d) DLS number distribution, and (e) zeta potential distribution 
(measured at 2 nM particle concentration), of 13 nm citrate-stabilised gold nanoparticles.   
 
 
The UV-Vis absorption spectrum of the 9 nM citrate-coated gold nanoparticles exhibits a 
highly absorptive SPR peak at 520 nm (as discussed in Section 1.3), with log  = 8.5. Sizing 
of the nanoparticles by DLS gives an average number distribution (vida infra)  hydrodynamic 
diameter of 13±4 nm, and an average intensity distribution (vida infra) diameter of 29±12 nm 
(86%) and 998±624 nm (14%). Dynamic light scattering measures the rate at which LASER 
scattering from the bulk colloidal suspension fluctuates due to constructive and destructive 
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interferences of  the scattered light, off particles diffusing in Brownian motion.85 The 
calculated hydrodynamic radius is the radius of a theoretical sphere that has the same 
diffusion coefficient as the measured species, and it can be affected significantly by the 
surface structure of the nanoparticles; surface-bound molecules will affect the diffusion speed 
of the nanoparticles. Hydrodynamic radii distributions are calculated from the rate of 
scattering fluctuations, with respect to the intensity of the scattered light, i.e. the probability of 
light being scattered from a sphere of a given size, and this gives the intensity distribution. 
This does not scale with the number of particles, because larger particles scatter a lot more 
than smaller particles. The fundamental intensity distribution can, however, be converted to a 
number distribution, using Mie theory,85,86 to weight the probability in terms of particle 
concentration, although this dramatically scales up the errors in the measurements, and 
assumes that all particles are spherical and homogenous. 
 
The scattering intensity contribution arising from a micrometer scale aggregates (14% of the 
intensity distribution) in the citrate gold nanoparticle sample (Figure 2.17c)  implies that there 
are measureable aggregates present in this macroscopic sample. However, once converted to a 
number distribution, to account for the fact that the intensity of light scattered by a particle is 
a function of its diameter to the sixth power, it is clear that these are present in negligible 
concentration, i.e. <<1%. The nanoparticles have a zeta potential of −40±5 mV, measured in 
water at a 2 nM nanoparticle concentration, which is significant enough to stabilise the 
nanoparticles with respect to aggregation. The zeta potential is the electrokinetic potential 
between the dispersion medium and the stationary layer of fluid associated to the particle, 
which is measured by analysing the electrophoretic mobility of the particles by LASER 
Doppler spectroscopy. Electrostatically stabilised sols require large zeta potentials (either 
positive or negative) to prevent fusion of the gold cores by means of repulsive forces. 	
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2.4	 Direct	 Attachment	 of	 RuSH	 to	 Citrate‐stabilised	 13	 nm	 Gold	
Nanoparticles	
Direct addition of the cationic RuSH complex to 13 nm citrate gold nanoparticles was 
attempted and monitored by UV-Vis absorption spectroscopy, as shown in Figure 2.18. 
Unlike previous work in the group, in which neutral lanthanide complexes are successfully 
added directly to citrate gold nanoparticles,43,61 full surface coverage of the gold nanoparticles 
was unsuccessful with the RuSH complex. Surface-coverage of ca. 1,400 europium(III) 
complexes per nanoparticle has been achieved in the group with a pentetic acid chelating 
group, appended with two similar hexyl-thioester groups for surface attachment to gold, 
which is thought to have a similar complex footprint as RuSH.61 
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Figure 2.18 UV-Vis absorption spectra of citrate gold nanoparticles (1 mL, 9 nM) (bold), and with the 
addition of RuSH complex (1 L, 3 mM), to give a final complex concentration of 3 M (dashed line). 
 
 
Addition of only ca. 400 complexes of RuSH (1 L, 3 mM) per particle to citrate-stabilised 
13 nm gold nanoparticles (1 mL, 9 nM), calculated from the concentration of lumiphores of 
nanoparticles in the solution, gives rise to the sudden formation of a new SPR band in the 
UV-Vis spectrum, between 600–800 nm, and a reduction in the absorbance at 520 nm. This 
new band formation suggests that plasmon coupling between agglomerating nanoparticles is 
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occurring,87 and thus indicates that flocculation of the nanoparticles is occurring in solution, 
following the addition of the cationic RuSH complex. When colloidal particles aggregate 
additional resonances occur in the UV-Vis absorption spectrum, at wavelengths longer than 
the individual particles. This gives rise to a red-shift and a broadening of the convoluted 
SPR.66,87 Similar effects have been observed with the addition of ruthenium tris(bipyridine) to 
citrate gold nanoparticles of varying sizes.11 This signal growth, between 600–800 nm in the 
UV-Vis absorption spectrum, is also observed at much reduced concentrations, as shown in 
Figure 2.19, and the flocculation can be observed to some extent by TEM, although 
nanoparticle distributions which dry on a surface are not overly representative of 
agglomeration structures in the sol. All colloidal suspensions eventually turned steel-blue and 
sedimented out of suspension following the addition of RuSH. 
 
Figure 2.19 UV-Vis absorption spectra of (a) 0.7 nM 13 nm citrate-stabilised gold nanoparticles (bold 
solid line) and with the addition of 6–100 nM RuSH complex (dashed lines), and (b) 0.7 nM 
nanoparticles (bold solid line) and upon addition of 9 M RuSH complex. Transmission electron 
micrographs of (c) citrate-stabilised gold nanoparticles, (d) final titre of (a), i.e. 0.7 nM nanoparticles 
+ 100 nM RuSH, and (e) final titre of (b), i.e. 0.7 nM nanoparticles + 9 M RuSH. 
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The citrate nanoparticles are stabilised by the electrostatic repulsion between the 
citrate/chloride shells absorbed to each gold nanoparticle centre. Once the RuSH complex 
binds to the surface of these nanoparticles, its 2+ charge will attract the negative shells of 
neighbouring partially-coated nanoparticles, leading to flocculation and subsequent 
aggregation of the particles in solution. Addition of nanomolar concentrations to 0.7 nM 
nanoparticles (ca. 5–150 complexes per nanoparticle) gives rise to bimodal SPR formation 
again, as observed in Figure 2.19a, and the TEM shown in Figure 2.19d clearly shows clusters 
of nanoparticles, which despite drying artifacts that can occur on the grid, look different to the 
control study of bare citrate nanoparticles in Figure 2.19c. Addition of micromolar 
concentrations of RuSH to 0.7 nM nanoparticles, i.e. 13,000 complexes per nanoparticle, 
gives rise to a broad single SPR peak at ca.600 nm, and large aggregates are observed in the 
TEM (Figure 2.19e). 
 
2.5	Interactions	of	Triton™	X	100,	TWEEN®	20,	and	Zonyl®	7950	with	
13	nm	Citrate‐stabilised	Gold	Nanoparticles	
It was not possible to directly attach cationic RuSH complexes to citrate-stabilised gold 
nanoparticles, and therefore a surfactant-mediated coating strategy was investigated, in an 
attempt to circumvent the aggregation problem. A surfactant pre-coating step has been 
introduced to the functionalization process, as previously employed by Aslan et al,. to coat 
citrate-stabilised nanoparticles with alkylthiols.66 The surfactant is added to displace the 
negative citrate shell around the particles and stabilise the particles sterically, before addition 
of the cationic complex. In this study we have evaluated three commercially available 
surfactants: Triton™ X-100, TWEEN® 20, and Zonyl® 7950, as pre-coating moieties to 
allow subsequent attachment of RuSH without aggregation of the nanoparticles. 
Triton™ X-100 bears a hydrophilic polyethylene oxide chain with an aromatic hydrophobic 
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group (Figure 2.9b), and similarly TWEEN® 20, which is a derivative of sorbitan 
monolaurate, has four hydrophilic polyethylene oxide chains and a single hydrophobic 
aliphatic chain (Figure 2.9a). Zonyl® 7950 is a fluorosurfactant, with a hydrophilic methyl-
methacrylate head-group, and a hydrophobic perfluorinated alkyl chain (Figure 2.9c). The 
surface-coating of 13 nm citrate gold nanoparticles with each surfactant is summarised in 
Figure 2.20 below: 
  
Figure 2.20 Surface-functionalisation of gold nanoparticles with three commercial surfactants: 
Triton™ X-100; TWEEN® 20 and Zonyl® 7950. 
 
 
Each surfactant was titrated into the 13 nm citrate gold nanoparticles, and surface binding to 
the surface of the gold nanoparticles is apparent for all three by the shift in the SPR peak in 
the UV-Vis absorption spectra; the absorption of the surfactant molecules to the gold surface 
changes the surface dielectric constant of the particles,43,88 resulting in the observed shifts in 
the SPR (Figure 2.21).  
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Figure 2.21 UV-Vis absorption spectra of 13 nm gold nanoparticles (9 nM) (bold solid line) + (a) 
TWEEN® 20 (2 mM) (dashed line), +(c) Triton™ X-100 (0.6 mM)(dashed line)  and + (e) 
Zonyl® 7950 (12 mg mL−1) (dashed line). max of SPR peak vs. [surfactant] titrations shown in (b), (d) 
and (f). 
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Upon the titration of the TWEEN® 20 surfactant into 9 nM citrate gold nanoparticles, a 5 nm 
bathochromic shift in the SPR is observed (Figure 2.21a–b). Similarly the Triton™ X-100 
surfactant gives rise to a 4 nm red-shift (Figure 2.21c–d), whereas the Zonyl® 7950 surfactant 
only gives rise to a 1 nm bathochromic shift in the SPR of the nanoparticles (Figure 2.21e–f). 
The SPR peak wavelength of the gold nanoparticles shifts as the dielectric constant of the 
local surrounding medium changes, due to binding at the nanoparticle surface.66 Saturation is 
observed in the max vs. surfactant concentration binding plots, upon addition of each 
surfactant to 9 nM gold sols, at ca. 400 M for both Triton™ X-100 and TWEEN® 20, and at 
ca. 1 mg mL−1 (ca. 1 nM) for the Zonyl® 7950 fluorosurfactant. No induced aggregation is 
observed by UV-Vis absorption spectroscopy or by DLS upon addition of excess of each of 
the tested surfactants, as shown in Figures 2.21 and 2.22. 
 
The zeta potentials and hydrodynamic diameters of the surfactant-coated nanoparticles were 
also studied to analyse the surface binding of each surfactant. Excess surfactant (beyond the 
saturation point observed by the SPR shift in the UV-Vis absorption spectra, Figure 2.20) was 
added to the 9 nM citrate-stabilised gold nanoparticles, and the solutions were then diluted to 
2  nM and the DLS and zeta potential measurements were recorded, as displayed in Figure 
2.22 and Table 2.3.  
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Figure 2.22 DLS intensity distribution graph of citrate gold nanoparticles (black solid line), and 
particles coated in TWEEN® 20 (blue dashed line), Triton™ X-100 (red dashed line) and 
Zony®l 7950 (green dashed line), all measured at 2 nM particle concentration, with 2.5 mg mL−1 
surfactant, in deionised water. 
 
 
The addition of excess TWEEN® 20 and the Triton™ X-100 surfactant (10 mg mL−1 
surfactant, 9 nM gold nanoparticles) both give rise to a peak at low diameter in the DLS, by 
comparison with the bare citrate gold nanoparticles,  which is likely to be due to micelle 
formation of the excess of each of the surfactants in water. This is not observed at the 
concentrations used with Zonyl® 7950. In all cases, upon addition of the surfactant, the most 
intense peak in the scattering intensity distribution is at ca. 30 nm, with a marginal increase 
(5–30%) in the peak intensity from the uncoated citrate-stabilised gold nanoparticles. This 
indicates that the surface interaction of each surfactant adds steric bulk to the hydrodynamic 
diameter of the particle, slowing down its diffusion in solution slightly.  
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Table 2.3 DLS and zeta potential data for 13 nm gold nanoparticles coated in surfactants 
Particle Coating: Citratea TWEEN®20a Triton™ X-100a Zonyl® 7950a 
 
DLS: Intensity 
Distribution / nm (%) 
 
29±12  (86) 
998±624 (14) 
 
32±13 (94) 
2.0±0.4 (6) 
 
31±13  (95) 
2.0±0.7 (5) 
 
38±18 (100) 
 
DLS: Number 
Distribution / nm (%) 
 
13±4(100) -b -b 17±5 (100) 
Zeta Potential / mV  −40±5 −17±4 −7±2 −72±4 
a colloidal dispersions of 2 nM gold nanoparticles, and 2.5 mg mL−1 surfactant, in deionised water.
b number distributions not given as all contribution from micelle peak. 
All errors are quoted as ±1 standard deviation.
 
The zeta potential of the citrate particles is −40±5 mV, and upon addition of the neutral 
non-ionic surfactants TWEEN® 20 and Triton™ X-100, the zeta potential reduces in 
magnitude to −17±5 mV and −7±4 mV respectively, as the negatively charged citrate ions are 
displaced by neutral surfactant in each case. Physisorption of both the neutral surfactant 
molecules TWEEN® 20 and Triton™ X-100 is evident from the change in the zeta potential 
and the shift on the SPR in the UV-Vis absorption, whereas aggregation is not induced by the 
sacrifice in surface charge, as demonstrated by the DLS data. Electrostatically stabilised sols 
require large zeta potentials to prevent fusion of the gold cores by means of repulsive forces, 
while steric stabilisation can also be employed to inhibit aggregation with neutral surface 
charges. In contrast, upon addition of the Zonyl® 7950 fluorosurfactant, the zeta potential 
increases in magnitude to a larger negative value of −72±2 mV. Although this surfactant is 
neutral, it has a perfluorinated alkyl chain with multiple polarised C–F bonds and, therefore, it 
is assumed from these data that the surfactant presents numerous partial negative charges to 
the outer surface of the hydrodynamic radii of the particles. Similar effects have been seen 
with silica nanoparticles.89  
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2.6	Surfactant‐mediated	Labelling	of	13	nm	Citrate	Nanoparticles	with	
RuSH,	 Using	 the	 Surfactants	 Triton™	 X‐100,	 TWEEN®	 20,	 and	
Zonyl® 7950	
Each surfactant-coated nanoparticle system was subsequently screened to see if the addition 
of RuSH could be achieved without aggregation of the particles, as shown below in the 
schematic (Figure 2.23). Nanoparticles were tested at three different particle concentrations: 
9 nM, 3.5 nM and 0.7 nM, because aggregation is driven by inter-particle interactions which 
are more likely to occur at higher particle concentration.  
 
Figure 2.23 Surface-functionalisation of gold nanoparticles with RuSH, mediated by a pre-coating 
step with three commercial surfactants: TritonTM X-100, TWEEN® 20, and Zonyl® 7950. 
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In each case 8,000 equivalents of RuSH ( i.e. 8,000 RuSH complexes per nanoparticle) were 
added to the nanoparticles (9 nM, 3.5 nM and 0.7 nM) following the addition of varying 
concentrations of each surfactant TRITON™ X-100 (0.1–20 mM), TWEEN® 20 (0.04–
8 mM) and Zonyl® 7950 (0.05–10 mM), as shown below in Figure 2.24. In each case, the 
surfactant was added to the nanoparticles, and stirred for 20  min, and then the RuSH was 
subsequently added. The photographs (Figure 2.24) were taken 30 min after the final 
solutions were obtained.  
Figure 2.24 Screening surfactant-coated nanoparticles for attachment in RuSH. Nanoparticles (1,4,7 
= 9 nM, 2,5,8 = 3.5 nM, 3,6,9 = 0.7 nM) coated in (i) Zonyl® 7950, (ii) TWEEN® 20, and (iii) 
Triton™ X-100, at concentrations of (a) 0.05 mg mL−1, (b) 0.5 mg mL−1, (c) 1 mg mL−1, (d) 5 mg 
mL−1, and (e)10 mg mL−1, (f) 0 mg mL−1, and (g) 0 mg mL−1. (a–e, g) contain 8,000 equivalents of 
RuSH, (f) is an uncoated control.  
 
 
Triton X-100 is not able to prevent the RuSH complex from aggregating the gold 
nanoparticles at any concentration combination of nanoparticles and surfactant tested, as can 
be seen in Figure 2.24(iii); at all three concentrations of nanoparticles tested (i.e. 9 nM, 
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3.5 nM and 0.7 nM), the nanoparticles immediately turned dark in colour (7a–7e, compared 
with the control uncoated nanoparticles in 7f, 8a–8e compared with 8f, and 9a–9e compared 
with 9f), as new resonances formed in the UV-Vis absorption spectra due to aggregation. The 
UV-Vis absorption spectra presented in Figure 2.25 shows the series of 0.7 nM nanoparticles 
tested.  
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Figure 2.25 UV-Vis absorption spectra of gold nanoparticles (0.7 nM)(sold black line), and gold 
nanoparticles (0.7 nM) + Triton™ X-100 surfactant (0.1–20 mM) + RuSH (5.5 M)(dashed coloured 
lines). Gold nanoparticles (0.7 nM) with no surfactant and RuSH (5.5 M)(black bold solid line).UV-
Vis absorption spectra recorded 30 min after RuSH addition. 
 
 
At all concentrations of surfactant added, a large increase in the absorbance between 600–
800 nm was observed, as aggregation was occurring, and within 12 hrs the particles 
aggregated, and sedimented out of suspension. Therefore this surfactant was deemed 
unsuitable for mediating attachment of the RuSH to citrate gold nanoparticles.  
 
Unlike the Triton™ X-100 surfactant the TWEEN® 20 is able to offer some stability to the 
nanoparticles upon addition of RuSH. At 9 nM and 3.5 nM concentrations of nanoparticles, 
the TWEEN® 20 did not prevent flocculation in solution with addition of RuSH, and after 
30 min the solutions were all very dark (either blue or purple) in colour (Figure 2.24(ii)). The 
UV-Vis absorption spectra at 3.5 nM is presented in Figure 2.26. 
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Figure 2.26 UV-Vis absorption spectra of gold nanoparticles (3.5 nM)(sold black line), and gold 
nanoparticles (3.5 nM) + TWEEN®  20 surfactant (0.04–8 mM) + RuSH (25 M)(dashed coloured 
lines). Gold nanoparticles (3.5 nM) with no surfactant and RuSH (25 M)(black bold solid line).UV-
Vis absorption spectra recorded 30 min after RuSH addition. 
 
 
Aggregation was apparent with the 3.5 nM nanoparticles at all the concentrations of surfactant 
tested, but a significant reduction in the absorbance between 600–800 nm was observed with 
4–8 mM TWEEN® 20 present, although the max of the SPR with 8 mM surfactant was still 
red-shifted with respect to the particles without RuSH (at 525 nm), at 533 nm. However, at 
the lower nanoparticle of 0.7 nM, the addition of milimolar TWEEN® 20 seemed to 
significantly reduce the aggregation of the nanoparticles, as shown in Figure 2.27, and the 
SPR has a max at 525 nm in 8 mM surfactant. After 12 hours, the solutions with 4 mM and 8 
mM TWEEN® 20 remained suspended in solution. 
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Figure 2.27 UV-Vis absorption spectra of gold nanoparticles (0.7 nM)(sold black line), and gold 
nanoparticles (0.7 nM) + TWEEN®  20 surfactant (0.04–8 mM) + RuSH (5.5 M)(dashed coloured 
lines). Gold nanoparticles (0.7 nM) with no surfactant and RuSH (5.5 M)(black bold solid line).UV-
Vis absorption spectra recorded 30 min after RuSH addition. 
 
 
In contrast to the Triton™ X-100 and TWEEN® 20 surfactants, the Zonyl® 7950 is able to 
stabilise the 9 nM gold nanoparticles with respect to aggregation, with addition of the RuSH 
complex, as shown below in Figure 2.28, and in Figure 2.24(i). Addition of ≥0.1 mM 
fluorosurfactant allowed addition of RuSH without signs of aggregation, and the SPR has a 
max at 521–522 nm in all cases.  
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Figure 2.28 UV-Vis absorption spectra of gold nanoparticles (9 nM)(sold black line), and gold 
nanoparticles (9 nM) + Zonyl®  7950 surfactant (0.1–10 mM) + RuSH (70 M)(dashed coloured 
lines). Gold nanoparticles (9 nM) with no surfactant and RuSH (70 M)(black bold solid line).UV-Vis 
absorption spectra recorded 30 min after RuSH addition. 
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Following these screening tests, nanoparticles have been coated with luminescent RuSH 
complexes with the aim of producing luminescent nanoprobes for imaging, using both 
TWEEN® 20 and Zonyl® 7950 as stabilising surfactants. Nanoparticles were synthesised at 
0.7 nM concentrations with TWEEN® 20, as they not that stable, whereas particles coated 
with Zonyl® 7950 could be made at 9 nM and remained stable for several weeks. 
 
2.6.1	Further	 Investigations	 into	Similar	Surfactants	 to	Zonyl®	7950,	with	
Gold	Nanoparticles	
The striking superiority of the commercial surfactant  Zonyl® 7950 in stabilising the particles 
and mediating the attachment of the luminescent RuSH complex has been examined further 
by testing structurally similar molecules to try to ascertain the crux of its efficacy. As Zonyl® 
7950 consists of a methyl methacrylate head group and a perfluorinated alkyl chain (Figure 
2.9), a control poly(ethylene glycol) methyl ether methacrylate moity (MMA-PEG) was 
studied to infer information about the head group, and 1H,1H,2H-perfluoro-1-decene 
(perfluorodecene) was studied to assess the role of the tail group (Figure 2.29). 
 
Figure 2.29 UV-Vis absorption spectra of 13 nm citrate gold nanoparticles (9 nM) (solid line) and 
with addition of (a) MMA-PEG (3 mM) (dashed line) and (b) perfluorodecene (5 mM) (dashed line). 
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Addition of 3 mM MMA-PEG surfactant to 9 nM citrate gold nanoparticles gives rise to a 
1 nm red-shift in the SPR, as can be seen in Figure 2.29a, and the zeta potential neutralised to 
0.0±0.2 mV (at 2 nM particles, 0.7 mM MMA-PEG), compared with −40±5 mV for uncoated 
citrate gold nanoparticles (2 nM), and thus it is evident that the MMA-PEG does bind to the 
gold particles. In contrast, addition of up to 5 mM perfluorodecene (using a stock solution of 
20% v/v perfluorodecene dissolved in isopropanol as it is immiscible with water) to the 
nanoparticles (9 nM) gives rise to no measurable shift in the SPR of the UV-Vis absorption 
spectum (Figure 2.29b), and the zeta potential remains constant, at −39±6 mV (at 2 nM 
particles, 1 mM perfluorodecene).  Thus, there is no evidence of the perfluorinated aliphatic 
chain binding to the gold nanoparticles. Immediate aggregation was observed at 0.7 nM, 
3 nM, and 9 nM concentrations of the nanoparticles, each with excess  of either 
perfluorodecene (70 mM) or MMA-PEG (40 mM) present, upon the addition of 8000 
equivalents of RuSH. These two controls demonstrate that it is likely that it is the 
methacrylate head group of the Zonyl® 7950 surfactant that binds to the gold nanoparticles, 
or at least facilitates the binding of the fluorosurfactant to the surface due to its polarity. In 
addition, the perfluorinated chains are necessary to ensure a significant negative zeta potential 
at the surface of the particles to allow addition of the RuSH complex; the poly(ethylene 
glycol) moiety cannot replace the perfuorinated chains and stabilise the sol upon addition of 
the RuSH complex and the fluorinated chain does not bind to the gold particles alone. 
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2.7	Synthesis	and	Characterisation	of	Ru‐T20‐AuNP13	
To synthesise RuSH-coated gold nanoparticles using TWEEN® 20 as a mediating surfactant, 
0.7 nM citrate gold nanoparticles (zeta potential = −41±5 mV, measured at 0.7 nM in 
deionised water) were coated with 1 mM TWEEN® 20 (zeta potential = −15±3 mV, 
measured at 0.7 nM in deionised water), and then the RuSH complex (synthesised in situ 
from the oxidatively stable thioester analogue RuSAc) was titrated into the resulting sol, up to 
9 M, as shown below in Figure 2.30. 
 
Figure 2.30 UV-Vis absorption spectra 0.7 nM 13 nm gold nanoparticles + 1 mM TWEEN® 20 
solution (black) and titration of 1–9M RuSH into the surfactant-nanoparticle mixture (red). Inset: 
SPR max vs. [RuSH] plot. 
 
 
Upon titration of RuSH into the TWEEN® 20 surfactant-coated gold nanoparticles (Figure 
2.30), it was difficult to follow a shift in the max value of the SPR band due to its convolution 
with the rising singlet MLCT band of the Ru(II) complex at 410–500 nm; initially a 1 nm red-
shift is observed, but with [RuSH] > 2 M, convolution of the SPR absorbance with the 
RuSH absorbance gives rise to a slight blue-shift in the peak position. However, a lack of 
SPR peak broadening indicates the lack of nanoparticle aggregation. The zeta potential of the 
final sol, in its non-isolated form was −31±5 mV, measured at 0.7 nM in deionised water). It 
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was not possible to isolate the RuSH/TWEEN® 20-coated nanoparticles by centrifugation, as 
the particles flocculated and aggregated. However, it was possible to isolate a sol that did not 
sediment out of suspension, from free complex and surfactant in the solution, by means of 
size-exclusion chromatography using Sephadex® G-25, as has been performed previously 
with coated 13 nm gold nanoparticles.43,90 The coated nanoparticles elute with water at the 
solvent front, through the void volume of the column, in a single pink band. The isolated 
nanoparticles dilute in the column, and the final particles, at a concentration of 0.3 nM, have a 
zeta potential of −24 mV ± 3 mV. The zeta potential decreases in magnitude upon addition of 
the neutral surfactant, as discussed earlier, and then increases to a more negative potential of 
−31±5 mV (non-isolated at 0.7 nM) and −24±3 mV (isolated at 0.3 nM) upon the addition of 
the RuSH complex. These data suggest that the RuSH complex displaces some of the neutral 
TWEEN® 20 surfactant, and the counter ions of the RuSH complex are at the extremity of 
the hydrodynamic radius, thus giving a more negative surface charge felt in the electric field 
compared with the TWEEN® 20 coated nanoparticles without complex. However the zeta 
potential is not substantial enough to stabilise the particles well by means of electrostatics, 
and following isolation by size-exclusion chromatography, the SPR of the particles drastically 
red-shifts to 535 nm (Figure 2.31),  and the DLS mean intensity distribution value increases 
significantly from 31±13 nm (94%), (3503±1256 nm (6%)) (uncoated citrate gold 
nanoparticles) to 47±22 nm (93%), (4±1 nm (7%, micelles)) (non-isolated RuSH/T20-coated 
gold nanoparticles) and to 195±97 nm (99%), (28±6 nm (1%)) (isolated Ru-T20•AuNP13) 
following size-exclusion chromatography. The DLS mean number distribution value of the 
isolated Ru-T20•AuNP13 particles is 26±19 nm, compared with 16±5 nm for uncoated 
citrate gold nanoparticles (Figure 2.31). These data indicate that the particles flocculate 
together in solution.  
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Figure 2.31 (a)UV-Vis absorption spectra of 13 nm gold nanoparticles (0.7 nM) + TWEEN® 20 
(1 mM + RuSH (9 M) (solid line), and the isolated Ru-T20•AuNP13 particles following size-
exclusion chromatography (dashed line). (b) DLS intensity distributions and (c) DLS number 
distributions of 13 nm citrate gold nanoparticles (green), gold nanoparticles (0.7 nM) mixed 
with TWEEN® 20 (1 mM) surfactant (blue), nanoparticles (0.7 nM) + TWEEN® 20 (1 mM + 
RuSH (9 M) (black) and isolated Ru-T20•AuNP13 (red). Number distributions for non-isolated 
particles with TWEEN® 20 surfactant are not shown, because they are dominated by the micellar 
peaks at 2 nm diameter. 
 
  
Despite this, the TEM image (Figure 2.32) shows the nanoparticles as discreet 13 nm 
particles, rather than agglomerated gold centres, and a colloidal dispersion of the flocs is 
maintained as opposed to their sedimentation out of suspension. 
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Figure 2.32 TEM images of isolated Ru-T20•AuNP13 particles air-dried onto grids. 
 
 
The isolated Ru-T20•AuNP13 sol was analysed by inductively-coupled plasma optical 
emission spectroscopy (ICP-OES) against calibration standards to find the Au:Ru ratio to be 
72:1 (atoms), which equates to ca. 1400 Ru complexes per nanoparticle, assuming each 
13 nm particle contains 105 gold atoms (see Appendix 2.1).76 This gives the RuSH complex a 
molecular footprint of 0.6 nm × 0.6 nm when bound to the nanoparticle surface, which is 
reasonable for the given complex. This footprint is the surface-area per complex, but it is 
important to remember that there are co-coating moieties, i.e. surfactant molecules, also 
within this area. It must also be noted, that this calculation makes several assumptions: firstly 
that all the nanoparticles in the solution are 13 nm in diameter, whereas they actually vary by 
at least 10%,  secondly that all the Ru(II) complexes detected in the isolated nanoparticle 
samples are bound to the nanoparticle in a single monolayer, with no multi-layers formed 
through disulphide bond formation, and thirdly it uses the spherical cluster approximation91 to 
estimate the number of atoms per nanoparticle (this does not take into account the fact that 
hard spheres cannot pack to fill space exactly). Therefore, these accumulated errors render the 
calculated surface coverages throughout this thesis as crude approximations, and the absolute 
values are not overly meaningful. However, the order of magnitude of the values is useful to 
assess whether the isolated samples have sensible concentrations of complex bound to the 
surface, and the relative numbers between different nanoparticles are informative. 
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2.8	Synthesis	and	Characterisation	of	Ru‐Z•AuNP13	
13 nm gold nanoparticles were labelled with RuSH (synthesised in situ from the oxidatively 
stable thioester analogue RuSAc) using Zonyl® 7950 as a pre-coating surfactant to prevent 
the aggregation of the nanoparticles upon attachment of cationic lumiphores. Following the 
preliminary screening (Section 2.6), gold nanoparticles coated with Zonyl® 7950 appear to be 
very resistant to aggregation upon addition of RuSH, and nanoparticle concentrations of 9 nM 
can be labelled. Citrate gold nanoparticles (9 nM) (zeta potential = −40 mV ± 5 mV, at 2 nM) 
were coated with fluorosurfactant (1.2 mg mL−1, ca. 1 mM), and then the RuSH complex was 
titrated into the resulting sol, up to 70 M, as shown in Figure 2.33. 
 
Figure 2.33 UV-Vis absorption spectra of 13 nm citrate gold nanoparticles (9 nM) (black bold line), 
+ Zonyl® 7950 (1 mM) (black dashed), + 1–70 uM RuSH (red), and isolated Ru-Z•AuNP13 (blue). 
Supernatant following the first centrifugation shown in grey. 
 
 
Upon addition of the Zonyl ® 7950 surfactant, the SPR red-shifted by 1 nm, to 521 nm, as 
previously observed in Section 2.5 (Figure 2.21), but following the titration of RuSH into the 
surfactant-coated gold nanoparticles, no shift in the SPR peak max is observed, which 
indicates that the dielectric constant at the surface does not change significantly. However, the 
retention of the SPR peak indicates the lack of nanoparticle aggregation. The particles cannot 
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be isolated by size-exclusion chromatography as the fluorosurfactant transports the unbound 
RuSH complex through the void volume of the stationary phase with the functionalised 
nanoparticles, presumably due to the formation of micelles, and thus separation of the 
particles from unbound material does not occur (See Appendix 3). The particles were isolated 
by three repeats of centrifugation, decantation of the supernatant, and resuspension in 
deionised water, at 12,000 g for 15 min, to render 9 nM Ru-Z•AuNP13 (zeta potential = 
−48±2 mV), with an SPR peak max = 522 nm. Excess RuSH complex is clearly removed 
from the isolated Ru-Z•AuNP13 nanoparticles, as can be seen in the UV-Vis absorption 
spectrum of the first supernatant removed in the centrifugation process to isolate 
Ru-Z•AuNP13 (Figure 2.33, grey line). Isolation of the particles by centrifugation, as 
opposed to size-exclusion chromatography is advantageous as the final volume of the 
colloidal suspension can be controlled to vary the particle concentration, and high 
concentration particles can be obtained; column chromatography always leads to dilution of 
the particles upon isolation from the free species in solution. As a control Zonyl® 7950-
coated gold nanoparticles were synthesised under identical conditions, without the RuSH 
complex, and purified by centrifugation to give Z•AuNP13 (zeta potential = −61± 4mV, at 
2 nM), also with an SPR peak with max = 522 nm. The difference in the surface charge with 
the presence of the RuSH complex is evident; the zeta potential is less negative as the RuSH 
complex displaces some of the electronegative fluorosurfactant. However, fluorosurfactant 
still remains, most likely packed between the RuSH complexes, maintaining the electrostatic 
stability of the resulting Ru-Z•AuNP13 nanoparticles. 
 
The uncoated 13 nm citrate gold nanoparticles, isolated Z•AuNP13 and isolated 
Ru-Z•AuNP13 have been characterised by DLS to examine the hydrodynamic diameters of 
the gold nanoparticles coated with the different surface environments, as shown in Figure 
2.34. 
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Figure 2.34 (a) DLS intensity distributions and (b) DLS number distributions, of 2 nM citrate gold 
nanoparticles (solid line), 2 nM Z•AuNP13 (dashed line) and 2 nM Ru- Z•AuNP13 nanoparticles 
(bold solid line).(c) TEM image of Ru- Z•AuNP13particles. 
 
 
The measurements were all performed on 2 nM suspensions of particles, and a peak at 
ca.35 nm was observed in each case in the mean intensity distribution, with citrate 
nanoparticles having a mean intensity diameter of 29±12 nm (86%), (see section 2.3, Figure 
2.17), the Z•AuNP13 of 39±15 nm (100%) and Ru-Z•AuNP13 of 38±18 nm (100%). These 
equate to average number distributions of 14±4 nm, 20±6 nm, and 17±5 nm for citrate gold 
nanoparticles, Z•AuNP13, and Ru-Z•AuNP13 respectively. A 30% increase in the mean 
intensity distribution hydrodynamic diameter is observed when the fluorinated surfactant 
binds to the surface of the gold nanoparticles, as discussed in Section 2.5 (Figure 2.22), but no 
further increase in diameter is observed upon addition of RuSH. Thus, there is no evidence of 
nanoparticle aggregation, which is consistent with the large negative zeta potential of 
−48±2 mV. The TEM image of Ru-Z•AuNP13 confirms the uniformity of the nanoparticles 
(Figure 2.34c). 
 
In order to reveal more information about the surface environment surrounding the gold 
nanoparticles in Ru-Z•AuNP13, Z•AuNP13, and bare citrate-coated gold nanoparticles, 
heavy metal staining techniques were employed, using phosphotungstic acid (PTA), as can be 
seen in Figure 2.35. The gold nanoparticle cores are easily visualised by electron microscopy 
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(as can be seen in Figure 2.35c), as the gold nucleations are electron dense and absorb 
electrons strongly, whereas any surface-coating made up of predominantly low-Z atoms will 
be transparent to the electron beam. Heavy metal staining of organic matter is often employed 
to incorporate electron-opaque heavy atoms into the matrix to enhance contrast in electron 
microscopy. Samples can be stained either ‘positively’, i.e. the heavy metal stain is 
incorporated into the material of interest, or ‘negatively’, in which the background is stained, 
leaving the material of interest as transparent sections on the grid against the dark electron-
dense background.92,93 When using PTA as a heavy metal stain, it is the phosphotungstate 
anions that provide the constrast, which is important when considering the interaction upon 
positive staining. Negatively stained images (Figures 2.35a, 2.35c, and 2.35e) are not easy to 
analyse because achieving homogenous staining of the background without artifacts is 
difficult. However, coronas of low contrast do appear to surround the Ru-Z•AuNP13 (Figure 
2.35a), indicating that there is a surface coating present. Similar features can be seen in Figure 
2.35c for Z•AuNP13, although in this instance it is less clear. However, this does not appear 
to be visible for the bare citrate-coated gold nanoparticles. 
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Figure 2.35 Stained TEM images of (a–b) Ru-Z•AuNP13, (c–d) Z•AuNP13, and (e–f) citrate gold 
nanoparticles. Samples in (a), (c), and (e) are negatively stained with phosphotungstic acid, and 
samples in (b), (d), and (f) are positively stained with phoshotungstic acid.  
 
 
The nanoparticles positively stained with PTA look no different to unstained samples for the 
bare citrate-coated nanoparticles (Figure 2.35f) and the Z•AuNP13 (Figure 2.35d), whereas a 
grey corona is visible surrounding the gold nanoparticle cores in Ru-Z•AuNP13, Figure 
(Figure 2.35b). This is unsurprising because phototungstate ions tend to replace anions in 
(a) (b)
(d)(c)
(f)(e)
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biological materials,94 and can thus exchange with the RuSH counter ions in Ru-Z•AuNP13, 
to give the surface-coating electron contrast, whereas this does not occur in Z•AuNP13. 
Ru-Z•AuNP13 were analysed by X-ray photoelectron spectroscopy (XPS), along with citrate 
gold nanoparticles and Z•AuNP13 in order to elucidate more information about the binding 
environments at the gold surface in each case (Figure 2.36), and peak fitting was performed 
by Dr Marc Walker, University of Warwick. 
 
 
Figure 2.36 XPS data of citrate gold nanoparticles (a and d), Z•AuNP13 (b and e) and  
Ru-Z•AuNP13 (c and f) with the raw data (open circles) the summation fitting envelope (solid black 
line) and deconvoluted fitting peaks (dashed lines) Fitting curves for Au 4f peaks for Au0shown in 
red,95and for shifted Au 4f environments shown in green and blue. Fitting curves for C 1s peaks shown 
in grey, and for Ru 3d peaks shown in orange.  
 
 
A single Au 4f core level component, with 4f7/2 and 4f5/2 binding energies at 84.00 eV and 
87.68 eV respectively, is observed for the citrate gold nanoparticles (Figure 2.36a), 
corresponding to the sole presence of  to Au(0),95 whereas a striking difference is observed 
upon the addition of the Zonyl® 7950 surfactant to the nanoparticles (Figure 2.36b); two 
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different 4f core level components are evident upon XPS analysis of Z•AuNP13, with the 
Au(0) peaks at 84.31 eV (4f7/2) and 87.97 eV (4f5/2) (63 %) and a second state (37 %) shifted 
to an increased binding energy by +0.95 eV, at 85.27 eV (4f7/2) and 88.91 eV (4f5/2). This is 
indicative of oxidised Au(I) present at the surface, due to the binding of the fluorosurfactant 
to the gold nanoparticles.96 Whether this is attributed to the methacrylate head group of the 
fluorosurfactant, or the perfluorinated chain is unclear from these data, as both O and F are 
very electronegative species which could interact with surface gold atoms. The displacement 
of the citrate anions by the Zonyl® 7950 surfactant is also evident in the C 1s region (Figures 
2.35d and 2.35e). In Figure 2.36d there are three distinct carbon states, at 285.88 eV, 
287.21 eV, and 289.29 eV which are likely to be the C–H, and different CO environments, 
respectively,95 present in the citrate or oxidised citrate product capping the particles.6,7 
However, these peaks are absent upon addition of the fluorosurfactant, following the 
displacement of the citrate ions, and the isolated Z•AuNP13 particles have C 1s peaks with 
much higher binding energies, i.e. at 292.43 eV and 294.60 eV (Figure 2.36e), due to the C–F 
carbon 1s states,95 and a strong F 1s peak, with a binding energy of 689.41 eV (see survey 
scan, Appendix 4). Interestingly, the Au 4f7/2 and 4f5/2 binding energies of the isolated 
Ru-Z•AuNP13 nanoparticles (Figure 2.36c) differ significantly to the particles coated in the 
surfactant alone (Figure 2.36b), evidencing the ability of the RuSH complex to competitively 
bind to the gold by well-known S–Au chemistry, and displace the Zonyl® 7950 at the gold 
surface. The Au 4f7/2 and 4f5/2 peaks do not too fit well with the single Au(0) component 
(peaks at 84.15 eV (4f7/2) and 87.82 eV (4f7/2)), rather with a second Au state (9 %) at higher 
binding energy, shifted by +0.39 eV peaks at 84.54 eV (4f7/2) and 88.21 eV (4f7/2)). However, 
the Au(I) peaks that were present in the Au 4f region (shifted by +0.95 eV from Au(0) for 
Z•AuNP13 are no longer present for Ru-Z•AuNP13. A Au 4f7/2 binding energy of 84.54 eV 
is consistent with gold-thiol binding at the surface.97 The overall Au 4f region is similar to 
that observed for previously reported glutathione-capped nanoclusters (< 2nm)98 and 
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dodecanethiol-capped 1–4 nm gold nanoparticles.99 Although, by inspection of the Au 4f 
region of the XPS data, the fluorosurfactant does not appear to be bound to the surface of the 
gold nanoparticles in Ru-Z•AuNP13, it is still present as can be seen in the C 1s (Figure 
2.36f) and the F 1s (Appendix 4) region; the C–F C 1s peaks remain at 294.50 eV and 
292.49 eV  (Figure 5f) and the F 1s peak is present at 689.34 eV (Appendix 4). This is 
commensurate with the large negative zeta potential that is observed for Ru-Z•AuNP13. 
Evidence of the RuSH complex can be seen with a new C 1s peak at 285.91 eV, and Ru 3d5/2 
and 3d3/2 peaks are evident at 281.42 eV and 285.59 eV respectively (Figure 2.36f), which are 
consistent with XPS data reported by Agnès et al. for Ru(bpy)32+ complexes grafted onto 
diamond.100  
 
Ru-Z•AuNP13 were analysed by ICP-OES to give the atomic Au:Ru ratio of 63:1. This ratio 
equates to ca. 1600 Ru complexes per nanoparticle (see Appendix 2.2), which is very similar 
to the ratio with the TWEEN® 20 surfactant (1400 complexes per nanoparticle). A 
corresponding molecular footprint of 0.6 nm × 0.6 nm is calculated for the RuSH complex, 
when bound to the Ru-Z•AuNP13 nanoparticles, which is the same as that observed for 
Ru-T20•AuNP13 (Section 2.7). Therefore the different surfactants used do not significantly 
alter the packing density of the ruthenium(II) complex on the gold nanoparticle surface.  
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2.9	 Photophysical	 Characterisation	 of	 Ru‐T20•AuNP13	 and	
Ru‐Z•AuNP13	
The photophysical properties of the isolated Ru-T20•AuNP13 and Ru-Z•AuNP13 
dispersions were characterised, as presented in Figure 2.37.  
 
Figure 2.37 UV-Vis absorption spectrum (solid line), excitation spectrum, em = 630 nm (dashed line) 
and steady-state emission spectrum, exc = 450 nm (bold solid line) of (a) Ru-T20•AuNP13 (0.3 nM) 
and Ru-Z•AuNP13 (1 nM). All spectra corrected for instrument response. 
 
 
Upon excitation at 450 nm, both Ru-T20•AuNP13 and Ru-Z•AuNP13 exhibit broad red 
emission with max = 655 nm and 640 nm, respectively. The UV-Vis spectra are dominated by 
the SPR of the colloid in each case, and the excitation spectra of both Ru-T20•AuNP13 and 
Ru-Z•AuNP13, measured at em = 630 nm, resemble the UV-Vis absorption spectrum and 
excitation spectrum of the free RuSAc (Section 2.2.2, Figures 2.14 and 2.15). The max of the 
Ru-T20•AuNP13 luminescence is red-shifted by 5 nm, with respect to the free RuSAc 
complex emission in 1 % CH3CN, water (emission peak max value at 650 nm), whereas that 
of Ru-Z•AuNP13 is blue-shifted by 10 nm. The photophysical data of the colloids are 
summarised below in Table 2.4.  
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Table 2.4 Summary of the photophysical properties of gold nanoparticles coated with the RuSH 
complex, with control solution studies.
 Φ / %a τ / nsb λmax / nmc
Ru-T20•AuNP13 
 
-d 
 
 
305±10% 
[375±10%]  
 
655 
 
 
Ru-Z•AuNP13 4±1e 
 
340±10%
[690±10%] 
 
640 
 
RuSAc 
in 1% CH3CN/H2O 
2.0±0.5 
 
260 
[325] 
 
650 
 
9 M RuSAc, 1 mM 
TWEEN® 20 
in 1% CH3CN/H2O 
 
2.5±0.5 
 
 
340 
[405] 
 
660 
 
 
9 M RuSAc, 1 mM 
Zonyl® 7950 
in 1% CH3CN/H2O 
 
3.0±0.5 
 
 
405 
[610] 
 
635 
 
 
a aerated Φs measured using an integrating sphere. 
b lifetimes measured in aerated solutions, deaerated measurements shown in square brackets. Errors estimated as 
±6% by comparison on 3-5 different samples, unless otherwise stated. 
c error estimated as ±3 nm. 
d Φ measurement not possible due to low signal intensity at such low lumiphore concentrations. 
e Φ measured of nanoparticles measured using a solution of uncoated citrate gold nanoparticles as a reference 
solution with the integrating sphere. A calibrated  neutral density filter was also employed due to low signal. 
 
 
For comparison, the steady-state luminescence was measured for the free RuSAc complex 
(9 M) in 1 % CH3CN, water with 1 mM TWEEN® 20 surfactant, and the max value of the 
emission peak is at 660 nm. This 10 nm red-shift in the emission peak suggests that the 
TWEEN® 20 surfactant stabilises the charge-separated MLCT excited state, and this appears 
to occur on the Ru-T20•AuNP13 nanoparticle surface as well, although to a lesser extent, 
presumably because the complex is surrounded with less surfactant. In contrast, the 
max=635 nm when RuSAc complex (9 M) in 1 % CH3CN, water with 1 mM Zonyl® 7950 
surfactant, i.e. blue-shifted by 15nm,  which suggests that the fluorosurfactant presents a non-
polar environment to the Ru(II) complex, commensurate with its perfluronated alkyl chains, 
destabilising the MLCT state. This same effect is also seen on the Ru-Z•AuNP13 
nanoparticles, again to lesser extent, similar to TWEEN® 20.   
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The observed luminescence lifetime of the isolated Ru-T20•AuNP13 colloid, with excitation 
at 445 nm and emission collected at  630 nm, is 305 ns ±10 % (aerated) and 375 nm ±10 % 
(deaerated), which is slightly increased (by ca. 15%) from that of the free complex in 
1 % CH3CN, water (260 ns ±6 % (aerated), 325 ns ±6 % (deaerated)). Time-resolved 
luminescence was also studied for the free RuSAc complex (9 M) in 1 % CH3CN, water 
with 1 mM TWEEN® 20 surfactant, and luminescence lifetimes of 340 ns ±6 % (aerated) and 
405 ns ±6 % (deaerated) were observed. These lifetimes are ca. 10% longer than 
Ru-T20•AuNP13, which is probably due to the RuSH interacting with less surfactant when 
bound on the nanoparticle surface in Ru-T20•AuNP13, than in a solution of 100 equivalents 
surfactant. However, the increase is barely significant given the errors in the lifetimes. An 
increase in the lifetime of the luminescence excited state of the ruthenium(II) complex in the 
presence of TWEEN® 20 surfactant, accompanied by an increase in the Φ (the free complex 
in an aqueous environment has a  of 2.0±0.5%, whereas the control solution of RuSH 
complex (9 M) in 1 % CH3CN, water with 1 mM TWEEN® 20 surfactant, has a  
2.5±0.5%), is indicative of a reduction in the non-radiative decay rate from the excited state. 
This appears to be due to the surfactant rather than the gold nanoparticle on Ru-
T20•AuNP13. (If an increase in the radiative rate of decay from the excited state was being 
observed, then an increase in Φ would be accompanied by a decrease in the lifetime of the 
excited state). Unfortunately, it was not possible to measure the  of the ruthenium(II) 
complex on the Ru-T20•AuNP13 particles due to the low signal intensity at such low 
concentrations.  
 
Luminescence lifetimes (em nm, em = 630 nm) of 340 ns ±10 %  (aerated) and 690 ns 
±10 %  (deaerated) were observed for isolated Ru-Z•AuNP13, which are increased by 30% 
(aerated) and 115% (degassed) with respect to the free RuSAc complex in water, and similar 
to that of the complex mixed with fluorosurfactant in solution. In contrast to the 
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Ru-T20•AuNP13 particles, however, Ru-Z•AuNP13 appear to be far more sensitive to 
molecular oxygen. An increase in the observed luminescence lifetimes is again attributed to 
the surfactant reducing the non-radiative decay rates of the Ru(II) complex excited state, 
which is confirmed by an increase in the  in solution to 3.0±0.5% upon addition of 
fluorosurfactant (from 2.0±0.5% RuSAc, aqueous environment). The presence of the 
surfactant may increase the rigidity of the lumiphore, thus reducing the access to vibrational 
states of the ground state to decay the excited state non-radiatively. The  of the 
Ru-Z•AuNP13 nanoparticles was measured as 4±1 %, using uncoated gold nanoparticles as 
the reference material, so that the absorbance of the Ru(II) complex only is taken into account 
when measuring the . This value is similar to that of the Ru(II) complex / fluorosurfactant 
mixture in solution, which is consistent with the liftetime data, and again demonstrates that 
luminescence quenching is not being induced by attachment of RuSH to the gold 
nanoparticles. 
 
As a control study, to further verify that the frequently reported quenching of lumiphores by 
gold nanoparticles,31,39,41,48-50 was not being observed, citrate gold nanoparticles were titrated 
into a mixture of the RuSH complex in 1 % CH3CN, water with 0.04 mM Zonyl® 7950, and 
the steady-state luminescence spectra were recorded, corrected for instrument response and 
integrated. The integrated luminescence peak areas were plotted against [gold nanoparticles] 
to analyse the signal intensity upon addition of the nanoparticles, as shown in Figure 2.38. 
The concentrations for this experiment were kept low to eliminate internal filtering effects of 
the nanoparticles from significantly affecting the results.  
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Figure 2.38 The change in luminescence intensity of RuSH (0.15 mM) with Zonyl® 7950 (0.04 mM) 
in 1% CH3CN, water, upon the addition of 13 nm citrate-stabilised gold nanoparticles. exc = 450 nm. 
Spectra were corrected for instrument response. 
 
 
As can be seen, the luminescence intensity remained constant (± 10%) across the whole 
titration, and even when there was an excess of gold nanoparticles in the solution (assuming 
binding saturation occurs at 1600 RuSH per nanoparticle, from the ICP-OES data) the 
emission intensity remained constant. The luminescent lifetime was measured at the 
beginning (365 ns ±10 %) and end of the titration (375 ns ±10 %), at 630 nm, and also 
remained constant within error. Thus it is evident that we do not observe quenching effects 
upon the addition of gold nanoparticles to the complex/fluorosurfactant mixture. 
	
2.10	Conclusion	
In conclusion, the interaction of three commercially available surfactants, Triton™ X-100, 
TWEEN® 20 and Zonyl® 7950  with citrate-stabilised gold nanoparticles has been reported, 
and it has been determined that TWEEN® 20 can be used to produce low concentration 
flocculated particles in solution, coated in the RuSH complex, whereas Zonyl® 7950 can 
effectively facilitate the luminescent labelling of the particles at high nanomolar 
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concentrations with a dicationic surface-active ruthenium polypyridyl complex in a pre-
coating process. Although the TWEEN® 20 is able to mediate RuSH attachment to gold 
nanoparticles to some degree, the resulting colloid has limited applications for imaging due to 
its low concentration and formation of flocs. Whilst the cellular uptake of aggregates of 
particles is possible,70 this renders the dose and uptake mechanism of the particles difficult to 
control. The Zonyl® 7950 not only mediates the functionalisation by means of stable particle 
formation, but also increases the  and thus the brightness of the RuSH complex. Although 
there are many references in the literature to the undesired quenching effects of lumiphores by 
gold nanoparticles,31,39,41,48-50,57  this is not observed with the tailor-made surface-active 
ruthenium polypyridyl complex RuSH. The lack of quenching is attributed to the design of 
RuSH, in which the lumiphore centre is distanced from the gold surface by a hexyl spacer-
group. 
 
By employing the Zonyl® 7950 fluorosurfactant in the nanoparticle coating process, RuSH 
complex can be used to label gold nanoparticles efficiently with multiple lumiphore tags to 
produce bright luminescent nanoprobes with good colloidal stability at 9 nM concentrations. 
These nanoprobes have great potential as imaging probes, and furthermore, new applications 
may be envisaged in the development of new nanomaterials in which the properties are 
manipulated by the surface-grafted transition metal complex. 
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2.12	Experimental	
2.12.1	General	Synthesis	
All precursors to these reactions were purchased from Sigma-Aldrich. The TWEEN® 20, 
TritonTM X-100, Zonyl® 7950, poly(ethylene glycol) methyl ether methacrylate (av. MW = 
500), and 1H,1H,2H-perfluoro-1-decene were purchased from Sigma-Aldrich and used 
without further purification. 
 
Zonyl® 7950, which is a commercial surfactant product containing a mixture of species 
within the formula, was characterised by GC-MS and NMR. 1H NMR (300 MHz, d6-DMSO): 
δH = 3.77 (septuplet, 6H, H–C of isopropanol), 3.63 (s (b), 2H, CH2 of fluorosurfactant), 2.94 
(s (b), 2H, CH2 of fluorosurfactant), 2.68–2.54 (m, 1.5H), 2.51 (s, 0.5H), 2.45–2.17 (m, 2H), 
1.01 (d (3JHH = 6.3 Hz), 36H, CH3– of isopropanol). 13C{1H} PENDANT (150 MHz, d6-
DMSO): δC = 175 (C=O of fluorosurfactant), 117/114/110/107 (CF2s of fluorosurfactant), 62 
(CH of isopropanol), 56/49 ( CH2 of fluorosurfactant), 24 (CH3 of isopropanol). GC-MS 
reveals two peaks in the total ion current chromatogram, which correspond to m/z 452 and m/z 
552, with relative intensity integrals of 14.5 and 11.5 respectively. Thus, an average 
molecular weight of m/z 500 is approximated. 1H NMR reveals that the surfactant is 
formulated with isopropanol, and by integration of the resonance due to the six methyl 
protons per isopropanol molecule, relative to one of the fluorosurfactant CH2 proton 
resonances, the ratio of fluorosurfactant: isopropanol is estimated as 6:1. Thus, 1 mole of 
fluorosurfactant = fluorosurfactant molecule+6 isopropanols, with a total molecular mass of 
500 + (6×60)  900.  Therefore, 1 mg mL−1 = (1/900)/10−3 = 1 mM.   
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Synthesis of 4,4’-dihydroxy-2,2’-bipyridine 
N N
O O
N N
HO OH
AcOH
HBr
3 3
5
6
5
6  
4,4’-dihydroxy-2,2’-bipyridine was synthesized according to the method of Gorman and 
coworkers.101 To a solution of 4,4’-dimethoxy-2,2’-bipyridine (3.055g, 14.13 mmol) in glacial 
acetic acid (180 mL) was added HBr (aq) (25 mL , 48 wt % in water, 146 mmol). The mixture 
was refluxed overnight at 140 oC under N2 (g).  The mixture was allowed to cool and the 
solvent was removed in vacuo to render a white solid. The residue was dissolved in water 
(100 mL) and neutralised to pH 7 by adding aqueous ammonium hydroxide, and a white 
precipitate formed. The white solid (2.425 g, 12.89 mmol, 91 % yield) was filtered and dried, 
and used in the next step without further purification. 1H NMR (300 MHz, NaOD/D2O): δH = 
7.74 (s, 1H, OH), 7.38 (d, 2H, 3JH5= 5.9 Hz, H6), 6.34 (d, 2H, 4JH5 = 2.4 Hz, H3), 5.85 (dd, 
2H, 3JH6 = 5.9 Hz, 4JH3= 2.4 Hz, H5). EI-MS(+): m/z 188.1 [M]+.. IR υmax (cm−1): 3209 (C–H), 
3059 (C–H), 2760 b (O–H, H-bonded), 1594 (C–Cring/C–Nring), 1523, 1475, 1393, 1218. Data 
agree with previously reported studies75,101 and thus no further characterisation was 
performed. 
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Synthesis of BpyHex 
 
Method adopted from Dr Shiva Farabi.75 To a solution of 4,4′-dihydroxybipyridine (2.03 g, 
10.8 mmol) in anhydrous DMF was added NaH (5.00 g, 125 mmol, 60 % w/w in mineral oil), 
and the white suspension was stirred at 60 °C under nitrogen for 1 hr. 6-bromohex-1-ene 
(8.06 g, 49.4 mmol) was added dropwise, and the reaction mixture was heated at 60 °C for 20 
h to render a pale yellow/brown solution. The reaction was cooled to room temperature and 
the NaH was quenched by adding ice-cold ethanol (150 mL). The solvent was removed in 
vacuo and the pale brown residue was extracted with CH2Cl2/H2O and dried over MgSO4. The 
CH2Cl2 was removed in vacuo and the crude product was purified by recrystallisation from 
ethanol to yield BpyHex (2.32 g, 6.58 mmol, 61 % yield) as a crystalline white solid. 1H 
NMR (400 MHz, CDCl3): δH = 8.45 (d, 2H, 3JH5 = 5.7 Hz, H6), 7.94 (d, 2H, 4JH5 = 2.5 Hz, H3), 
6.82 (dd, 2H, 3JH6 = 5.7 Hz, 4JH3 = 2.6 Hz, H5), 5.91–5.74 (m, 2H, 3JH12 = 17.1 Hz, 3JH13 = 10.3 
Hz, 3JH10 = 6.6 Hz, H11), 5.09–5.00 (m, 2H, 3JH11 = 17.1 Hz, 2JH13 = 2.0 Hz, 4JH10 = 1.5 Hz, 
H12), 5.00–4.94 (m, 2H, 3JH11 = 10.3 Hz, 2JH12 = 2.0 Hz, 4JH10 = 1.3 Hz, H13), 4.14 (t, 4H, 3JH8 
= 6.5 Hz, H7), 2.20–2.07 (m, 4H, H10), 1.90–1.78 (m, 4H, H8), 1.65–1.53 (m, 4H, H9). 13C 
NMR (100 MHz, CDCl3): δC = 166.1 (C2), 157.9 (C4), 150.1 (C6), 138.3 (C11), 114.9 (C12), 
111.3 (C5), 106.7 (C3), 67.8 (C7), 33.3 (C10), 28.4 (C8), 25.2 (C9). TOF ES-MS(+) m/z: 375.2 
[M+Na]+·, 353.2 [M+H]+·. IR υmax (cm−1): 3070 (C–H), 3008 (C–H), 2952 (C–H), 2920 (C–H), 
1577 (C–Cring/C–Nring), 1558, 1456, 1297, 1245, 1003. 
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Synthesis of Ru(bpy)2Cl2 
 
Method adopted from Dr Shiva Farabi75 2-methoxyethanol (200 mL) was purged with 
nitrogen for 15 min and Ru(COD)Cl2 (dichloro(1,5-cyclooctadiene)ruthenium (II) polymer) 
(501.0 mg, 1.79 mmol) and LiCl (593.5 mg, 14.0 mmol) were added.  The suspension was 
stirred at reflux for 30 min under nitrogen.  2,2′-bipyridine (547.8 mg, 3.51 mmol, 1.96 eq) 
was dissolved in 2-methoxyethanol (50 ml) and added dropwise to the refluxing mixture, over 
15 min.  The solution was left to reflux overnight to give a dark purple solution.  This was 
cooled to room temperature under nitrogen, and the solvent was removed in vacuo to render a 
dark oil.  This oil was added to cold, fast-stirring acetone (100 ml) in an ice-bath and left to 
stir for 1 hr, and then placed in the fridge overnight to precipitate.  The black solid was 
filtered, and washed with water and diethyl ether to give [Ru(bpy)2Cl2].2H2O (385.8 mg, 
0.741 mmol, 41% yield) as a dark green solid, which streaks purple upon scratching. 1H NMR 
(300 MHz, DMSO): δH = 9.97 (d, 2H, 3JHc = 4.7 Hz, Hb), 8.64 / 8.49 (d, 2H, 3JHd/Hi = 7.8 Hz, 
He/Hh), 8.07 (m, 2H, Hd), 7.77 (m, 2H, Hc), 7.68 (m, 2H, Hi), 7.51 (d, 2H, 3JHj = 4.6 Hz, Hk), 
7.10 (m, 2H, Hj). 13C NMR (100 MHz, DMSO): δC = 160.1/158.1 (Cf/Cg), 153.1 (Cb), 151.9 
(Ck), 134.5 (Cd), 133.2 (Ci), 125.3/125.2 (Cc/Cj), 122.8/122.4 (Ce/Ch). TOF ES-MS(+): m/z 
523.0 [M+K]+·, 507.0 [M+Na]+·, 481.1 [Ru(bpy)2(OCH3)Cl+H]+·, 449.0 [M−Cl]+·. TOF LD-
MS(+): m/z 484.2 [M]+·, 449.4 [M−Cl]+·, 413.5 [M−2Cl]+·, 328.7 [M−bpy]+·, 293.2 
[Ru(bpy)Cl]+·. UV-VIS (DCM) λmax [nm]: 555, 378, 300. IR υmax (cm−1): 3100 (C–H), 3069 
(C–H), 3029 (C–H), 1613(C–Cring/C–Nring), 1601(C–Cring/C–Nring), 1460, 1442, 1418, 1308, 
1265.  
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Synthesis of RuHex76 
 
Ru(bpy)2Cl2.2H2O (107.7 mg, 0.207 mmol) and BpyHex (119.1 mg, 0.338 mmol) were 
heated to reflux in ethanol (10 mL) for 17 hr under nitrogen to give a deep red solution.  This 
was cooled to room temperature and was concentrated to 3 mL in vacuo.  A saturated aqueous 
solution of NH4PF6 (3.5 mL) was added, followed by H2O (7 mL), and a red precipitate was 
formed.  The flask was put in the fridge for 30 min, and the red solid was filtered under 
suction, washed with water and diethyl ether to yield RuHex (131.6 mg, 0.125 mmol, 60 % 
yield) as a red solid. 1H NMR (400 MHz, CD3CN): δH = 8.47 (2×d, 4H, 3JHd/Hi = 8.3 Hz, 
He/Hh), 8.06–7.99 (m, 4H, Hd/Hi), 7.97 (d, 2H, 4JH5 = 2.5f Hz, H3), 7.81/7.71 (2×d, 4H, 
3JHc/Hj= 5.5 Hz, Hb/Hk), 7.43–7.39/7.38–7.33 (2×m, 4H, Hc/Hj), 7.41 (d, 2H, 3JH5 = 6.5 Hz, 
H6), 6.90 (dd, 2H, 3JH6 = 6.5 Hz, 4JH3 = 2.5 Hz, H5), 5.86 (m, 2H, 3JH12 = 17.1 Hz, 3JH13 = 
10.3 Hz, 3JH10 = 6.6 Hz, H11), 5.05 (m, 2H, 3JH11 = 17.1 Hz, H12), 4.97 (m, 2H, 3J11 = 
10.3 Hz, H13), 4.19 (t, 4H, 3JH8 = 6.5 Hz, H7), 2.17–2.09 (m, 4H, H10), 1.85–1.77 (m, 4H, H8), 
1.61–1.51 (m, 4H, H9). 13C NMR (100 MHz, CD3CN): δC = 153.0 (C6), 152.7/152.5 (Cb/Ck), 
139.5 (C11), 138.3 (Cd/Ci), 128.3 (Cc/Cj), 125.0 (Ce/Ch), 115.3 (C12), 115.0 (C5), 112.3 (C3), 
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70.5 (C7), 33.8 (C10), 28.7 (C8), 25.7 (C9). TOF ES-MS(+): m/z 911.1 [M−PF6]+, 383.2 
[M−2PF6]2+. IR υmax (cm−1): 2935 (C–H), 2867 (C–H), 1612 (C–Cring/C–Nring), 1491, 1465, 
1445, 1337, 1314, 1219.  
 
Synthesis of RuSAc76 
 
A solution of thioacetic acid (100 mg, 1.31 mmol) and ABCN (1,1′-azobiscyclohexane 
carbonitrile) (120 mg, 0.49 mmol) in dry THF (2 mL) was heated at 60 °C and degassed 
under nitrogen for 30 min.  RuHex (105.9 mg, 0.100 mmol) was dissolved in THF (4 mL), 
and added dropwise to the solution.  The double bond disappearance was monitored by proton 
NMR. The reaction was stirred at 60 °C followed by addition of one portion of ABCN 
(120 mg, 0.49 mmol) and thioacetic acid (100 mg, 1.31 mmol) after 15 hr, and another 
portion of ABCN (120 mg, 0.49 mmol) and thioacetic acid (100 mg, 1.31 mmol) after 24 hr.  
After a total of 40 hr stirring the reaction was pushed to completion and the ABCN was 
quenched with saturated NaHCO3 solution (10 mL).  The THF was removed in vacuo, and the 
residue was extracted in CH2Cl2/H2O, washed with brine, and dried over MgSO4. The CH2Cl2 
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was removed in vacuo and the solid was filtered under suction, and washed with a copious 
amount of hexane and diethyl ether to yield RuSAc (52.9 mg, 0.044 mmol, 43.8 % yield) as a 
red solid.1H NMR (400 MHz, CD3CN): δH = 8.47 (2×d, 4H, 3JHd/Hi = 8.1 Hz, He/Hh), 8.06–
7.99 (m, 4H, Hd/Hi), 7.97 (d, 2H, 4JH5 = 2.5 Hz, H3), 7.81/7.71 (2×d, 4H, 3JHc/Hj = 5.5 Hz, 
Hb/Hk), 7.43–7.39/7.37–7.33 (2×m, 4H, Hc/Hj), 7.41 (d, 2H, 3JH5 = 6.5 Hz, H6), 6.90 (dd, 2H, 
3JH6 = 6.5 Hz, 4JH3 = 2.5 Hz, H5), 4.18 (t, 4H, 3JH8 = 6.5 Hz, H7), 2.85 (t, 4H, 3JH11 = 7.3 Hz, 
H12), 2.27 (s, 6H, H15), 1.84–1.76 (m, 4H, H8), 1.61–1.53 (m, 4H, H11), 1.52–1.38 (m, 8H, 
H9/H10).13C NMR (100 MHz, CDCl3): δC = 153.0 (C6), 152.7/152.5 (Cb/Ck), 138.3 (Cd/Ci), 
128.5 (Cc/Cj), 125.1 (Ce/Ch), 115.1 (C5), 112.3 (C3), 70.6 (C7), 30.8 (C15), 30.2 (C11), 29.4 
(C12), 29.1 (C8), 28.9/25.8 (C9/C10). TOF ES-MS(+): m/z 1063.2 [M−PF6]+, 459.1 
[M−2PF6]2+. Anal. Calc. for C46H52F12N6O4P2RuS2 : C 45.73, H 4.34, N 6.96.  Found: 
C 45.66, H 4.17, N 7.03. IR υmax (cm−1): 2930 (C–H), 2857 (C–H), 1683 (C=O), 1611 (C–
Cring/C–Nring), 1556, 1492, 1464, 1444, 1396, 1339, 1278, 1222, 1120. UV-VIS (CH3CN) λmax 
[nm] (log ε): 462 (4.1), 436 (sh), 289 (4.8). Emission (CH3CN, λexc = 450 nm) λmax [nm] = 
645.  
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Synthesis of RuSH:  
 
NH4OH (aq) solution (50 μl, 30 % wt) was added to RuSAc (100 μl, 1.52 mM in CH3CN, 
152 nmol) and stirred for 10 min in a sealed vial to give RuSH in situ, directly prior to 
titration into the colloid. TOF LD-MS(+): m/z 829.7 [M−2PF6]+. 
 
Synthesis of 13 nm citrate gold nanoparticles 
Synthesis according to Grabar et al. (preparation 1).5 All glassware was washed with aqua 
regia (HCl:HNO3, 3:1), rinsed with deionised water and dried in an oven overnight. 
HAuCl4.3H2O (49.85 % Au) (0.0988 g, 0.2501 mmol) was dissolved in deionised water (250 
mL), and the solution was heated to reflux, with vigorous stirring. A solution of trisodium 
citrate (0.2858 g, 0.9718 mmol) in deionised water (25 mL water, 38.87 mM) was added 
rapidly to the vortex. The yellow solution slowly darkened to a deep burgundy colour, and 
was kept at reflux for 10 min. The solution was cooled to room temperature, with stirring for 
a further 15 mins to yield 13 nm gold nanoparticles. Colloids were kept at room temperature 
and in the dark. UV-VIS (H2O) λmax [nm]: 520 (SPR), 260. Diameter = 13± 1 nm (DLS 
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number distribution), = 29 ± 12 nm (86 %), 998 ± 624 nm (14 %)) (DLS intensity 
distribution). Zeta potential = −40±5 mV (2 nM in deionised water). 
 
Synthesis of Ru-T20•AuNP13: 
13 nm citrate gold nanoparticles (80 L) were diluted in deionised water (920 L), and 
TWEEN® 20 (10 L, 125 mM) was added to give a final nanoparticle concentration of 
0.7 nM, and a final surfactant concentration of 1.2 mM. The solution was stirred for 20 min 
and the max of the SPR was monitored by UV-Vis absorption spectroscopy. RuSH complex 
(2.5 μl, 3.5 mM, (made in situ, NH4OH(aq) 30 % w/w:CH3CN (1:1) solution)) was added into 
the nanoparticle/surfactant solution, whilst monitoring the coating process by UV-Vis 
absorption spectroscopy. The particles were isolated by size-exclusion chromatography on 
Sephadex® G-25, eluting with water, to give a final nanoparticle concentration of 0.3 nM 
(estimated by UV-Vis absorption spectroscopy). UV-Vis (H2O) λmax [nm] = 525 (SPR). 
Diameter = 26± 19 nm (DLS number distribution), = 195±91 nm (99%), 28±6 nm (1%), (DLS 
intensity distribution), zeta potential = −24±3 mV (isolated, 0.3 nM in deionised water 
diluent). Emission (H2O, λexc = 450 nm) λmax [nm] = 655.  Lifetime (H2O, λexc = 445 nm, λem 
= 630 nm) = 305 ns (aerated), = 375 ns  (degassed). ICP-OES Au:Ru atomic ratio = 72:1. 
 
Synthesis of Ru-Z•AuNP13:  
Zonyl® 7950 (CH2–C(CH3)COOC2H4(CF2)nF, MW ca. 500, 1 μl, 1.15 g mL−1) was added to 
13 nm citrate gold nanoparticles (1 mL, 9 nM nanoparticles, zeta potential at 2 nM in 
deionised water = −40 ±5 mV,  diameter = 13±4 nm (DLS number distribution), = 29±12 nm 
(86 %), 998±624 nm (14 %) (DLS intensity distribution)) to give fluorosurfactant coated 
nanoparticles (9 nM nanoparticles), with a final fluorosurfactant concentration of ca. 1mM. 
(Isolated Z●AuNP13, by three rounds of centrifugation, decantation of the supernatant and 
resuspension of the pellet have a zeta potential of −61±4 mV (2 nM in deionised water) and 
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diameter of 20±2 nm (DLS number distribution), and of 32±15 nm (DLS intensity 
distribution)). A solution of RuSH (20 μl, 3.5 mM, (made in situ, NH4OH(aq) 30 % 
w/w:CH3CN (1:1) solution)) was added to the fluorosurfactant / nanoparticle mixture (not 
isolated), and was stirred for 20 min. The particles were centrifuged at 12,000 g for 15 min, 
and the supernatant was decanted from each pellet to remove unbound material. The 
nanoparticles were resuspended in deionised water, and this was repeated twice to give 
Ru-Z●AuNP13. UV-Vis (H2O) λmax [nm] = 522 (SPR). Diameter = 18±5 nm (DLS number 
distribution), = 30±10 nm (27%), 166±86 nm (27%), (DLS intensity distribution), zeta 
potential = −48±2 mV (isolated, 2 nM in deionised water diluent). Emission (H2O, λexc = 450 
nm) λmax [nm] = 640.  Lifetime (H2O, λexc = 445 nm, λem = 630 nm) = 340 ns (aerated), = 690 
ns  (degassed). Φ (H2O, λexc = 355 nm) = 4% (aerated). ICP-OES Au:Ru atomic ratio = 63:1. 
 
2.12.2	Staining	of	Nanoparticles	for	TEM	
Negative staining of nanoparticles with PTA 
For negative staining, nanoparticles (50 L, 9 nM, aqueous) were added to a 200-mesh 
formvar-coated copper TEM grid. After 20 min the solution was wicked off the grid with 
filter paper, taking care not to remove all the liquid, and aqueous PTA solution (50 L, 1% 
w/v solution, solid PTA purchased from Sigma Aldrich) was added to the grid. The solution 
was wicked off the grid with filter paper, leaving a very thin layer of stain on the grid to air-
dry. 
 
Positive staining of nanoparticles with PTA 
Nanoparticle samples were positively stained by centrifuging the nanoparticles (1 mL, 9 nM, 
aqueous) at 12000 g for 15 min, decanting the supernatant, and redispersing in aqueous PTA 
solution (total volume of 1mL, 1% w/v solution). After 24 hr the colloidal dispersion was 
centrifuged at 12000 g for 15 min, the supernatant was decanted, and the particles were 
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redispersed in deionised water (total volume 1 mL). The nanoparticle solution (50 L, 9 nM) 
was added to a TEM grid, and after 20 min the solution was wicked off the grid with filter 
paper. The grid was washed with water and left to air-dry. 
 
2.12.3	X‐ray	Photoelectron	Spectroscopy	
Gold nanoparticles (100 L, 9 nM) were air-dried on 1 cm × 1 cm silicon wafers. The x-ray 
photoemission spectroscopy (XPS) data were collected at the Science City Photoemission 
Facility, School of Physics, University of Warwick, with the help of Dr Marc Walker. More 
details of which are available at http://go.warwick.ac.uk/XPS. The samples investigated in 
this study were mounted on Omicron sample plates using electrically conductive carbon tape 
and loaded in to the fast-entry chamber. Once a pressure of less than 1 × 10−7 had been 
achieved (approx. 1 hour), the samples were transferred to a  12-stage storage carousel, 
located between the preparation and main analysis chambers, for storage at pressures of less 
than 2 × 10−10 mbar. 
 
XPS measurements were conducted in the main analysis chamber (base pressure 
2 × 10−11 mbar), with the sample being illuminated using an XM1000 monchromatic Al kα 
x-ray source (Omicron Nanotechnology). The measurements were conducted at room 
temperature and at a take-off angle of 90°. The photoelectrons were detected using a Sphera 
electron analyser (Omicron Nanotechnology), with the core levels recorded using a pass 
energy of 10 eV (resolution approx. 0.47 eV). The data were analysed by Dr Marc Walker, 
using the CasaXPS package, using Shirley backgrounds, mixed Gaussian-Lorentzian (Voigt) 
lineshapes and asymmetry parameters where appropriate. All binding energies were calibrated 
to the C 1s peak at 284.6 eV.102  
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3.1 Introduction 
Optical imaging at the nanoscale can lead to breakthroughs in the biomolecular sciences, 
providing information on the monitoring of specific cellular processes, such as protein 
trafficking and the targeting of cell organelles, with high spatial resolution.1-5 Specifically, 
luminescence imaging has many advantages over colorimetric optical imaging, including 
higher resolution and sensitivity, and several advantages over electron imaging, such as 
significantly faster acquisition times and live cell imaging. This is discussed in Chapter One. 
Noble metal nanoparticles and quantum dots provide good candidates as optical nanoscale 
probes for detection by different imaging modalities, and have the potential to target specific 
biomolecules, tissues or diseases with modifications of their outer shell properties.6-9  
 
Gold nanoparticles offer an inert scaffold onto which one can assemble a variety of functional 
probes, using very simple S–Au self-assembly, and their high surface area: volume ratio is 
extremely attractive for this.3 In general, gold nanoparticles are deemed to be relatively 
biocompatible, compared with many inorganic nanoparticles,1,10 and thus lend themselves to a 
host of biomedical applications, including imaging,10,11 chemical sensing12 and theranostic 
nanomedicine.13 In parallel with the interest in biomedical applications, a growing number of 
questions are being raised concerning the effects of nanoparticles on human health and the 
environment, and thus the toxicology of nanoparticles is becoming more important with the 
advances and exposure to nanotechnology.14,15 Therefore it is incredibly important to 
investigate the complex processes that govern the cellular uptake and fate of given 
nanomaterials, and thus there are several studies of gold nanoparticle uptake in tissues and 
tumours, both in vivo16,17 and in vitro.3,18,19  
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The cellular uptake of nanoparticles is affected by both particle size and surface 
functionality,3,20,21 and the importance of the size of nanoparticles and quantum dots has been 
highlighted for their uptake  in tumour tissues,22,23 as well as in cell lines.24,25  
 
Chan and co-workers have investigated the effect of the size of citrate-stabilised gold 
nanoparticles on cellular uptake in a HeLa (human cervical cancer) cell line in the 14–74 nm 
size range.24 Cells were incubated with particles, washed, and the gold uptake was analysed 
by inductively-coupled plasma atomic absorption spectroscopy (ICP–AES), at various time 
points. It was found that the uptake (number of nanoparticles per cell) was greatest for 50 nm 
gold nanoparticles, and that the uptake of all sizes saturated after ca. 6 hr. The mechanism 
was speculated to be via endocytosis, in which the particles are engulfed by the cell and 
localised in a vesicle of extracellular fluid, see schematic in Figure 3.1, below.26  
 
 
Figure 3.1 Schematic representation of the cellular endocytic uptake mechanism of 
nanoparticles. 
 
 
The group has also investigated the size-dependence of uptake of transferrin-coated gold 
nanoparticles made from citrate-stabilised precursors (transferrin is an iron-binding protein 
found in the blood).27 Mammalian cells  (fibroblasts, HeLa cells and SNP19 human brain 
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tumour cells) were incubated with 14–100 nm transferrin-coated gold nanoparticles, and again 
the 50 nm particles were found to enter all mammalian cells tested faster than the 14 nm and 
100 nm particles. The group postulate that the 50 nm particles are the optimum size for the 
cell membrane to wrap around the particle and enclose it in a vesicle in the cells tested.27 
Many further investigations into the cellular uptake of functionalised gold nanoparticles made 
from citrate-stabilised precursors, have been performed within the literature; unsurprisingly 
the surface-functionalisation of the nanoparticles can drastically  alter both the uptake and the 
cellular response,21,28 and many such studies have been reviewed by Mirkin,29 and more 
recently by Khlebstov.30 
 
3.1.1 Chapter Outline 
In this chapter, luminescent gold nanoparticles coated with the RuSH complex, as developed 
in Chapter Two, (using the optimized coating method mediated with the fluorinated 
surfactant, Zonyl® 7950), are used to investigate the cellular uptake in A549 human lung 
cancer cells. The advantage of coating gold nanoparticles with a luminescent complex, rather 
than using other luminescent nanoprobes such as quantum dots, is that the size of the gold 
nanoparticle can be tuned independently of its luminescent properties. In order to investigate 
whether the size of the gold nanoparticle core has an effect on the photophysical properties of 
the labelling ruthenium(II) complex, the studies of 13 nm luminescent gold nanoparticles in 
Chapter Two, i.e. Ru-Z•AuNP13, have been developed further by growing larger 
nanoparticles. 100 nm gold nanoparticles have been coated with RuSH, and the properties of 
the resultant Ru-Z•AuNP00 are compared to Ru-Z•AuNP13.  Larger particles open up the 
prospect of single nanoparticle detection by optical techniques, as each individual particle 
should exhibit a stronger luminescence intensity, per particle, due to the greater number of 
surface-grafted lumiphores. 
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In order to assess the potential of such nanoparticles in biological imaging applications, the 
uptake of both Ru-Z•AuNP13 and Ru-Z•AuNP100 in A549 cells has been studied by 
confocal luminescence microscopy and electron microscopy to determine cellular localisation. 
In addition to this, gross cellular labelling has been studied by flow cytommetry, and 
toxicology studies have been performed. The findings in this chapter have been recently 
published by the author.31 
 
The synthesis of RuSH, which is made in situ from RuSAc, is described in Chapter Two 
(Section 2.2), and the structures of the RuSAc and RuSH complexes are shown in Figure 3.2, 
and schematics of Ru-Z•AuNP13 and Ru-Z•AuNP100 are presented in 3.3. 
 
 
Figure 3.2 Structures of RuSAc and RuSH complexes discussed in this chapter. 
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Figure 3.3 Schematics of Ru-Z•AuNP13 and Ru-Z•AuNP100 discussed in this chapter. 
 
 
3.2 Seed-mediated Growth of 100 nm Gold Nanoparticles 
There are several reports in the literature of synthetic routes towards large (> 20 nm) gold 
nanoparticles, including one-pot reactions32 and seed-mediated processes.33-36 In general, the 
former produce low concentration, highly polydisperse gold nanoparticles, with little shape 
control, whereas seed-mediated growth offers more control over shape and size.36 Cetyl 
trimethylammonium bromide (CTAB)-stabilised nanoparticles have been grown from seeds 
by Liz-Marzán and co-workers,33 with a post-synthetic cleanup step to obtain spherical 
particles only. Another popular synthesis, proposed by Perrault et al.34 uses hydroquinone as a 
reducing agent to produce nanoparticles in the 50–200 nm range, but these particles are still 
relatively polydisperse, and the benzoquinone oxidation product is toxic. Natan’s group have 
also used hydroxylamine as a reducing agent,36 but again shape-control is problematic. In this 
chapter, 100 nm aqueous gold nanoparticles have been synthesised in a seeded-growth 
method, using a synthesis adapted from a recent publication by Ziegler and Eychmüller;37 this 
simple synthetic process requires no post-synthesis cleanup steps, and uses nontoxic, 
biocompatible reducing agents which can easily be replaced by thiol-appended groups to 
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allow surface functionalisation. The nanoparticles were prepared in a three step growth 
process,31 starting with 13 nm citrate-stabilised gold nanoparticles, which were synthesised 
according to the standard citrate reduction, described in Chapter Two, Section 2.3.38 In brief, 
HAuCl4 is added to nanoparticle seeds, and a mixture of sodium citrate and ascorbic acid is 
slowly added to reduce the gold(III) ions to gold(0), whilst nucleating on the nanoparticle 
seeds, as shown below in Figure 3.4. 
 
Figure 3.4 Schematic of the seeded-growth synthesis used to produce 100 nm gold nanoparticles. 
 
 
In each growth step, the nanoparticles tend to double in size, approximately; the 13 nm seeds 
grow to ca. 25 nm in step one, which then grow to ca. 50 nm in step two, and finally grow to 
ca. 100 nm in the third growth step. Size is estimated by inspection of the TEM data. UV-Vis 
absorption spectra and TEM images were recorded at each stage of the growth process to 
elucidate information about the particle sizes at each step, as shown below in Figure 3.5. 
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Figure 3.5 TEM images of air-dried nanoparticles, following the nanoparticle growth process, of a) 
13 nm seeds, b) 25 nm particles following the first growth step, c) 50 nm particles following the 
second growth step, and d) 100 nm particles following the third (final) growth step. e)Normalised UV-
Vis absorption spectra of the 13 nm seeds(bold solid line), 25 nm particles (solid line), 50 nm 
particles(bold dashed line), and 100 nm particles (dashed line). 
 
 
The SPR of the nanoparticles shifts to the red as the particles increase in size at each growth 
step (Figure 3.5e); the 13 nm seeds have an SPR max = 520 nm (as described in Chapter Two, 
Section 2.3), whereas the 25 nm particles have SPR max = 522 nm (Figure 3.5e). The SPR 
max of the 50 nm and 100 nm particles are observed at 533 nm and 566 nm respectively 
(Figure 3.5e). This is because the SPR is the collective oscillation of electrons in the 
nanoparticle, which is smaller than the mean free path of an electron in bulk gold, and thus the 
resonant electronic motion is determined by the size of the particle; as the diameter increases 
in size the resonant frequency decreases.39 All particles displayed good particle stability (for > 
1 month), and although the 50 nm and 100 nm particles settle out of solution within 24 hr 
(due to their mass), redispersion is quickly achieved by a short (ca. 30 s) sonication. 
 
The resulting 40 pM 100 nm gold aqueous sol (for concentration calculation see Appendix 
1.2) was characterised by UV-Vis absorption spectroscopy, DLS, electrophoretic light 
scattering (zeta potential), as shown below in Figure 3.6, and by TEM (Figure 3.5e). 
  Chapter Three 
103 
 
 
Figure 3.6 (a) UV-Vis absorption spectrum of 40 pM 100 nm gold nanoparticles. (b) Sizing of the 
100 nm gold nanoparticles by nanoparticle tracking analysis. c) DLS Intensity distribution and (d) 
DLS number distribution of 100 nm gold nanoparticles, measured at 10 pM concentration.  
 
 
The UV-Vis absorption spectrum has a highly absorptive SPR peak with log = 10.9 at 
566 nm, in terms of nanoparticle concentration, and the absorption band at 295 nm is due to 
the absorption of the ascorbic acid (Figure 3.6a); this disappears upon centrifugation, 
decantation of the supernatant and resuspension of the particles in deionised water. Sizing of 
the nanoparticles by DLS gives an average number distribution hydrodynamic diameter of 
98±27 nm (Figure 3.6d), and an average intensity distribution diameter of 136±62 nm (Figure 
3.6c). The nanoparticles were also large enough to detect by NanoSight nanoparticle tracking 
analysis (NTA), and track as single nanoparticles by laser scattering on a microscope ( = 
405 nm) using tracking software (Figure 3.6b); the mean diameter = 119 nm, and the mode = 
79 nm, with a standard deviation of 102 nm. The NTA, DLS and TEM data all corroborate 
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each other, in terms of sizing the ‘100 nm’ gold nanoparticles synthesised. Electrophoretic 
light scattering measurements reveal that the 100 nm gold nanoparticles have a zeta potential 
of −33±3 mV, measured at 4 pM concentration in deionised water. This is marginally less 
than that of the 13 nm citrate gold nanoparticles (Chapter Two, Section 2.3), which have a 
zeta potential of −40±5 mV, measured in water at a 2 nM nanoparticle concentration.  
3.3 Synthesis and Characterisation of Ru-Z•AuNP100 
As was observed with the direct addition of RuSH to 13 nm citrate-stabilised gold 
nanoparticles in Chapter Two (Section 2.4), addition of RuSH (synthesised in situ from 
RuSAc) to the 100 nm gold nanoparticles gives rise to the immediate aggregation of the 
nanoparticles, evident from a colour change from a purple to a grey colour, and subsequent 
sedimentation of solid out of suspension. Unlike 100 nm nanoparticles that are not 
aggregated, the sedimentation formed of these aggregates does not redisperse into solution 
upon sonication. In a similar fashion to the 13 nm gold nanoparticle studies in Chapter Two 
(Section 2.4, Figures 2.18 and 2.19), the titration of 5–20 M RuSH complex into 40 pM 
100 nm gold nanoparticles gives rise to SPR reduction at 566 nm and to the growth of a new 
plasmonic band at >700 nm, due to plasmon coupling between aggregating nanoparticles40, as 
shown below in Figure 3.7. 
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Figure 3.7 UV-Vis absorption spectra of 100 nm gold nanoparticles (1 mL, 40 pM) (bold), and with 
the addition of RuSH complex (5-20 M)(dashed). 
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In order to circumvent nanoparticle aggregation upon functionalization with the RuSH 
lumiphore, the pre-coating fluorosurfactant, Zonyl® 7950 was employed, as shown below in 
Figure 3.831,41 in a similar fashion to Ru-Z•AuNP13, reported in Chapter Two, Section 2.8; 
100 nm gold nanoparticles were initially coated with Zonyl® 7950, RuSH was subsequently 
added, and the coated 100 nm particles were isolated by centrifugation, followed by 
decantation of the supernatant and resuspension of the pellet in deionised water.   
 
 
 
Figure 3.8 Synthesis of Ru-Z•AuNP100, with the initial coating of the 100 nm gold nanoparticles with 
Zonyl® 7950 fluorosurfactant, followed by the addition of RuSH complex. 
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The addition of Zonyl® 7950 to the 100 nm gold nanoparticles gives rise to 1 nm red-shift in 
the SPR (indicated by the black arrow, Figure 3.9), and no further shift in the SPR is observed 
upon subsequent titration of RuSH complex (indicated by the red arrow, Figure 3.9), as 
shown below in Figure 3.9. This is identical to the changes in UV-Vis absorption observed 
during the preparation of Ru-Z•AuNP13, discussed in Chapter Two (Section 2.8).  
 
Figure 3.9 UV-Vis absorption spectra of 100 nm gold nanoparticles (40 pM) (black solid line), 
+ Zonyl® 7950 (1 mM) (black dashed), + 5–60 uM RuSH (red). 
 
 
 Isolated Ru-Z•AuNP100 have a SPR absorption with max = 567 nm (see Section 3.3.1, 
Figure 3.11) and have been characterised by DLS (Figure 3.10a,b), NanoSight NTA (Figure 
3.10c), and TEM (Figure 3.10d), to analyse the size of the coated nanoparticles.  
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Figure 3.10 (a) DLS intensity distributions and (b) DLS number distributions, of 4 pM 100 nm gold 
nanoparticles (solid line), 4 pM Z•AuNP100 (dashed line) and 4 pM Ru- Z•AuNP100 nanoparticles 
(bold solid line).(c) NanoSight NTA Ru-Z•AuNP100. (d) TEM image of Ru- Z•AuNP100 particles. 
 
 
As a control Zonyl® 7950-coated gold nanoparticles were synthesised under identical 
conditions, without the RuSH complex, and purified by centrifugation to give Z•AuNP100, 
also with an SPR peak with max = 567 nm. DLS measurements of uncoated 100 nm gold 
nanoparticles, Z•AuNP100 and Ru-Z•AuNP100, all reveal a single peak in the scattering 
intensity distribution at ca. 130 nm and a single peak in the number distribution at ca.90 nm, 
showing an absence of aggregates in all cases. The uncoated 100 nm nanoparticles having a 
mean intensity diameter of 136±62 nm (100%), (Section 3.2), the Z•AuNP100 of 131±51 nm 
(100%) and Ru-Z•AuNP100 of 122±51 nm (100%). These equate to average number 
distributions of 98±27 nm, 92±21 nm, and 76±22 nm for uncoated nanoparticles, 
Z•AuNP100, and Ru-Z•AuNP100 respectively. Sizing by NTA gives a mean particle size of 
100 nm for Ru-Z•AuNP100, with a modal value of 79 nm (Figure 3.10c), and TEM reveals 
the Ru-Z•AuNP100 nanoparticles as quite monodisperse spherical nanoparticles with a gold 
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core diameter of ca.100 nm. All sizing data in Figure 3.10 confirm the uniformity of the 
Ru-Z•AuNP100 nanoparticles. 
 
Electrophoretic light scattering measurements of the uncoated nanoparticles, Z•AuNP100, 
and Ru-Z•AuNP100 were performed at 4 pM concentrations to analyse the change in the zeta 
potentials of the nanoparticles upon functionalization (see Table 3.1). In a similar fashion to 
the 13 nm gold nanoparticles described in Chapter Two (Section 2.8), upon addition of 
fluorosurfactant, the zeta potential of the isolated Z•AuNP100 increases in magnitude to a 
larger negative voltage of −47±3 mV (4 pM in deionised water), with respect to that of 
−33±3 mV (4 pM in deionised water) for the uncoated 100 nm gold nanoparticles. (This 
compares to an increase from −40±5 mV to −61±4 mV for uncoated 13 nm nanoparticles and 
Z•AuNP13 respectively.) This is attributed to the partial negative charges of the 
fluoropolymer C–F bonds on the peralkyl chains, presented to the outer surface of the 
hydrodynamic radii of the particles, as discussed in Section 2.5 (Chapter Two). Addition of 
the RuSH complex to the 100 nm nanoparticles also changes their surface charge, as 
previously observed in the preparation of Ru-Z•AuNP13 (Section 2.8); isolated 
Ru-Z•AuNP100 nanoparticles have a zeta potential of −35±3 mV (4 pM in deionised water), 
which is less negative than that of Z•AuNP100 (47±3 mV) as the RuSH complex displaces 
some of the electronegative fluorosurfactant. The zeta potential data are summarised below in 
Table 3.1. 
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Table 3.1 Summary of zeta potential data for 
Ru-Z•AuNP100 and related particles for comparison 
Nanoparticles Zeta Potential / mVa 
 
uncoated 13 nm gold 
nanoparticles 
 
 
−40±5 
Z•AuNP13 
 
−61±4 
 
Ru-Z•AuNP13 
 
−48±2 
 
uncoated 100 nm gold 
nanoparticles 
 
 
−33±3 
 
Z•AuNP100 
 
−47±3 
Ru-Z•AuNP100 
 
−35±3 
a measured at 4 pM in deionised water. Errors quoted as ± 1SD. 
 
 
The zeta potential data for the 100 nm nanoparticles are all ca. 20% lower than their 13 nm 
nanoparticle equivalents, which is expected from the eletrophoretic mobility measurements; 
the surface area:volume ratio decreases by a factor of ca. 7 as the particle radius increases by 
the same factor, and thus the mobility of the nanoparticles in an electric field will reduce. 
 
The surface-coating of RuSH complexes to the gold nanoparticles in Ru-Z•AuNP100 is 
estimated as 108,000 complexes per nanoparticle, by inspection of the singlet MLCT band in 
the UV-Vis absorption spectrum of the first supernatant from the isolation process, due to the 
insufficiently low ruthenium(II) signal at the nanoparticle concentrations prepared for ICP–
OES analysis (See Appendix 2.3).31 108,000 complexes per nanoparticle is equivalent to a 
molecular footprint of 0.5 nm × 0.5 nm, which is similar to that observed for the 
Ru-Z•AuNP13 particles (i.e. 1400 RuSH complexes per nanoparticle, 0.6 nm × 0.5 nm 
footprint, Section 2.8, Appendix 2.2). 
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3.3.1 Photophysical Properties of Ru-Z•AuNP100 
The isolated Ru-Z•AuNP100 particles are luminescent upon excitation at 450 nm, with broad 
red emission spanning the range 550–800 nm, and max = 640 nm. The UV-Vis absorption 
spectrum, excitation spectrum, measured at em = 630 nm, and the steady-state luminescence 
spectrum, exc = 450 nm, are presented below in Figure 3.11.  
 
Figure 3.11 UV-Vis absorption spectra (solid line), excitation spectra, λem = 630 nm (dashed line), 
and luminescence spectra, λexc = 450 nm (bold solid line) of 10 pM RuS•AuNP100. Spectra corrected 
for instrument response.  
 
 
The UV-Vis absorption spectrum is dominated by the SPR of the gold nanoparticles, with 
max = 567 nm. The excitation spectrum resembles the UV-Vis absorption spectrum and 
excitation spectrum of the free RuSAc (Section 2.2.2, Figures 2.14 and 2.15), as is also 
observed for Ru-Z•AuNP13 (Chapter Two, Section 2.9), and the time-resolved luminescence 
studies reveal that the observed luminescence lifetime of Ru-Z•AuNP100 = 360 ns ±10% 
(aerated) and 630 ns ±10% (degassed), with excitation at 445 nm and emission collected at 
630 nm. The luminescent properties of the ruthenium(II)-coated gold nanoparticles are 
virtually identical, and thus the size of the nanoparticle core appears to have no effect upon 
the lumiphore properties: both Ru-Z•AuNP13 and Ru-Z•AuNP100 have luminescence with 
max = 640 nm, and equivalent aerated and degassed lifetimes, within error. (The observed 
luminescence lifetime of Ru-Z•AuNP13 = 340 ns ±10 % (aerated) and 690 ns ±10 %  
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(deareted), discussed in Chapter Two, Section 2.9). This corroborates the fact that the 
nanoparticle surface plasmon does not interact with the luminescence of the RuSH complex, 
because if it did the effect would be size-dependent. Hence, we do not observe the oft cited 
luminescence quenching42-47 with the RuSH complex in either Ru-Z•AuNP13 or Ru-
Z•AuNP100.  
 
Ru-Z•AuNP100 were imaged in Brownian motion within a 100 mm deep, 1 mm wide 
microchannel (ibidi), by epiluminescence microscopy, as shown in Figure 3.12. 
 
 
Figure 3.12 Luminescence image and spectrum (inset) of RuS•AuNP100 imaged in Brownian motion 
within a 100 µm deep, 1 mm wide ibidi microchannel, by epiluminescence microscopy. λexc = 450 nm, 
λem > 510 nm. The emission spectrum (inset) is taken from the field of view in the image. 
 
 
Ru-Z•AuNP100 nanoparticles are visualised as bright spots in the epiluminescence image 
(Figure 3.12), in which the particles are excited at 450 nm, and the signal is detected using a 
dichroic mirror at >510 nm. A luminescence spectrum was collected by feeding the 
luminescence signal from the image field-of-view to the spectrometer, confirming the 
characteristic profile of the Ru-Z•AuNP100 nanoparticles (inset). Successful detection of the 
nanoparticles by luminescence microscopy allows imaging applications to be explored in the 
following section for cellular interactions with the nanoparticles.  
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3.4 Cellular Uptake Studies of Ru-Z•AuNP13 and Ru-Z•AuNP100 in 
A549 Cells 
To investigate their potential as cell imaging agents, A549 human lung cancer cells were 
incubated with Ru-Z•AuNP13 and Ru-Z•AuNP100 by Dr Robert Harris and Mr Sunil 
Claire, in collaboration with Dr Nikolas Hodges. Cells were incubated for 24 hr, and fixed 
cells were stained with Hoechst 33258, a nuclear stain which fluoresces intensely upon 
binding to the A-T rich regions of dsDNA. Confocal luminescence images of the cells are 
shown below in Figures 3.13 and 3.14. 
  
 
Figure 3.13 Confocal images of RuS•AuNP13 in A549 cells following incubation for 24 hr. (a) white 
light transmission image, (b) reflection image exc = 633 nm, em = 623–643 nm, (c) ruthenium 
luminescence, red channel, exc = 453 nm, em = 555–800 nm, (d) nuclear Hoechst staining, blue 
channel, exc = 405 nm, em = 410–455 nm, (e) overlay of blue and red channel, (f) overlay of blue 
channel and reflection transmission image. White scale bar represents 20 m. 
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Figure 3.14 Images of RuS•AuNP100 nanoparticles in A549 cells monitored by confocal 
luminescence and reflection microscopy. (a) white light transmission image, (b) reflection image exc 
= 488 nm, em = 478–498 nm, (c) Ru-Z•AuNP100 luminescence, red channel, exc = 453 nm, em = 
555–800 nm, (d) nuclear Hoechst staining, blue channel, exc = 405 nm, em = 410–455 nm, (e) 
overlay of blue and red channels, and (f) overlay of blue channel and transmission image. White scale 
bar is 20 m.  
 
 
Gold nanoparticles appear as bright spots in the confocal reflection images (Figures 3.13b and 
3.14b) due to the high elastic scattering cross-section of the gold nanoparticles in comparison 
with that of biological tissue,48 and dark spots in the transmission images due to the 
absorption of white light. The RuSH luminescence signal is visualised in the red channel 
(Figures 3.13c and 3.14c), in which the Ru(II)-coated nanoparticles are excited by a 453 nm 
laser, and emission is gated between 555–800 nm. Co-localisation of the red (RuSH 
emission) and reflection (gold scattering) signals in both Figures 3.13 and 3.14 confirms the 
stability of the nanoprobe after the 24 hr incubation. Cellular uptake by A549 cells was 
observed for both Ru-Z•AuNP13 and Ru-Z•AuNP100 nanoparticles, and the luminescent 
nanoparticles were bright enough to image effectively by confocal luminescence microscopy, 
with each image taking ca. 60 s to acquire. Un-treated Hoechst-stained control cells were also 
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imaged by confocal microscopy; no bright spots were visible in the reflection channel, and 
luminescence was absent in the red channel (see Appendix 7).  
 
The Ru-Z•AuNP100 nanoparticles are large enough to image as single nanoparticles in the 
cells, and to investigate this further, a convolution of the point-spread function from the 
confocal luminescence measurements was convolved with a simple model of a nanoparticle 
sphere by Mr Sunil Claire and Dr Iain Styles. Due to the effects of light diffraction, the model 
predicts that individual Ru-Z•AuNP100 nanoparticles should appear as 300 nm particles, 
which is consistent with the actual measurements obtained.
31
  
 
To monitor the uptake and accumulation of nanoparticles in cells over time, a pulse-chase 
experiment with Ru-Z•AuNP13 was performed by Dr Robert Harris.31 In this experiment, 
A549 cells are incubated with Ru-Z•AuNP13 for 24 hr, and then washed to remove any 
extracellular nanoparticles. The cells are then further cultured for 3 days, post-treatment, and 
imaged each day. Pulse-chase images as shown below in Figure 3.15. 
 
Figure 3.15 Pulse-chase confocal images of the distribution of Ru-Z•AuNP13 in A549 cells, following 
incubation for 24 hr (pulse), (a) immediately after the 24 hr treatment ,and  (b) 1 day, (c) 2 days, and 
(d) 3days post-treatment. Nuclear Hoechst staining, blue channel, exc = 405 nm, em = 410–455 nm, 
and ruthenium luminescence, red channel, exc = 453 nm, em = 555–800 nm. Scale bar = 10 m. 
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Interestingly, even 3 days post-treatment in the chase experiment, which is estimated to 
represent ca. three cell divisions (based on the number of nuclei per field of view), many of 
the cells contained Ru-Z•AuNP13 nanoparticles, demonstrating the long half-life and poor 
clearance of these particles.31 Importantly, cell division proceeds seemingly unperturbed by 
the Ru-Z•AuNP13, and no toxic effect is obvious by inspection of the micrographs. 
 
Analysis of the confocal luminescence images of A549 cells incubated with Ru-Z•AuNP100 
reveal that sometimes the nanoparticles localise within the nucleus. Co-localisation of the red 
channel and the blue (nuclear stain) channel in the confocal luminescence images shown 
below in Figure 3.16 indicate nuclear localisation of the Ru-Z•AuNP100 nanoparticles. 
 
 
Figure 3.16 Confocal luminescence images of nuclear localisation of Ru-Z•AuNP100 in A549 cells 
which has been stained with Hoechst. Nuclear Hoechst staining, blue channel, exc = 405 nm, em = 
410–455 nm, and Ru-Z•AuNP100 luminescence, red channel, exc = 453 nm, em = 555–800 nm. 
Scale bar = 10 m.  
 
 
In contrast, little evidence of nuclear uptake of Ru-Z•AuNP13 is observed, although it cannot 
be excluded, as it is believed that accumulations of Ru-Z•AuNP13 are required for their 
visualisation.31 However, it is possible that the larger nanoparticles are selectively found in 
the nucleus due to their size; the crossing of the nuclear envelope (a double phospholipid 
bilayer membrane, embedded with proteins), may only occur when the cells divide, and the 
nuclear envelope breaks down. Subsequently, when the new nuclear envelopes form for the 
daughter cells, it is possible that Ru-Z•AuNP100 get trapped in the nucleus, whereas 
Ru-Z•AuNP13 are expelled out of the nucleus through the pores in the envelope. 
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Electron microscopy was also performed on ca. 100 nm slices of treated A549 cells to 
examine the intracellular localisation of the functionalized nanoparticles within the cells, 
following the uptake in more detail (Figures 3.17 and 3.18).  
 
 
Figure 3.17 TEM images of a cell section, from an A549 cell that has been incubated with 
Ru-Z•AuNP13 for 24 hr (a), and zoomed images (b–d). 
 
 
The Ru-Z•AuNP13 (Figure 3.17) and Ru-Z•AuNP100 (Figure 3.18) appear as dark spheres 
against the cell section, and are found throughout the cell. Ru-Z•AuNP13 tend to be localised 
in vesicles, as can be seen in Figure 3.17c and 3.17d, which is indicative that the nanoparticles 
are taken up by endocytosis,26 and no Ru-Z•AuNP13 nanoparticles were observed in the 
nucleus in the samples imaged. 
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Figure 3.18 Electron microscopy of a  cell section, from an A549 cell that has been incubated with 
Ru-Z•AuNP100 for 24 hr. (a) TEM image, (b) SEM image and (c) EDX spectra of region of interest 
(inset), taken from the field of view imaged in (b). 
 
 
Ru-Z•AuNP100 were observed throughout the A549 cells, within the cytoplasm, within 
vesicles (Figure 3.18a and 3.18b) and occasionally within the cell nucleus.31 Energy-
dispersive X-ray spectroscopy (EDX), which provides chemical atomic characterisation, was 
performed on a single RuS•AuNP100 in the cell shown in Figure 3.17b, to confirm that the 
observed high contrast dark spots were indeed gold nanoparticles (see spectra in Figure 
3.18c). The electron microscopy performed corroborates the luminescence imaging 
performed, and confirms that the nanoparticles are indeed internalised by A549 cancer cells, 
rather than just adhering to the surface of the cells.  
 
In order to test whether nanoparticle uptake could be observed by fluorescence-activated cell 
sorting flow cytometry (FACS), A549 cells dosed with Ru-Z•AuNP100 for 24 hr were 
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washed (to remove excess nanoparticles) and analysed by FACS (schematic of FACS shown 
in Figure 3.19, data shown in Figure 3.20).  
 
 
Figure 3.19 Schematic of a FACS flow cyometry set-up. 
 
 
During FACS analysis, cells are focussed into a stream of liquid, and each suspended cell 
passes through a laser beam (in this instance a 488 nm laser), and the scattering intensity and 
fluorescence (luminescence) intensity is recorded at various emission wavelengths, selected 
by band-pass filter, as shown in Figure 3.18. These data are recorded per cell, and usually 
several thousand cells are analysed to obtain statistical data. Comparison of the FACS data for 
A549 cells dosed with Ru-Z•AuNP100 with control cells (incubated without nanoparticles) 
reveals that there is no difference in the forward scatter of cells, a measure of cell size 
between control and treated cells. However, the median red luminescence increased 19-fold in 
the dosed cells, with respect to the control, indicating the presence of fluorescent red 
nanoparticles within the cell, as can be seen below in Figure 3.20. 
 
  Chapter Three 
119 
 
 
Figure 3.20 Cellular uptake of nanoparticles by FACS flow cytometry. (a) un-dosed control A549 
cells, and (b) A549 cells incubated with Ru-Z•AuNP100 for 24 hr. exc = 488 nm, det = 488 nm for 
forward scatter (y-axis, a measure of cell size), and det>670 nm for luminescence signal (x-axis).One 
dot represents data for one cell. 50,000 cells were analysed in each experiment.  
 
 
These data are promising as they demonstrate that the macroscopic cell luminescence can be 
detected by FACS, and thus the nanoparticles can be used as cell labels. In addition to this, 
more detailed uptake studies and time courses could be performed in the future by this 
technique, in a fraction of the time that is required for quantitative microscopic cell imaging. 
The ability to analyse several thousand cells in minutes means that statistically significant 
data can be obtained with ease and without subjective bias. 
  
Toxicity assays have been performed by Mr Sunil Claire using both an MTT colorimetric 
assay, which assess mitochondrial function, and an adenylate kinase release assay, to 
determine cell viability by detecting cell membrane integrity. Both assays show that no 
statistically significant toxicity of either Ru-Z•AuNP13 or Ru-Z•AuNP100 is observed at 
concentrations up to five times the concentrations used for the imaging studies, over a 24 hr 
period.31  Although these 24 hr studies cannot determine that there is an absence of 
cytotoxicity, because it is possible for toxic responses to take longer than 1 day to present 
themselves, these assays show that no toxicity is observed on the time-scale of the 
microscopy experiments. 
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3.5 Conclusion 
Gold nanoparticles have been synthesised successfully at 100 nm in diameter, and 
functionalised with the luminescent complex, RuSH, using Zonyl® 7950 fluorosurfactant to 
prevent aggregation. The resulting Ru-Z•AuNP100 nanoparticles have 105 lumiphores per 
nanoparticle, and exhibit bright red luminescence with similar photophysical properties to the 
Ru-Z•AuNP13 nanoparticles. Importantly, no luminescence quenching is observed when the 
RuSH complex is grafted to 100 nm gold nanoparticles. Cellular uptake studies of both 
Ru-Z•AuNP13 and Ru-Z•AuNP100 nanoparticles have been performed, and both sizes of 
particle can be imaged in cell by conventional and widely-available optical microscopy 
methods, with sensible acquisition times. Electron microscopy has been employed to verify 
the cellular internalisation of the nanoparticles observed by luminescence microscopy. The 
possibility to visualise uptake by optical techniques is hugely advantageous over electron-
based methods, both in terms of preparation and imaging time, as well as being able to image 
live cells. Gross cell labelling is also possible by flow cytometry techniques, which opens up 
many opportunities for more detailed uptake studies to be performed on a statistically 
significant scale. 
 
The Ru-Z•AuNP13 and Ru-Z•AuNP100 nanoprobes do not present any significant toxicity 
in cells, and no dissociation of the RuSH complex from the nanoparticle surface is observed 
following 24 hr incubation in a biological environment. In addition, the brightness of the 
particles allows the imaging of single Ru-Z•AuNP100 nanoparticles associated with DNA 
material of the nucleus. Therefore, these particles have great potential for cellular imaging 
probes, which can be developed further by attaching other cargo to the labelled gold 
nanoparticles, using simple S–Au chemistry. 
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3.7 Experimental  
3.7.1 General Synthesis 
RuSH (3.5 mM (aq) 30 % w/w:CH3CN (1:1)) was synthesised in situ from its RuSAc 
precursor, as described in Chapter Two, Section 2.12.1. Zonyl® 7950 was purchased from 
Sigma Aldrich and 13 nm gold nanoparticles were synthesised by the citrate reduction 
method,38 as described in Section 2.12.1. 
 
Synthesis of 100 nm gold nanoparticles: 
This method was adapted from that published by Ziegler and Eychmüller.37  
The following stock solutions were prepared for the seeded-growth synthesis: ascorbic acid 
(aq) (502 mg, 2.85 mmol, 1% w/v); trisodium citrate dehydrate (aq) (500 mg, 1.70 mmol, 1% 
w/v); HAuCl4.3H2O (aq) (100 mg, 0.25 mmol, 0.2% w/v); citrate gold nanoparticle seeds 
(9 nM) used as prepared in Section 2.12.1.  
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13 nm citrate gold nanoparticles (6 mL, 9 nM colloid in water) were diluted in deionised 
water to 40 mL, and all further steps were performed under stirring.  The Au3+ stock solution 
(4 mL, 0.2% w/v ) was diluted to 20 mL in deionised water, then added dropwise over 15 min 
to the seeds. Ascorbic acid stock solution (1 mL, 1% w/v) was combined with trisodium 
citrate stock solution (0.5 mL, 1% w/v) and diluted to 20 mL in deionised water. This solution 
was added dropwise over 15 minutes to give a dark red solution. The mixture was refluxed for 
30 min at 100 ºC. An aliquot of the reaction mixture (9 mL) was left to cool, and was diluted 
to 40 mL. Au3+ stock solution (4 mL, 0.2% w/v), diluted to 20 mL, and was added dropwise to 
the diluted aliquot over 15 min. Ascorbic acid stock solution (1 mL, 1% w/v) and trisodium 
citrate stock solution (0.5 mL, 1% w/v) were diluted to 20 mL, and added dropwise over 15 
min. The mixture was refluxed at 100 ºC for 30 min to render a red/purple solution, and an 
aliquot of the reaction mixture (40 mL) was left to cool. Au3+ stock solution (16 mL, 0.2% 
w/v) was diluted to 20 mL and added dropwise to the aliquot over 15 min. Ascorbic acid stock 
(4 mL, 1% w/v) with trisodium citrate stock (2 mL, 1% w/v), diluted to 20 mL, was added 
dropwise to the mixture over 15 min to give a dark brown colloid. The mixture was refluxed 
for 30 min at 100 ºC, and allowed to cool to yield 100 nm gold nanoparticles as an 
orange/light brown colloid in water (40 pM), with a purple colour due to the SPR absorption, 
visible when held up to the light. UV-VIS (H2O) λmax [nm] = 567 (SPR). Zeta Potential (4 pM 
in deionised water diluent) = −33±3 mV. 
 
Synthesis of Ru-Z•AuNP100:  
Zonyl® 7950 (CH2–C(CH3)COOC2H4(CF2)nF, MW ca. 500, 1 μl, 1.15 g mL
−1) was added to 
100 nm citrate gold nanoparticles (1 mL, 40 pM nanoparticles, zeta potential at 4 pM in 
deionised water = −33±3 mV,  diameter = 98±21 nm (DLS number distribution), = 136±62 
nm (DLS intensity distribution)) to give fluorosurfactant coated nanoparticles (40 pM 
nanoparticles), with a final fluorosurfactant concentration of ca. 1mM (isolated Z●AuNP100, 
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by three rounds of centrifugation, decantation of the supernatant and resuspension of the 
pellet have a zeta potential of −47±3 mV (4 pM in deionised water) and diameter of 
92±21 nm (DLS number distribution), and of 131±51 nm (DLS intensity distribution)). A 
solution of RuSH (20 μl, 3.5 mM, (made in situ, NH4OH(aq) (30 % w/w):CH3CN (1:1) 
solution)) was added to the fluorosurfactant / nanoparticle mixture (not isolated), and was 
stirred for 20 min. The particles were centrifuged at 12,000 g for 90 s, and the supernatant 
was decanted from each pellet to remove unbound material. The nanoparticles were 
resuspended in deionised water, and this was repeated twice to give Ru-Z●AuNP100. UV-
Vis (H2O) λmax [nm] = 567 (SPR). Diameter 76±22 nm (DLS number distribution), = 122±51 
nm (DLS intensity distribution), = 100 nm (mean diameter by NanoSight NTA). Zeta 
potential = −35±3 mV (isolated, 4 pM in deionised water diluent). Emission (H2O, λexc = 
450 nm) λmax [nm] = 640.  Lifetime (H2O, λexc = 445 nm, λem = 630 nm) = 360 ns (aerated), = 
630 ns (degassed). 
 
3.7.2 Cell Studies with Ru-Z•AuNP13 and Ru-Z•AuNP100 
Cell culture was performed by Mr Sunil Claire and Dr Robert Harris in the School of 
Biosciences, University of Birmingham, and Confocal luminescence microscopy was carried 
out by both Mr Sunil Claire and the author. Toxicology data was obtained by Mr Sunil Claire, 
and flow cytometry was performed by Dr Nikolas Hodges.31 
 
Preparation of Cells for Electron Microscopy 
Cells were grown on coverslips and incubated with nanoparticles as described in the protocol 
for luminescence microscopy,31 by Sunil Claire. Following incubation cells were washed 
twice in PBS and fixed in 2.5% gluteraldehyde for 24 hours. Samples were subsequently 
prepared at the Centre for Electron Microscopy, University of Birmingham: Samples were 
placed in 1% osmium tetroxide solution and gradually dehydrated with alcohol and propylene 
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oxide. The cells were embedded in resin and ultrathin sections (50–150 nm) were obtained 
and mounted onto formvar-coated 200 mesh copper electron microscope grids.  Samples were 
stained with uranyl acetate to improve cell contrast.  
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Chapter Four 
 
Peptide-mediated 
Delivery of 
Luminescent 
Nanoparticles in Cells 
 
 
 
  
  Chapter Four 
128 
 
4.1 Introduction 
This chapter discusses the preparation of different peptide sequences attached to gold 
nanoparticles in order to target the delivery of nanomaterials in biological systems. The amino 
acid abbreviations and structures used in this chapter are presented in Appendix 8. Peptide-
coated nanoparticles are of interest in the field of biomedicine for the delivery of nanodevices 
into living organisms.1-4 Nanomedicine is an ever growing area of research, but the progress 
in theranostic nanomaterials depends heavily on the development of targeted delivery.5 
Nanoparticles offer a scaffold on which to assemble targeting, labelling and therapeutic 
probes, thereby producing a multifunctional nanovehicle, as presented in the schematic of 
Figure 4.1. The targeting probe needs to deliver the cargo with high specificity to reduce the 
undesirable side-effects of unwanted therapeutic activity on healthy tissue.6  
 
Figure 4.1 Schematic of theranostic nanomaterials assembled by attachment of multiple probes onto a 
gold nanoparticle scaffold. 
 
 
Understanding the effects of nanomaterials on cellular functions can provide useful insight 
into potential therapeutic applications. For example, gold nanoparticles have proved to be 
effective anti-cancer drug delivery systems7,8 and photothermal cancer treatment agents.9-14 
Nanoparticle-mediated photothermal therapy exploits the unique absorptive properties of gold 
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nanoparticles; the particles absorb electromagnetic radiation at wavelengths resonant with the 
SPR, and can convert this energy into heat with almost 100 % efficiency on a picosecond 
timescale.15 The localised heat produced can induce cellular damage and destroy diseased 
tissue, and is thus considered to be a potential anti-cancer therapeutic. The potential to target 
specific disease biomarkers, by modifying the particle surface with targeting vectors,16 opens 
up new pathways towards diagnosis and treatment of disease using such therapeutic methods. 
 
4.1.1 Stabilising Gold Nanoparticles with Peptides 
In 2004 Lévy and co-workers designed a short pentapeptide sequence, CALNN, to stabilise 
aqueous gold nanoparticles. The CALNN sequence (shown in Figure 4.2) incorporates a cysteine 
residue at the N-terminus, which provides a thiol functional group for attachment to gold 
nanoparticles. The alanine (A) and leucine (L) amino acids are relatively hydrophobic and 
promote the self-assembly of the peptide close to the particle surface to minimise their exposure 
to water. The two asparagine (N) amino acids are hydrophilic, which aids the solubility of the 
nanoparticles at the peptide terminus facing the solvent.17  
 
 
Figure 4.2 CALNN peptide sequence. 
 
 
The resulting CALNN-coated gold nanoparticles are very stable in aqueous buffer, can be freeze-
dried, stored as powders and redispersed. Gold nanoparticles functionalised with CALNN, and 
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longer derivatives of the peptide, have since been used in the delivery of gold nanoparticles into 
HeLa cells (human ovarian cancer cell-line).18,19  
 
4.1.2 Cell-penetrating Peptides 
The cell membrane (plasma membrane) is comprised of a phospholipid bilayer, which is 
abundant in negatively charged heparan sulphate proteins on the extracellular face.20 The 
effective transport of hydrophilic molecules (such as proteins, peptides, drugs and dyes) into 
cells is very difficult due to the impermeable barrier of the membrane to such moieties, and 
thus there has been a growth of interest in the development of cell-penetrating peptides (CPP) 
due to their potential as transport vectors for attached cargo. The mechanism of cargo delivery 
can either be via penetration of the membrane or by endocytic processes, and is found to be 
greatly affected by the size and nature of the cargo.21-24  
 
In the field of synthetic peptides, there are several properties of amino acids which can be 
exploited to induce transport across the cell membrane. Hydrophobicity helps to translocate 
cargo but often leads to solubility problems in water,23 and therefore there are two main 
strategies employed in CPP design: The first mechanism for cell penetration is to use 
electrostatic recognition, by producing peptides which contain multiple positively charged 
amino acid groups; amino acids such as lysine, histidine, ornithine and arginine, which are all 
cationic at physiological pH, interact strongly with the negatively-charged cell 
membrane.20,23-25 The most popular naturally occurring peptides that have been found to 
penetrate the cell membrane through screening assays are: the Tat peptide, which is the 48–60 
amino-acid chain peptide (GRKKRRQRRRPPQ) taken from the Tat protein found in the 
HIV-1 virus;25 and penetratin, from the Drosophila (fruit fly).26 Both of these peptides are 
rich in arginine residues, which are particularly favourable because they can form bidentate 
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hydrogen bonds with the cell membrane through the guanidinium head group on the side-
chain (as shown in Figure 4.3), and are particularly potent in facilitating cell delivery.13,25,27 
Amongst the polyarginines, sequences of seven or nine arginine residues have been the most 
widely used.20 The second mechanism for cell penetration is to utilise amphiphilic peptides 
which can interact with the lipid bilayer of the cell membrane. Primary amphiphilic peptides 
can be used by the sequential assembly of hydrophobic and hydrophilic domains within the 
sequence, or the secondary structure can play a role in cell delivery; amphiphilic alpha-helical 
structures expose the hydrophilic amino acids to one side of the helix, and the hydrophobic 
residues to the other, making the peptide ideal for binding to a lipid bilayer, such as the model 
amphiphilic peptide (MAP).28 
 
 
Figure 4.3 Schematic of strategies to cross the cell membrane. 1- electrostatic interaction of the 
guanidinium head group of an arginine residue  with the negatively charged cell membrane. 2- 
insertion of an amphiphilic peptide structure into the amphiphilic cell membrane due to 
hydrophobicity. 
 
 
Similar structure occurs naturally in membrane proteins such as ion channels.  However, these 
amphiphilic peptides can irreversibly destabilise the cell membrane and induce cytotoxicity.23  
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So far, a simplistic picture of nanoparticles coated with targeting peptides has been assumed, 
in which the nanoparticles present the targeting peptides to the bulk solvent, and thus can 
interact accordingly. This tenet holds true in simple solvent systems, such as water or buffer. 
However, the picture is far more complex in biological matrices and it is important to 
consider these additional effects upon the surface-chemistry of the nanoparticles when trying 
to achieve targeting. As with many foreign bodies, nanoparticles can be surrounded by a 
dynamic layer of proteins and other biomolecules following contact with biological media, 
which is often referred to as a protein ‘corona’.29 This in situ protein layer is complex and 
variable, and can mask targeting motifs on the surface. The corona can also create a 
recognition signature on the surface of the particle, and direct its internalisation route both in 
vitro and in vivo, thus directing the nanoparticle off its intended target.30,31 Therefore, peptide-
mediated specific delivery of nanoparticles is far from trivial in biological systems. 
 
4.1.3 Peptide-mediated Delivery of Luminescent Gold Nanoparticles in 
Cancerous Cells 
The cellular uptake of nanoparticles has been found to depend on both particle size and the 
surface functionality,32-35 and many types of nanomaterials are thought to enter cells by 
endocytic pathways, which compartmentalise the particles in vesicles of extra-cellular fluid 
within the cell. However, it is usually desirable to deliver nanomaterial into the intracellular 
fluid (cytosol), so that the surface-functionalisation is exposed to the intra-cellular 
environment, which can be achieved by coating the particles in CPP. Capping gold 
nanoparticles with Tat and penetratin peptides has been found to enhance the cellular uptake 
and, in some instances, deliver many particles into the cytosol.13,18,36,37 Similarly, 
polyarginine-capped 20 nm gold nanoparticles have been reported to increase uptake in Jurkat 
(human T lymphocyte) cells, up to five-fold.38 Polyarginines have also been conjugated to 
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quantum dots to aid their cellular uptake,27,39 and work by Lagerholm et al. shows that their 
cellular uptake increases by two orders of magnitude in a variety of mammalian cell lines.39   
 
Despite the developments in nanoparticle delivery with CPP, such peptides are inherently 
non-specific in their translocation properties,40 whereas targeted delivery is desirable for most 
in vivo applications of cellular delivery. Intrinsically, nanoparticles can be very useful for 
targeted delivery to tumour tissue, using their size as a passive targeting technique; upon 
injection in vivo, particles < 5nm tend to be removed from the blood rapidly by renal 
clearance via the kidneys, and microsized particles are mechanically filtrated from the blood 
and cleared by the liver and the spleen, whereas nanoparticles in the 10–500 nm size range 
can have long circulation half-lives.6 In addition to this, the vasculature of tumorous tissue 
tends to be fenestrated and the lymphatic system poor, due to the speed at which the tissue 
grows, and therefore tumours are more permeable to nanoparticles than normal tissue. This is 
referred to as the enhanced permeation and retention (EPR) effect, and can be exploited as a 
passive targeting strategy for drug delivery to tumour tissue, although the effect is not 
substantial.5,41,42   
 
The active targeting of cancerous cells for drug delivery can be achieved by exploiting the 
disparity in local pH between cancerous and non-cancerous tissue. Cancer cells tend to suffer 
oxygen deprivation (hypoxia) because they rapidly outgrow their blood supply. The cells 
adapt to the hypoxic environment and metabolise glucose through alternative pathways. This 
increases the acidity of the extracellular environment, mainly due to the production of lactic 
acid, and the slightly reduced pH in the extracellular environment of cancerous cells can 
therefore be employed as an effective cancer biomarker;43,44 normal non-cancerous human 
tissue has an average pH of 7.5, and human tumour tissue of 7.0.45 Acid-activated peptide 
delivery of nanoparticles is an established strategy for targeted distribution; surface-bound 
  Chapter Four 
134 
 
peptides which can shield their cell-penetrating function, and then unmask this upon pH 
change, can potentially target cancerous cells. A recent example of such strategy by Jin et 
al.,46 employs a modified Tat peptide to deliver micelles, in which all the amines in the lysine 
side-chains were converted to succinyl amides, to inhibit the Tat peptide’s non-specific 
interactions with cell membranes. Upon interaction with acidic tumour tissue, the amides can 
hydrolyse to amines, and restore the function of the Tat peptide (see Figure 4.4) to allow 
translocation across the membranes of the tumorous cells and delivery of the attached 
micelles (ca. 100 nm in diameter).46  
 
Figure 4.4 Schematic, adapted from Shen et al, showing CRRKR portion of Tat sequence. 46 
 
 
Another acid-activated peptide, which has been developed by Engelman and co-workers, is 
the pH low insertion peptide (pHLIP), which is derived from a sequence in 
bacteriorhodopsin.47-50 In the isolated pHLIP form 
(AAEQNPIYWARYADWLFTTPLLLLDLALLVDADEGTCG), the carboxylic acid side 
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chains of the aspartic acid residues (D) can be either deprotonated (at pH > 7) or protonated 
(at pH < 7). At pH>7, the peptide is hydrophilic, water-soluble and weakly coordinates to the 
cell membrane, with no ordered secondary structure. However, at pH<7, the protonated 
peptide is hydrophobic, which induces its partitioning from aqueous solution by insertion into 
cell membrane via the formation of a transmembrane α-helix structure (See Figure 4.5).51,52 
The peptide also has a cysteine residue near the C-terminus, which can attach to cargo 
through the thiol group for cellular insertion.  
 
 
Figure 4.5 Schematic of the insertion mechanism of pHLIP across the cell membrane. Adapted from 
reference.53 
 
 
The delivery of 13 nm gold nanoparticles using pHLIP (by attaching the gold to the peptide 
via the cysteine using S−Au chemistry) has been reported recently by Pikramenou and co-
workers, for pH-controlled delivery into platelets.3  The nanoparticles were also labelled with 
a luminescent europium(III) probe for optical tracking of the pH-active probes. However, the 
europium(III) complex has to be excited in the UV region of the electromagnetic spectrum 
(ca. 340 nm), which is often not possible with glass optics and conventional microscopes, and 
is also undesirable for biological tissue. Similarly, the pH-sensitive uptake of pHLIP-coated 
1 nm nanogold by HeLa cells (human ovarian cancer cells) and in vivo in a murine model has 
been reported by the Engelman group.54 Cellular uptake was analysed in a destructive fashion 
by fixing cells and then treating them with silver enhancement solution, in order to visualise 
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the gold nanoparticles, and an enhancement by a factor of 1.6 was observed for cells 
incubated with particles at acidic pH (6.5). The gold content of organ tissue following the in 
vivo studies was analysed by inductively-coupled plasma mass spectrometry (ICP-MS) of 
digested tissue, and enhanced gold concentrations were found in the tumorous tissue due to 
the peptide. More recently, Zhang and Tan55 have pushed the application of pHLIP-mediated 
delivery of nanoparticles further towards pH-targeted drug delivery systems, for the delivery 
of 140 nm mesoporous silica nanoparticles (with 3 nm pores), and loaded with Doxorubicin (a 
chemotherapy drug) to tumorous tissue.  
  
4.1.4 Peptide-mediated Nuclear Targeting of Nanoparticles 
The cell nucleus is a desirable target for many applications because the genetic information 
and transcription machinery all reside within the nuclear envelope. Therefore, nuclear 
targeting opens up a route to both diagnosis of disease phenotype and gene therapy.56 
Targeting the nucleus of a cell is not trivial because the probe must firstly enter the cell, 
secondly escape the endosomal or lysosomal pathways to be exposed to intracellular fluid, 
thirdly possess a nuclear localising signal to interact with the nuclear pore, and finally 
physically be able to cross the nuclear envelope (a double phospholipid bilayer membrane, 
embedded with proteins).57 The nuclear uptake of gold nanoparticles has been shown by 
attachment of peptides to gold nanoparticles and nanorods, namely well-known nuclear 
localisation signal (NLS) peptides, by El-Sayed and co-workers.57,58 However, Brust and co-
workers have studied nanoparticle uptake in cancer cells and found that gold nanoparticles 
capped in a mixture of NLS peptides with Tat and penetratin (CPPs) did cross the nuclear 
membrane, whereas particles coated with each single peptide did not.18 Similarly Feldheim 
and co-workers59,60 attached similar NLS peptide-conjugated BSA (bovine serum albumen) to 
gold nanoparticles, but nuclear uptake was only observed if the particles were injected into the 
cytosol; they were not translocated to the nucleus following cell incubation from outside of 
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the cell membrane because the particles became trapped in endosomal compartments 
following endocytic uptake.  
 
A new synthetic peptide, C105Y (CSIPPEVKFNKPFVYLI) has been found to enhance gene 
expression by conjugating the peptide to polylysine-condensed DNA complexes, forming 
DNA nanoparticles of ca. 25 nm.61-63 Since these empirical discoveries of enhanced 
expression with the C105Y peptide, Rhee and Davis have interrogated the mechanism by 
which the peptide itself enters the cell.63 Uptake and nuclear localisation within 10 min of 
incubation was observed for both fluorescently-labelled C105Y and PFVYLI peptides, but 
nuclear localisation was not observed for labelled SIPPEVKFNK sequences. Therefore it is 
believed that C105Y peptide enters the cell through the PFVYLI sequence. The internalisation 
process was observed at both 37 oC and 4 oC, which suggests that the uptake occurs in an 
energy-independent fashion (i.e. a non endocytic process), as endocytic pathways are 
completely inhibited at 4 oC; endocytosis is an energy-requiring process, unlike passive 
transport, and thus the process is retarded at low temperatures. In addition, control 
experiments with D-C105Y peptides (all amino acids of D isomers rather than L isomers) 
showed cellular internalisation, but no transport to the nucleus. This suggests that the cellular 
uptake is not receptor-mediated, as no specific spatial orientation is required, but that nuclear 
targeting is because the process is stereoselective. 
 
The mechanism by which C105Y appears to target the cell nucleus lends itself to attachment 
to gold nanoparticles as the N-terminal cysteine residue (C) can be used to attach to the 
nanoparticle, leaving the active PFVYLI sequence exposed at the C-terminus for targeting.63 
In addition, the non-endocytic uptake and successful translocation of 25 nm DNA 
nanoparticles with C105Y61-63 suggest that the peptide may prevent gold nanoparticles from 
becoming trapped in endosomes within the cell.  
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4.1.5 Chapter Outline 
In this Chapter, luminescent targeting nanoparticles have been synthesised by co-coating 
13 nm gold nanoparticles with the RuSH lumiphore and a peptide sequence. The following 
three peptides have been studied: CALNN, pHLIP, and C105Y. The synthesis of RuSH, 
which is made in situ from RuSAc, is described in Chapter Two (Section 2.2), and the 
structures of the RuSAc and RuSH complexes are shown in Figure 4.6. The structures of the 
three peptides studied are presented in Figure 4.7, and the co-coated peptide/RuSH 
nanoparticles discussed in this chapter are presented as schematics in Figures 4.8 and 4.9. 
 
 
 
Figure 4.6 Structure of the RuSAc and RuSH complex discussed in this chapter. 
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(a) CALNN 
 
 
(b) C105Y (CSIPPEVKFNKPFVYLI) 
 
 
(c) pHLIP (AAEQNPIYWARYADWLFTTPLLLLDLALLVDADEGTCG) 
 
Figure 4.7 Structures of the peptide sequences discussed in this chapter, each consisting of L-amino 
acids. Cysteine ‘SH’ groups are the expected sites at which each peptide will strongly bind to gold 
nanoparticles via S–Au chemistry (highlighted in red). 
 
 
 
 
 
Figure 4.8 Schematics of Ru-CALNN•AuNP13 (left) and Ru-pHLIP•AuNP13 (right). 
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Figure 4.9 Schematic of Ru-C105Y-Z•AuNP13. 
 
 
As a preliminary study, CALNN was chosen for its known stabilising effects imparted to gold 
nanoparticles (as discussed in Section 4.1), pHLIP was chosen for targeting cancer cells using 
pH-activated uptake, and C105Y for its nuclear targeting properties. Following the study of 
surfactant-mediated coating of nanoparticles with RuSH,64,65 outlined in Chapter Two, each 
peptide was examined to see if it could function in the same fashion as the surfactant moieties, 
displacing the citrate anions and preventing aggregation upon addition of the cationic RuSH 
complex. 
4.2 Synthesis and Characterisation of Co-coated Gold Nanoparticles 
with Peptides and RuSH 
RuSH and citrate-stabilised 13 nm gold nanoparticles were synthesised as reported in Chapter 
Two (Sections 2.2 and 2.3), and the three peptides were purchased from Alta Biosciences.  
The C105Y and CALNN peptides are both soluble in water, whereas the pHLIP sequence is 
not, and thus had to be dissolved in 10 % DMSO / phosphate buffer, as previously carried out 
by Davies et al.3 All three peptides contain a single cysteine amino acid which has a free thiol 
group available for binding to gold (Figure 4.7).  
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The surface coating of 13 nm citrate gold nanoparticles (9 nM) with CALNN, C105Y and 
pHLIP is monitored by UV-Vis absorption spectroscopy of the SPR (Figure 4.10).  
  
Figure 4.10 UV-Vis absorption spectra of 9 nM citrate gold nanoparticles (bold solid line) (a,c,e)and 
upon the addition of (a) 80 M CALNN (solid line), (b) 80 M pHLIP (solid line), and (c) 6 M 
C105Y (solid line). SPR max vs. [peptide] plotted for titrations of (b) 10–80 M CALNN (d) 10–80 M 
pHLIP, and (f) 2–6M C105Y, into 9 nM citrate gold nanoparticles ( x ). DLS intensity distributions 
vs. [peptide] also plotted in (f) as ( o ), with DLS intensity distribution of 2 M (solid), 4M (dashed) 
and 6 M (bold) C105Y shown in the inset. UV-Vis absorption error bars represent the precision of 
the spectrometer, and DLS error bars represent the calculated errors of the intensity distributions, ±1 
SD. 
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Absorption of peptide to the gold nanoparticle surface changes the surface dielectric constant, 
and results in a shift in the SPR max because the quantum-confined electrons oscillate at a 
slightly different frequency with this electronic change. Similar effects are seen with 
adsorption of surfactant molecules to gold nanoparticles in Chapter Two, Section 2.5. 
Titration of CALNN (0–80 M) into 13 nm gold nanoparticles (9 nM) gives rise to a 2 nm 
bathochromic shift to 522 nm in the SPR band (Figure 4.10a/b), as reported by Brust and co-
workers (with the addition of 0.7 mM CALNN to 7 nM 13 nm citrate gold nanoparticles),17 
and saturation occurs at ca. 20 M CALNN, i.e. ca. 2000 peptides per nanoparticle. The 
addition of pHLIP to the nanoparticles gives rise to a greater, 5 nm red-shift in the SPR max, 
to 525 nm (Figure 4.10c/d), similar to that reported by Pikramenou and co-workers,3 although 
in this Chapter the pHLIP peptide used has a cysteine thiol group at the C-terminus (Figure 
4.7), whereas in the study by Davies et al., a cysteine-thiopyridyl derivative was used.3 
Saturation is observed at ca. 50 M pHLIP (5500 peptides per nanoparticle), which indicates 
that pHLIP does not bind as strongly to the nanoparticles as CALNN. This is not surprising 
because the cysteine residue at the N-terminus of CALNN is far more exposed for binding to 
the gold surface than the cysteine in pHLIP, which is the penultimate amino-acid to the C-
terminus of a 38-amino acid chain. 
 
Unlike CALNN and pHLIP, addition of C105Y to citrate-stabilised gold nanoparticles 
induces a large red-shift and a broadening of the SPR upon titration into 13 nm citrate gold 
nanoparticles (Figure 4.10e/f), which is indicative of aggregation.66 DLS was performed 
during the titration (Figure 4.10f), and demonstrates that even upon addition of only 2M 
C105Y (200 peptides per nanoparticle) an increase in the average intensity distribution 
diameter is observed, from 26±10 nm to 280±240 nm (i.e. an increase in the average number 
distribution from 14±3 nm to 35±9 nm). The diameter increases further to 3590±2200 nm (i.e. 
730±190 nm, average number distribution) with 600 peptides per particle (Figure 4.10f inset). 
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This is unsurprising, because at pH 7 the C105Y peptide is monocationic due to protonation 
of the lysine sidechain (pKa = 10.67),67 whereas CALNN carries an overall neutral charge and 
pHLIP possesses a 5− charge. The positive charge of the C105Y peptide induces aggregation 
of the negatively charged citrate nanoparticles, as was observed with ruthenium(II) complexes 
in Chapter Two, and thus C105Y•AuNP13 could not be isolated. 
 
Nanoparticles coated in both CALNN and pHLIP were isolated by size-exclusion 
chromatography using Sephadex® G-25, eluting with water, analogous to the method used by 
Brust17 and Pikramenou.3 The coated nanoparticles elute first in a single band through the 
void volume of the column, isolating CALNN•AuNP13 and pHLIP•AuNP13 as aqueous 
sols; the excess free complex and peptide interact with the stationary phase and elute much 
more slowly. The zeta potential of the nanoparticles changes with the coating of each peptide; 
displacement of citrate anions by the neutral CALNN peptide gives rise to a reduction in the 
magnitude of the negative potential between the dispersion medium and the stationary layer of 
fluid associated with the particle, from −40±5 mV (uncoated citrate 13 nm gold nanoparticles) 
to −22±4 mV for isolated CALNN•AuNP13 (both measured at 2 nM). Similarly, 
displacement of the citrate anions with the negatively charged pHLIP peptide also reduces the 
negative zeta potential (from −40±5 mV) to −19±4 mV for isolated pHLIP•AuNP13 
(measured at 2 nM), in agreement with previously reported data.3 The bulky 38-amino acid 
peptide is likely to be less charge dense than the corresponding anions displaced at the 
surface, and thus a reduction in the zeta potential magnitude is expected, even though pHLIP 
bears a 5− charge.  
 
For the purpose of imaging, the targeted delivery of nanoparticles in cells, luminescent gold 
nanoparticles are prepared by coating 13 nm citrate gold nanoparticles with each peptide and 
RuSH, as described below.  
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4.2.1 Synthesis and Nanoparticle Characterisation of Ru-CALNN•AuNP13, 
Ru-pHLIP•AuNP13 and Ru-C105Y-Z•AuNP13.  
The co-coating of 13 nm gold nanoparticles with the luminescent ruthenium(II) complex 
RuSH and either CALNN or pHLIP (shown in Figure 4.11) is achieved in an analogous 
fashion to the method reported by Pikramenou and co-workers,3 in which gold nanoparticles 
are co-coated with pHLIP and a europium(III) complex.  
 
 
Figure 4.11 Schematic of co-coating procedure for peptide/RuSH gold nanoparticles, with CALNN. 
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The initial coating of the gold nanoparticles with peptide can stabilise the particles to some 
extent, with respect to aggregation, and subsequently the RuSH cationic complex can be 
added. This strategy is not possible, however, with the C105Y peptide, as it also induces 
aggregation of the nanoparticles due to its overall positive charge at pH 7. Therefore, a 
surfactant-mediated coating process was implemented to circumvent this problem.  
 
13 nm citrate gold nanoparticles (9 nM) are initially coated in peptide by adding either 
CALNN or pHLIP to a final concentration of 80 M. Subsequently, RuSH is added to the 
solution, and the SPR of the nanoparticles is monitored by UV-Vis absorption spectroscopy, 
as shown in Figures 4.12 and 4.13. 
 
Figure 4.12 UV-Vis absorption spectra of 1 mL (9 nM) 13 nm citrate gold nanoparticles (black solid 
line), with the addition of 80 M CALNN (black dashed line), followed by the titration of 4–7M (red 
full line). Final addition of 9M RuSH(red dashed) showed aggregation.   
 
 
CALNN provides some stabilisation with respect to aggregation (Figure 4.12), by comparison 
with the addition of 4 M RuSH directly to uncoated 13 nm citrate gold nanoparticles, which 
gives rise to an immediate aggregation of the particles, as discussed in Chapter Two (Section 
2.4). However, it was only possible to add 7 M (ca. 800 complexes per nanoparticles) RuSH 
before a significant increase in the SPR in the 550–750 nm range was apparent66 (red dashed 
line, Figure 4.12a), accompanied by a shift in the SPR peak to 531 nm (Figure 4.12b). 
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In a similar fashion to CALNN, the pHLIP sequence appears to stabilise the particles enough 
to add RuSH complex without aggregation being induced, although to a much greater extent 
with this longer peptide (Figure 4.13). There is no evidence of aggregation upon addition of 
RuSH into the 9 nM gold nanoparticles/80 M pHLIP solution by inspection of the SPR, 
which shifts an additional 5 nm upon addition of RuSH to the 80 M pHLIP/9 nM gold 
nanoparticle mixture, saturating at ca. 50 M RuSH (Figure 4.13b).  
 
 
Figure 4.13 (a) UV-Vis absorption specta of 9 nM 13 nm gold nanoparticles (black solid), with the 
addition of 80 M pHLIP (black dashed) and 80 M RuSH complex. (b) Titration of 20–95M RuSH 
into the 9 nM gold nanoparticles/80 M pHLIP solution, monitoring the shift in the SPR. 
 
 
Both Ru-CALNN•AuNP13 and Ru-pHLIP•AuNP13 were isolated from excess free 
complex and peptide by size-exclusion chromatography using Sephadex® G-25, in the same 
fashion as CALNN•AuNP13 and pHLIP•AuNP13, and characterised by UV-Vis absorption 
spectroscopy, as shown below (Figure 4.14). 
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Figure 4.14 (a) peptide=CALNN, (b) peptide = pHLIP. UV-Vis absorption spectra of non-isolated 
mixtures of gold nanoparticles (9 nM) / peptide (80 M) / RuSH (7 M (a) or 80 M (b)) (dashed 
line), and isolated Ru-CALNN•AuNP13 (a) / Ru-pHLIP•AuNP13 (b) (solid line) following size-
exclusion chromatography. 
 
 
Following isolation by size-exclusion, the max of the SPR for the isolated 
Ru-CALNN•AuNP13 persisted at 525 nm, suggesting that the surface environment was not 
altered significantly during the isolation process, and dilution in the column by a factor of 1.8 
was observed. The max of the isolated Ru-pHLIP•AuNP13 also remained the same as the 
pre-columned solution, at 530 nm, and dilution by a factor of 1.5 was observed.  
 
DLS (Figure 4.15) and electrophoretic light scattering have been used to analyse the coating 
process of the nanoparticles with peptide and RuSH; the particle properties of 
Ru-CALNN•AuNP13 and Ru-pHLIP•AuNP13 are summarised below in Table 4.1. 
Following the addition of peptide (either CALNN or pHLIP), the subsequent addition of 
RuSH is substantiated by changes in the SPR (Figures 4.12 and 4.13), the hydrodynamic radii 
(Figure 4.15, Table 4.1)  and the zeta potential of the particles (Table 4.1); in both instances 
the average number distribution of Ru-CALNN•AuNP13 and Ru-pHLIP•AuNP13 increases 
slightly with respect to their CALNN•AuNP13 and pHLIP•AuNP13 analogues, and the zeta 
potentials decrease in value.  In addition, the SPR max values red-shift, which indicates that 
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the surface dielectric constant has changes68 upon functionalisation with the ruthenium(II) 
complex. 
 
Figure 4.15 DLS intensity distribution (a) and number distribution (b) of 2 nM citrate gold 
nanoparticles (bold solid black line), CALNN•AuNP13 (dashed black line) and Ru-CALNN•AuNP13 
(solid red line). DLS intensity distribution (c) and number distribution (d) of 2 nM citrate gold 
nanoparticles (black), pHLIP•AuNP13 (blue) and Ru-pHLIP•AuNP13 (red).  
 
 
 
Table 4.1 Summary of nanoparticle characterisation data for nanoparticles 
coated with CALNN, pHLIP and RuSH complex 
sample diameter (DLS 
average number 
disctribution) / nm 
zeta potential 
(measured at 2 nM 
in water) / mV 
 
CALNN•AuNP13 
 
 
16±4 
 
−19±4 
Ru-CALNN•AuNP13 
 
20±5 −34±2 
pHLIP•AuNP13 
 
11±3 −22±4 
Ru-pHLIP•AuNP13 
 
13±3 −24±2 
All errors are quoted as ±1 standard deviation. 
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Isolated Ru-pHLIP•AuNP13 were analysed by inductively-coupled plasma optical emission 
spectroscopy (ICP-OES) and an atomic Au:Ru ratio = 48:1 was observed, corresponding to 
2000 complexes per nanoparticle and a molecular footprint of 0.5 nm × 0.5 nm (see Apeendix 
2.4).  This is a higher loading than could be achieved with CALNN (only 700 RuSH 
complexes per particle could be added) and  is similar to the loading of 1600 complexes per 
particle for the Ru-Z•AuNP13 nanoparticles and 1400 complexes per particle for the 
Ru-T20•AuNP13 particles discussed in Chapter Two (both corresponding to a molecular 
footprint = 0.6 nm × 0.6 nm). Isolated Ru-pHLIP•AuNP13 were also imaged by TEM, as 
shown below in Figure 4.16, showing the particles as discreet nanoparticles with gold core 
diameters of 13 nm.  
 
Figure 4.16 Transmission electron micrograph of Ru-pHLIP•AuNP13. 
 
 
In contrast to CALNN and pHLIP, co-coating 13 nm citrate gold nanoparticles with C105Y 
and RuSH proved impossible because both the peptide and the RuSH complex induce 
particle aggregation upon addition to the nanoparticles. Therefore, the strategy employed in 
Chapter Two, using the fluorosurfactant Zonyl® 7950 (Z) to stabilise the particles prior to 
coating, has been employed to circumvent this problem, as presented in the following 
schematic, Figure 4.17. 
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Figure 4.17 Schematic of surfactant-mediated co-coating procedure for peptide/RuSH gold 
nanoparticles, with C105Y.  
 
 
The citrate nanoparticles (9 nM) are initially coated in fluorosurfactant (ca. 1 mM), and then 
C105Y is added (80 M, 9000 peptides per nanoparticles), followed by an equimolar amount 
of RuSH (80 M), with respect to peptide. This process is followed by UV-Vis absorption 
spectroscopy, as shown in Figure 4.18. 
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Figure 4.18 UV-Vis absorption spectra of 13 nm uncoated citrate gold nanoparticles (black), with the 
addition of 1 mM Zonyl® 7950 fluorosurfactant (green dashed), upon the subsequent addition of 
C105Y peptide (80 M) (blue) and addition of RuSH complex (80 M) to this mixture (red solid line). 
Red dashed line shows the isolated Ru-C105Y-Z•AuNP13 (9 nM) following isolation by 
centrifugation. 
 
Upon addition of Zonyl® 7950 to the citrate nanoparticles, a 1 nM red-shift in the SPR is 
observed, to 521 nm, as observed previously in Chapter Two, Section 2.5 (Figure 2.21), and 
the subsequent addition of C105Y and RuSH does not shift the SPR peak (Figure 4.18).  The 
particles cannot be isolated by size-exclusion chromatography as the fluorosurfactant 
transports the unbound RuSH complex through the void volume of the stationary phase with 
the functionalised nanoparticles, and thus separation of the particles from unbound material 
does not occur (see Chapter Two, Section 2.8, and Appendix 3). Particles were therefore 
isolated by centrifugation, decantation of the supernatant and resuspension of the pellet in 
deionised water. Isolated Ru-C105Y-Z•AuNP13 have an SPR max of 525 nm, as can be seen 
in Figure 4.18, which is red-shifted by 4 nm from the non-isolated precursor. However, 
neither SPR peak broadening nor peak growth at 600–800 nm are observed, and thus 
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aggregation does not appear to be occurring.  Ru-C105Y-Z•AuNP13 and analogous 
C105Y-Z•AuNP13 (without the RuSH lumiphore label, with an SPR max of 522 nm) have 
been characterised by DLS and electrophoretic mobility measurements to give zeta potential 
data, which is presented in Figure 4.19 and Table 4.2 below.  
 
 
 Figure 4.19 DLS intensity distribution (a) and number distribution (b) of citrate gold nanoparticles 
(bold solid black line), Z•AuNP13 (dashed black line), C105Y-Z•AuNP13 (blue line), and  Ru-
C105Y-Z•AuNP13(red line,) measured at a concentration of 2 nM.  
 
 
Table 4.2 Summary of nanoparticle characterisation data for nanoparticles 
coated with C105Y, Zonyl® 7950 and  RuSH complex. 
 
Sample 
diameter (DLS 
average number 
distribution) / nm 
zeta potential 
(measured at 2 nM in 
water) / mV 
 
uncoated 13 nm 
citrate gold 
nanoparticles 
 
 
 
13±4 
 
 
 
−40±5 
 
Z•AuNP13 
 
 
20±2 
 
−61±4 
C105Y-Z•AuNP13 
 
19±6 −51±1 
Ru-C105Y-Z•AuNP13 
 
18±5 −57±4 
Ru-Z•AuNP13 
 
17±5 −48±2 
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A 30% increase in the mean intensity distribution hydrodynamic diameter is observed when 
Zonyl® 7950 binds to the surface of the gold nanoparticles, as discussed in Chapter Two 
Section 2.8,  but no further increase in diameter is observed upon addition of either C105Y, 
RuSH, or both C105Y and RuSH together. Thus, there is no evidence of nanoparticle 
aggregation, which is consistent with the large negative zeta potentials of −51±1 mV for 
C105Y-Z•AuNP13 and −57±4 mV for Ru-C105Y-Z•AuNP13. All the particles coated in 
Zonyl® 7950 exhibit larger negative zeta potential values than the uncoated citrate 
nanoparticles (|zeta potential|>40 mV), due to the electronegative C–F bonds of the 
fluorosurfactant, and thus the particles are quite stable in solution. 
 
4.2.2 Photophysical Characterisation of Ru-CALNN•AuNP13, 
Ru-pHLIP•AuNP13 and Ru-C105Y-Z•AuNP13.  
 
The photophysical properties of Ru-CALNN•AuNP13, Ru-pHLIP•AuNP13 and 
Ru-C105Y-Z•AuNP13 were investigated to determine whether the co-coating peptide has an 
influence upon the photophysical properties of the ruthenium(II) complex appended to the 
particles.  The UV-Vis absorption spectra of all three types of co-coated nanoparticles,  
Ru-CALNN•AuNP13 (Figure 4.20, solid line), Ru-pHLIP•AuNP13 (Figure 4.21, solid line) 
and Ru-C105Y-Z•AuNP13 (Figure 4.22, solid line) are dominated by the SPR of the gold 
nanoparticles, and the excitation spectra of the red emission, em = 630 nm, exhibit the typical 
LC and MLCT singlet states of the free RuSAc complex (see Chapter Two, Section 2.2.2) in 
each case (dashed line, Figures 4.20, 4.21(a) and 4.22). 
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Figure 4.20 UV-Vis absorption spectrum (solid line), excitation spectrum, em = 630 nm (dashed line) 
and steady-state emission spectrum, exc = 450 nm (bold solid line) of 4nm Ru-CALNN•AuNP13. 
Emission and excitation spectra are corrected for instrument response.  
 
 
The steady-state luminescence spectrum of Ru-CALNN•AuNP13 (bold line, Figure 4.20) 
presents a broad emission peak, with max at 650 nm, following excitation at 450 nm into the 
singlet MLCT state, with an observed luminescence lifetime of 230 ns ±10% (aerated) and 
300 ns ±10% (degassed), measured at a em = 630 nm. The emission properties of the 
ruthenium(II) complex bound in Ru-CALNN•AuNP13 are very similar to those of the free 
RuSAc complex in 1% CH3CN, water, which also has a max= 650 nm, and lifetimes of 
260 ns ± 6% (aerated) and 325 ns ± 6% (degassed). Within the error of the experiment, there 
is no evidence that the luminescence of the ruthenium(II) complex is quenched upon binding 
to the nanoparticles, and the surrounding CALNN peptide does not alter the photophysical 
properties of the complex with respect to the free complex in water. Similarly, the quenching 
by oxygen suggests that the complex is exposed to solvent, which is perhaps not surprising as 
CALNN is a short sequence and cannot shield the complex to the extent that this 
luminescence quenching pathway, which relies on bimolecular collision, is removed. 
 
In contrast, when Ru-pHLIP•AuNP13 particles are excited at 450 nm (bold line, Figure 4.21) 
they exhibit broad red emission at  max = 635 nm, and enhanced luminescence lifetimes of 
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550 ns ±10% (aerated) and 590 ns ±10% (degassed) are observed by time-resolved 
luminescence spectroscopy. 
 
Figure 4.21 (a) UV-Vis absorption spectrum (solid line), excitation spectrum, em = 630 nm (dashed 
line) and steady-state emission spectrum, exc = 450 nm (bold solid line), (b) (a)UV-Vis absorption 
spectrum (solid line), excitation spectrum, em = 350 nm (dashed line) and steady-state emission 
spectrum, exc = 280 nm (bold solid line of 1nm Ru-pHLIP•AuNP13.Emission and excitation spectra 
are corrected for instrument response. 
 
 The max value is blue-shifted by 15 nm from the free RuSAc complex in water, the aerated 
lifetime is increased ca. two-fold,  and the luminescence is far less oxygen-sensitive than both 
the free complex in water and Ru-CALNN•AuNP13. These results suggest that the pHLIP 
sequence shields the ruthenium(II) complex from the bulk solvent, as well as from quenching 
by 3O2, by creating a steric barrier to collisional quenching mechanisms. The blue-shift in the 
emission peak demonstrates that pHLIP exposes the ruthenium(II) complex to a less polar 
environment than the aquous solvent, and subsequently destabilises the emissive charge 
transfer state. This behaviour is not observed with the short CALNN pentapeptide, whereas 
the 38-amino acid peptide can protect the ruthenium(II) complex from solvent and molecular 
oxygen to a much greater extent. In addition to the ruthenium(II) complex emission from 
Ru-pHLIP•AuNP13, pHLIP contains two tryptophan (W) residues, which can be detected by 
fluorescence, following excitation at 280 nm (Figure 4.17 (b)). Steady-state emission was 
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observed at max = 346 nm, consistent with the tryptophan emission observed by Engelman 
and co-workers in the free peptide.69 
 
The steady-state luminescence spectrum of Ru-C105Y-Z•AuNP13, as presented in Figure 
4.22 (bold line), exhibits broad emission in the red region of the electromagnetic spectrum, 
with max = 640 nm, following excitation into the singlet MLCT state at exc = 450 nm.  
 
Figure 4.22 UV-Vis absorption spectrum (solid line), excitation spectrum, em = 630 nm (dashed line) 
and steady-state emission spectrum, exc = 450 nm (bold solid line) of 1 nM 
Ru-C105Y-ZAuNP13.Excitation and emission spectra are corrected for instrument response. 
 
Similar to the Ru-pHLIP•AuNP13 particles, the emission of the ruthenium(II) complex on 
Ru-C105Y-Z•AuNP13 is blue-shifted with respect to the free complex in water, although in 
this instance to a lesser degree, by 10 nm. The observed luminescence lifetime of the triplet 
MLCT state of the ruthenium(II) complex in Ru-C105Y-Z•AuNP13 is 380 ns ±10% 
(aerated) and 720 ns ±10% (degassed). The photophysical properties of 
Ru-C105Y-Z•AuNP13 are similar to those of Ru-Z•AuNP13, discussed in Chapter Two, in 
which red emission with max = 640 nm is also observed, with luminescence lifetimes of 
340±10% ns (aerated) and 690 ±10% ns (degassed). It is therefore clear that the presence of 
the fluorosurfactant influences the photophysical properties on the ruthenium(II) complex, 
and this has been explored extensively in Chapter Two. However, the presence of the C105Y 
peptide appears to enhance the luminescence lifetime of the ruthenium(II) complex 
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marginally with respect to Ru-Z•AuNP13. As is observed with the Ru-Z•AuNP13 particles, 
the ruthenium(II) complex still remains quite oxygen sensitive on Ru-C105Y-Z•AuNP13 
particles, unlike on Ru-pHLIP•AuNP13. 
 
Due to the effect of pHLIP on the photophysical properties of the ruthenium(II) complex upon 
co-coating of gold nanoparticles, the interaction of the peptide with the complex was studied 
separately in solution. Titration of 1–120 M pHLIP into 20 M RuSAc in 1 % 
CH3CN / water gives rise to a luminescence enhancement, with a steady-state integrated 
emission increase by a factor of 4. In addition to this, a 20 nm blue-shift in the max from 648 
nm (complex in water) to 628 nm is observed and the aerated lifetime increases by a factor of 
3 (Figure 4.19). The induced enhancement of both the steady-state emission and the observed 
lifetime of RuSAc by pHLIP indicates that the non-radiate rate of decay of the triplet MLCT 
excited state of RuSAc is reduced upon interaction with pHLIP. This suggests that the peptide 
protects the complex from molecular oxygen quenching. The blue-shift in the triplet MLCT 
emission band is indicative of the RuSAc complex being exposed to a less polar environment 
with respect to water, which destabilises the charge-separated excited state. It is likely that the 
interaction between the complex and pHLIP is electrostatically driven, as RuSAc is 2+ and 
pHLIP is 5−, and displacement of small counter ions by the long peptide sequence is 
entropically favourable. 
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Figure 4.23 (a) Steady-state emission, exc = 450 nm, and (b) time-resolved luminescence, exc = 445 
nm, em = 630 nm, of 20 M RuSAc in 1 % CH3CN / water (red) following the titration  of 1–120 M 
pHLIP (black and grey). (c) Plot of steady-state emission max and relative integrated corrected 
emission intensity vs. [pHLIP]. (d) Plot of luminescence lifetime of RuSAc vs. [pHLIP].Emission 
spectra are corrected for instrument response. 
 
 
The observed aerated luminescence lifetime (550 ns) and steady-state emission (max = 
635 nm) of the Ru-pHLIP•AuNP13 particles lies between the extremes of the data shown in 
Figure 4.23 which is expected on a nanoparticle surface where all moieties are bound to the 
gold nanoparticle via S–Au bonds, and thus the pHLIP is less free to interact with the 
ruthenium(II) complex. 
 
In summary, the CALNN peptide is able to stabilise the attachment of RuSH to aqueous gold 
nanoparticles to some extent, and the photophysical properties of the ruthenium(II) complex 
are unaffected by attachment to Ru-CALNN•AuNP13. In contrast, the co-coating of gold 
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nanoparticles with RuSH and pHLIP enhances the luminescence of the ruthenium(II) 
complex, hence, Ru-pHLIP•AuNP13 have great potential as optical imaging probes that can 
target delivery to cancer cells, which is explored in section 4.3. In order to co-coat 13 nm gold 
nanoparticles with C105Y and RuSH, the particles had to be coated initially in the 
fluorosurfactant Zonyl® 7950, to prevent aggregation, and the resulting particles again 
exhibited enhanced luminescence properties with respect to the free RuSAc complex in water. 
 
4.3 Applications of Peptide-mediated Delivery of Luminescent Gold 
Nanoparticles 
4.3.1 Cell Uptake of Ru-CALNN•AuNP13 
Preliminary imaging of A549 human lung cancer cells incubated with Ru-CALNN•AuNP13 
particles was attempted but the particles were not bright enough to image by confocal 
luminescence microscopy, as shown in Figure 4.24. Cell culture and incubation was 
performed by Mr Sunil Claire, and microscopy was carried out by the author. 
 
Figure 4.24 A549 cancer cells dosed with Ru-CALNN•AuNP13 and imaged by confocal microscopy. 
(a) overlay of blue channel (exc = 405 nm, em =410–545 nm ) and red channel (exc =453 nm / 476 
nm , em =555–800 nm ), (b) transmission channel, (c) reflection channel (exc =488 nm, em = 478–
498 nm). 
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Figure 4.24(a) shows no detectable ruthenium emission in the red channel, but the nuclei of 
the cells are visible in the blue channel as the cells were stained with Hoechst 33258 (nuclear 
stain). Aggregates of nanoparticles appear as black spots on the coverslip in the transmission 
image (Figure 4.24(b)), and white points of reflection in Figure 4.24(c), but are not bright 
enough to image from the ruthenium red luminescence channel. This is unsurprising as there 
are <800 complexes per nanoparticle. It is therefore concluded that although CALNN can 
facilitate low-labelling of the resulting nanoparticles with the ruthenium(II) optical probe,  
Ru-CALNN•AuNP13 particles are not suitable for imaging by confocal luminescence. 
 
4.3.2 pH-targeted Uptake of Ru-pHLIP•AuNP13 in Cancer Cells 
The selective uptake of nanoparticles by cancer cells, using their slightly reduced pH as a 
biomarker, is attempted in an in vitro model using Ru-pHLIP•AuNP13, by incubation of 
cancer cells with the particles at pH 6.4 and pH 7.5. To verify that the nanoparticles are stable 
at these pHs, particles were incubated at 0.6 nM in Tyrode’s buffer at pH 6.4 and 7.5 for 24 hr 
at 37 oC, to emulate the incubation conditions with the A549 cells. The nanoparticles were 
then analysed by DLS and UV-Vis absorption spectroscopy, as shown in Figure 4.25. 
 
 
Figure 4.25 (a) DLS Number distribution and (b) UV-Vis absorption Spectroscopy of 0.6 nM 
Ru-pHLIP•AuNP13 incubated for 1 hr in Tyrode’s buffer, at pH 6.4 (red) and pH 7.4 (black). 
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The particles maintained their SPR peak at 530 nm at both pHs, and DLS number 
distributions of 15±4 nm were observed in both cases, thus verifying that the particles are 
stable at both pHs used within the cell studies. 
 
A549 human cervical cancer cells were incubated with 0.6 nM Ru-pHLIP•AuNP13 at pH 
6.5 and pH 7.4 for 3 hr, by Dr Robert Harris and Dr Nikolas Hodges in the School of 
Biosciences, and imaged by confocal microscopy, as shown in Figure 4.26. Incubation of the 
cells in extracellular environments at pH 6.5 is used to model cancerous tissue, as has been 
employed previously,48,53,70 and extracellular changes to pH will not alter the intracellular pH 
as this is regulated by cells within 10–15 min.71 
 
 
Figure 4.26 Fixed A549 cells dosed with Ru-pHLIP•AuNP13 in serum-free media at (a) pH 6.5 (b) 
pH 7.4. A549 cells. Cells dosed and imaged by Dr Robert Harris. Images are overlays of blue channel 
(exc = 405 nm, em =410–545 nm) and red channel (exc =453 nm / 476 nm , em =555–800 nm). 
 
 
As can be seen in Figure 4.26, the Ru-pHLIP•AuNP13 nanoparticles are bright enough to be 
visualised by confocal luminescence microscopy, unlike Ru-CALNN•AuNP13.The red 
emission from Ru-pHLIP•AuNP13 was observed at both pHs in the red channels of Figures 
4.26(a) and 4.26(b). Cellular uptake of the nanoparticles was observed at both pHs, following 
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a 3 hr incubation time, but quantitative analysis of the nanoparticle uptake was difficult to 
assess by confocal microscopy, with only 20–30 cells in the field of view.  
 
In order to achieve statistical analysis of  Ru-pHLIP•AuNP13 uptake in cells at pH 6.5 and 
pH 7.4, HL-60 cells (human leukaemia white blood cells) were incubated with particles in 
Tyrode’s buffer for 30 min, and analysed by flow cytometry, using fluorescence-activated cell 
sorting (FACS). A shorter incubation time (30 min, rather than 3 was chosen to reduce the 
amount of particle uptake by endocytosis, and HL-60 cells were used for ease as the cells 
grow in suspension (unlike the adherent A459 cell line), which is more suitable for flow 
cytometry studies. The graph presented in Figure 4.27 shows the intensity of signal at > 620 
nm detected per cell, integrated over all cells detected in the flow cytometer, for control cells 
(undosed HL-60 cells) and cells dosed with of  Ru-pHLIP•AuNP13 at pH 7.5 and 6.4. 
 
 
Figure 4.27 Flow Cytometry of HL-60 cells incubated with Ru-pHLIP•AuNP13 in Tyrode’s buffer for 
30 min, at pH 6.5 (red) and pH 7.4 (green). Negative control (HL-60 cells incubated with no 
nanoparticles) shown in blue. Analysis of 50,000 cells was performed at each condition. 
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At pH 6.5 there was a 50% increase in uptake of Ru-pHLIP•AuNP13 particles as compared 
with the cells incubated with particles at pH 7.4, observed by the shift in the frequency value 
for the distribution of red signal per cell.  This is similar to the uptake enhancement that was 
observed for pHLIP-conjugated 1 nm gold nanoparticles by Engelman and co-workers,54 in 
which a 60% increase was observed. These preliminary cell studies confirm that pH-activated 
delivery of Ru-pHLIP•AuNP13 is possible in cancer cells, and the result is indeed promising 
for future applications of these nanoparticles.  
 
There are two main advantages of the Ru-pHLIP•AuNP13 system over the pHLIP-
conjugated 1 nm gold nanoparticles studied by Engelman and co-workers:54 Firstly, the 
particles are larger, i.e. 13 nm, and are thus more likely to be able to exploit passive EPR 
mechanisms to further enhance the selective targeting to tumorous tissue in vivo. Secondly, 
Ru-pHLIP•AuNP13 can be imaged by luminescence techniques, as opposed to staining cells 
with a silver solution post-fixing and subsequently imaging in bright-field mode.  
Luminescence detection offers high sensitivity, is less prone to artifacts, and can also be used 
to image live cells. In addition, unlike the  nanoparticles studied previously in the group by 
Davies et al.,3 which are visualised by epiluminescence microscopy using UV excitation of 
the europium(III) luminescent probe, Ru-pHLIP•AuNP13 can be detected using 
conventional confocal luminescence microscopy and FACS techniques, because the 
ruthenium(II) lumiphore can be excited in the visible range of the electromagnetic spectrum, 
between 400–500 nm, and the luminescence is bright enough to detect. 
 
4.4 Conclusions and Future Work 
13 nm gold nanoparticles have been successfully co-coated with a red luminescent ruthenium 
(II) polypyridyl complex, RuSH, and three different peptides; CALNN, pHLIP and C105Y. 
CALNN and pHLIP stabilised the 13 nm enough to add the cationic RuSH complex without 
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aggregation of the particles, although only 800 complexes per particle could be added to 
CALNN-coated particles before aggregation became apparent by inspection of the SPR by 
UV-Vis absorption spectroscopy. The long (36-amino acid) negatively charged sequence, 
pHLIP, was able to withstand aggregation by addition of 9,000 equivalents of RuSH, and 
isolated particles were loaded with 2000 complexes per particle. The monocationic peptide 
sequence C105Y aggregated the nanoparticles, and thus co-coating of particles with this 
peptide and RuSH was achieved using surfactant-mediated coating with Zonyl® 7950 
fluorosurfactant. The photophysical properties of the ruthenium(II) complex were found to 
vary when bound to nanoparticles with different co-coating moieties; The ruthenium(II) 
complex bound to nanoparticles in Ru-CALNN•AuNP13 behaved in a similar fashion to the 
free RuSAc complex in water (1% CH3CN), whereas a blue shift in the emission and 
enhanced luminescence lifetimes were observed in both Ru-pHLIP•AuNP13 and 
Ru-C105Y-Z•AuNP13 samples. 
 
Preliminary cell studies with Ru-pHLIP•AuNP13 show successful pH-targeted uptake in 
cancer cells; an uptake increase of 50% at pH 6.5 vs. pH 7.5 is observed, which demonstrates 
that these particles have the potential to improve nanoparticle delivery to tumor cells in vivo. 
Future in vitro studies of  Ru-pHLIP•AuNP13 uptake in  cancer cells vs. non-cancerous cells 
would lead to further insight into how such particles can be applied as targeted nanovectors, 
and eventually in vivo studies would demonstrate the capabilities of such particles in the body. 
It would also be of interest to look at the uptake and localisation of  Ru-C105Y-Z•AuNP13 
nanoparticles in cells, to see if the C105Y peptide maintains its nuclear targeting properties 
once bound to this complex nanovehicle.   
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4.6 Experimental 
4.6.1 General Synthesis 
RuSH (3.5 mM (aq) 30 % w/w:CH3CN (1:1)) was synthesised in situ from its RuSAc 
precursor, as described in Chapter Two, Section 2.12.1, directly prior to titration into the 
colloid. CALNN, C105Y and pHLIP, were purchased from Alta Biosciences with purities of 
>95 % for CALNN, >90 % for C105Y and >80 % for pHLIP (HPLC assay) and used without 
further purification. Zonyl® 7950 was purchased from Sigma Aldrich. 13 nm gold 
nanoparticles were synthesised by the citrate reduction method,72 as described in Section 
2.12.1. 
 
Synthesis of CALNN•AuNP13  
An aqueous solution of CALNN (20–80 μL, 1 mM) was titrated into 13 nm citrate gold 
nanoparticles, to a final peptide concentration of 80 M, and the max of the SPR was 
monitored by UV-Vis absorption spectroscopy to ensure saturation of the binding sites. The 
particles were isolated by size-exclusion chromatography on Sephadex® G-25. Dilution in the 
column was examined by UV-Vis absorption spectroscopy and the final nanoparticle 
concentration was estimated to be 5 nM. UV-Vis (H2O) λmax [nm] = 522 (SPR). 
Diameter = 16 ± 4 nm (DLS number distribution), = 30 ± 12 nm (DLS intensity distribution). 
Zeta potential= −22 ± 4 mV (isolated, 2 nM in deionised water).   
 
Synthesis of Ru-CALNN•AuNP13  
An aqueous solution of CALNN (20–80 μL, 1 mM) was titrated into 13 nm citrate gold 
nanoparticles (1 mL, 9 nM), to a final peptide concentration of 80 M, and the max of the 
SPR was monitored by UV-Vis absorption, as described for the preparation of 
CALNN•AuNP13. Following this, a solution of RuSH (0.5–2.0 μL, 3.5 mM (aq) 30 % 
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w/w:CH3CN (1:1)) was titrated in, again following the max of the SPR to a final RuSH 
concentration of 7 M. The particles were isolated by size-exclusion chromatography on 
Sephadex® G-25, and dilution in the column was examined by UV-Vis absorption 
spectroscopy. The final nanoparticle concentration was estimated to be 5 nM. UV-Vis (H2O) 
λmax [nm] = 525 (SPR). Diameter = 20 ± 5 nm (DLS number distribution), = 269 ± 269 nm 
(DLS intensity distribution). Zeta potential= −34 ± 2 mV (isolated, 2 nM in deionised water). 
Emission (H2O, λexc = 450 nm) λmax [nm] = 650. 
 
Synthesis of pHILP•AuNP13  
Adapted from procedure by Davies et al.333 A solution of pHLIP (5–40 μL, 2 mM in 10% 
DMSO, phosphate buffer saline) was titrated into 13 nm citrate gold nanoparticles (1 mL, 9 
nM), to a final peptide concentration of 80 M, and the max of the SPR was monitored by 
UV-Vis absorption spectroscopy. The particles were isolated by size-exclusion 
chromatography on Sephadex® G-25, and to give a final nanoparticle concentration of 6 nM 
(estimated by UV-Vis spectroscopy). UV-Vis (H2O) λmax [nm] = 525 (SPR). Diameter = 11 
± 3 nm (DLS number distribution), = 72 nm ± 66 nm (DLS intensity distribution). Zeta 
potential= −19 ± 4 mV (isolated, 2 nM in deionised water).   
 
Synthesis of Ru-pHILP•AuNP13  
A solution of pHLIP (5–40 μL, 2 mM in 10% DMSO, phosphate buffer saline) was titrated 
into 13 nm citrate gold nanoparticles (1 mL, 9 nM), to a final peptide concentration was 80 
M, in a similar fashion to the preparation of pHILP•AuNP13. A solution of RuSH (5–
25 μL, 3.5 mM (aq) 30 % w/w:CH3CN (1:1)) was titrated in, again following the max of the 
SPR, to a final concentration was 80 M. The particles were isolated by size-exclusion 
chromatography on Sephadex® G-25, and dilution in the column was examined by UV-Vis 
absorption spectroscopy; the final nanoparticle concentration was estimated to be 6 nM. UV-
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Vis (H2O) λmax [nm] = 530 (SPR). Diameter = 13 ± 4 nm (DLS number distribution), = 186 ± 
202 nm (DLS intensity distribution). ). Zeta potential= −24 ± 2 mV (isolated, 2 nM in 
deionised water). Emission (H2O, λexc = 450 nm) λmax [nm] = 635. ICP-OES Au:Ru atomic 
ratio = 48:1. 
 
Synthesis of C105Y-Z•AuNP13  
Zonyl® 7950 (CH2−C(CH3)COOC2H4(CF2)nF, MW ca. 500, 1 μl, 1.15 g mL
−1) was added to 
13 nm citrate gold nanoparticles (1 mL, 9 nM), to give fluorosurfactant coated nanoparticles 
(9 nM nanoparticles), with a final fluorosurfactant concentration of ca. 1mM. Subsequently, a 
solution of C105Y (80 μL, 1 mM, aqueous) was added, and the max of the SPR was 
monitored by UV-Vis absorption spectroscopy. The particles were isolated by centrifugation 
at 12,000 g for 15 min, followed by removal of the supernatant and re-dispersion in deionised 
water (1mL). This was repeated twice. UV-Vis (H2O) λmax [nm] = 523 (SPR). 
Diameter = 19± 6 nm (DLS number distribution), = 59 nm ± 36 nm (97%), 4240 nm ± 
1000 nm (3%) (DLS intensity distribution). Zeta potential= −51 ± 1 mV (isolated, 2 nM in 
deionised water).   
 
Synthesis of Ru-C105Y-Z•AuNP13  
Zonyl® 7950 (CH2–C(CH3)COOC2H4(CF2)nF, MW ca. 500, 1 μl, 1.15 g mL
−1) was added to 
13 nm citrate gold nanoparticles (1 mL, 9 nM), to give fluorosurfactant coated nanoparticles 
(9 nM nanoparticles), with a final fluorosurfactant concentration of ca. 1mL. Subsequently a 
solution of C105Y (80 μL, 1 mM, aqueous) was added, similar to the preparation of 
C105Y-Z•AuNP13. A solution of RuSH (20 μl, 3.5 mM (aq) 30 % w/w:CH3CN (1:1)) was 
added and the max of the SPR was monitored by UV-Vis absorption spectroscopy. The 
particles were isolated by centrifugation at 12,000 g for 15 min, followed by removal of the 
supernatant and re-dispersion in deionised water (1mL). This was repeated twice. UV-Vis 
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(H2O) λmax [nm] = 524 (SPR). Diameter = 18± 5 nm (DLS number distribution), 52 nm ± 33 
nm (93%), 2000 nm ± 1260 nm (7%) (DLS intensity distribution). Zeta potential= −57 ± 4 
mV (isolated, 2 nM in deionised water).   
 
4.6.2 Cell Studies with Ru-CALNN•AuNP13 
A549 tissue culture was performed by Mr Sunil Claire. Cells were incubated with 0.5 nM 
Ru-CALNN•AuNP13 for 24 hr in Dulbecco’s modified Eagle Medium as previously 
described.65 Cofocal microscopy was performed by the author. 
 
4.6.3 Cell Studies with Ru-pHLIP•AuNP13 
A549 tissue culture and microscopy was performed by Dr Robert Harris, School of 
Biosciences. Cells were incubated with 0.6 nM Ru-pHLIP•AuNP13 for 3 hr in serum-free 
media, using phosphoric acid to adjust the pH, and stained with Hoechst 33258 (3 µl, 2.5 µg 
mL−1).  Cell media was removed and the cells washed twice in PBS followed by fixation with 
methanol for 5 min followed by two further washes with PBS. Coverslips were removed and 
mounted on a droplet of Hydromount media (national diagnostics) on glass slides, sealed with 
clear nail varnish and stored for 24 hours at 4°C before imaging. 
 
Flow cytometry studies and HL-60 cell work was performed by Dr Nikolas Hodges, School 
of Biosciences. Cells were incubated with Ru-pHLIP•AuNP13 (0.6 nM in Tyrode’s buffer) 
for 30 min, and washed in PBS by centrifugation, resuspended in PBS and transferred to flow 
cytometry tubes for analysis (FACScalibur, BD Biosciences, USA).  Forward scatter, side 
scatter and red luminescence (exc=488 nm with light collected through a 620 nm band pass 
filter) of 50,000 cells were collected and Weasel freeware software was used for data analysis.  
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5.1	Introduction	
Transition metal complexes can be exploited in the design of luminescent nanoparticle flow 
tracers by taking advantage of their high photostability and large differences in excitation and 
emission wavelengths. Throughout this thesis so far, luminescent nanoparticles have been 
developed using a tailor-made surface-binding derivative of the archetypal low-spin d6 
transition metal lumiphore ruthenium tris(bipyridine), i.e. RuSH.1,2 Such nanoparticles were 
ideal for imaging cancer cells in vitro, but for flow imaging it is important to be able to ensure 
extremely high particle brightness so that the exposure time per image frame can be reduced 
as low as possible to increase the temporal resolution of the dynamic flow data. Therefore in 
this chapter surface-binding iridium(III) probes have been developed to label nanoparticles, 
because many iridium(III) complexes have superior luminescence efficiencies to 
ruthenium(II) complexes. 
 
5.1.1Cyclometallated	Iridium(III)	Polypyridyl	Complexes	
Cyclometallated iridium(III) complexes are an emerging choice of luminescent agent for 
imaging applications; they are used in organic light-emitting diode (OLED) applications,3-5  
dye-sensitised solar cells,6 and are beginning to flourish in the field of biological probes.7-9 
Interest in cyclometallated iridium(III) complexes began in the 1980s, when it was discovered 
that bipyridine ligands ortho-metallate upon complexation with the metal ion, to form 
complexes such as [Ir(Hbpy-C3,N’)(bpy)2]3+.10,11  Following this, efforts have been focussed 
on developing deliberately ortho-metallated  complexes with analogous polypyridyl 
complexes such as phenylpyridine (ppy). Bis(cyclometallated) iridium(III) compounds are 
most commonly applied to luminescence applications, usually of the generic formula 
[Ir(C^N)2(N^N)]+, whereby the (C^N) ligand is the cyclometallating monoanionic ligand and 
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the (N^N) ligand is a neutral chelating species, datively bonding through the N atoms, such as 
bipyridine, as shown in Figure 5.1.  
 
Figure 5.1 Schematic of generic Ir(III) cyclometallated complexes, i.e. [Ir (C^N)2(N^N)]+. 
 
 
The sigma-bonded carbon-metal bonds impart spectroscopic properties upon the complex 
which are quite disticnct from their N-coordinated equivalents; the MLCT state is 
dramatically stabilised by the sigma-donating C¯, and the MC d-d  transitions are very high in 
energy due to the ‘stong’ nature of the ligands such as ppy in the spectroscopic series.10 
Several groups have previously studied the excited-state properties of cyclometallated iridium 
complexes, especially with phenylpyridyl ligands, and it is believed that the luminescent state 
of such complexes is the lowest-lying excited state, which is the triplet LC state.12-14 
However, due to the proximity of the LC and MLCT state in cyclometallated complexes such 
as [Ir(ppy)2(bpy)]+ (Figure 5.1), strong mixing of the charge transfer state into the lowest 
triplet LC state is induced.14-16  In general structured bands with small shifts in the max upon 
reducing the temperature of the samples, are attributed to triplet LC transitions, whereas broad 
and structureless bands with large shifts in the max are characteristic charge transfer 
transitions. In addition to this mixing, many cyclometallated iridium(III) complexes exhibit 
significant spin-orbit coupling between the singlet MLCT state and the triplet LC state,  
which is mediated by the relativistic effects of the proximal heavy iridium(III) ion. Spin-orbit 
coupling of these states gives rise to the significantly enhanced oscilliator strengths of the 
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transitions in such iridium(III) complexes,with respect to those usually observed for triplet LC 
transitions, as shown in Figure 5.2.12,16 Further to this, empirical observations of the intense 
luminescence of several iridium(III) cyclometallated complexes  relative to their analogous 
rhenium(III) complexes, which only give measurable emission at low temperatures, are 
consistent with the strong spin-orbit splitting proposed.14,16,17  
 
Figure 5.2 Schematic showing the mixing of the low-lying LC and MLCT excited states in 5d6 
complexes, mediated by spin-orbit coupling.12 
 
 
The degree of mixing between the singlet MLCT state and the triplet LC state depends upon 
the energy gap between the two states and the strength of the spin-orbit coupling between the 
two wavefunctions.15 This can be studied by high resolution optical spectroscopy techniques, 
such as polarised single crystal absorption spectra and luminescence at cryogenic 
temperatures.14,16 Just a small degree of singlet MLCT character has a dramatic effect upon 
the photophysical properties of the resultant emissive state, increasing both the oscillator 
strength and radiative rate of decay, thus enhancing the phosphorescence efficiency and 
reducing the excited state lifetime.12 Therefore such complexes can display intense emission 
with long-lived emissive excited states, and the choice of ligand can drastically alter the 
excited-state characteristics. The ability to control the nature of the excited state is an 
advantage over the common ruthenium(II) polypyridyl complexes, which are confined to 
triplet MLCT states.7  
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Much of the biological imaging work using iridium(III) bis(cyclometallated) complexes has 
been pioneered by Lo and co-workers,7 who have developed iridium(III) complexes with 
various cyclometallating (C^N) ligands, and a third biomodal ancillary (N^N) ligand for 
coordination. The ancillary ligand incorporates reactive groups for bioconjugation,18,19 or 
molecular probes for various biological applications.20,21 In 2010, Lo reported a series of 
emissive Ir(III)  bis(cyclometallated) complexes coordinated to an ancillary ligand with a 
DNA-binding motif, as shown below in Figure 5.3.22 
 
Figure 5.3 Structures of Ir(III) complexes designed by Lo and co-workers for DNA-binding.22 
 
 
Cellular uptake of all complexes shown in Figure 5.3 was demonstrated in canine kidney cells 
(MDCK cell line) and considerable nuclear uptake was observed in all cases. The complexes 
were all found to intercalate with calf thymus dsDNA in in vitro studies, enhancing the 
emission of each complex in steady-state luminescence titrations; these complexes (Figure 
5.3) are the first example of Ir(III) polypyridyl that exhibit nuclear staining in cells. The group 
has also synthesised complexes that produce high levels of singlet oxygen (1O2) upon 
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photoexcitation, and such complexes demonstrate tuneable photodynamic activity.23 Research 
has also been undertaken by Pope and co-workers to try to design water-soluble 
cyclometallated iridium(III) complexes so that biological applications can be achieved more 
easily.24,25 
5.1.2	Labelling	Nanoparticles	with	Ir(III)	Complexes	
There are a few examples of strategies to label silica nanoparticles with iridium(III) 
polypyridyl complexes,26-29 whereas there are only two reports to date of labelling gold 
nanoparticles with iridium(III) complexes, both by Mayer and co-workers.30,31  The group 
initially developed a novel bifunctional heteroleptic Ir(III) complex, as shown in Figure 5.4, 
which upon addition of HAuCl4 under basic conditions, both reduced the Au3+ to Au0 and 
capped the resulting particles in situ, to give Ir(III)-functionalised gold nanoparticles 2–3 nm 
in size, which were soluble in THF.30 
 
Figure 5.4 Reduction of HAuCl4 and in situ capping process of resulting gold nanoparticles by the 
bifunctional Ir(III) complex with its 4,5-diazafluorenedithiolare ancillary ligand by Nasr et al.30 
 
 
The iridium(III) complex features a 4,5-diazafluorenedithiolate ligand which acts as the 
efficient reducing agent for the HAuCl4. Interestingly, however, studies of the uncomplexed 
ligand in a similar reaction reveal a very slow reduction process, thus demonstrating the 
essential role of the iridium(III) metal centre in the reduction mechanism. The free complex 
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displayed bright yellow luminescence with max at 537 nm, and a quantum yield of 40% in 
degassed acetonitrile. However, no luminescence was observed from the functionalised 
nanoparticles, and thus it is believed that significant non-radiative quenching  pathways from 
the emissive excited state are introduced upon grafting the complex to gold nanoparticles.30 
Although these particles have no potential as imaging probes, the synthesis of new 
nanocomposite materials presents promising candidates for catalysis. 
 
Mayer has recently published another study using a different bis(cyclometallated) heteroleptic 
Ir(III) complex, as shown in Figure 5.5, which is the first report of functionalising metallic 
nanoparticles with luminescent iridium(III) complexes that retain their luminescence upon 
immobilisation at the surface.31 5–6 nm gold and silver nanoparticles were synthesised by 
reduction of HAuCl4 with NaBH4 in the presence of dodecylamine, and then 
postfunctionalisation of the nanoparticles with the Ir(III) complex was achieved via ligand-
exchange. The exchange reaction was carried out at low concentrations of complex, to afford 
nanoparticles labelled with 2 to 15 complexes each. Low loading was performed to maintain 
colloidal stability and to minimise intermolecular charge transfer between grafted Ir(III) 
complexes.  
 
Figure 5.5 Functionalisation of gold and silver nanoparticles with luminescent Ir(III) cyclometellated 
complexes, by ligand-echange of dodecylamine-capped metal nanoparticles.31 
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Steady-state luminescence studies of the free complex vs. the same concentration of complex 
bound to nanoparticles revealed a reduction in signal intensity upon grafting the Ir(III) 
complex to both gold and silver nanoparticles, although more significant quenching was 
observed on the gold nanoparticles. In addition, a shortening of the observed luminescence 
lifetime of the complex was observed upon attachment to nanoparticles, and again a greater 
reduction in the lifetime was observed on the gold nanoparticles.  This difference in the 
quenching effect of each metal has been rationalised by the greater spectral overlap of the 
SPR of the gold nanoparticles (at 516 nm, compared with that of the silver nanoparticles at 
422 nm) and the luminescence of the iridium(III) complex (max of free complex in CH2Cl2 = 
633 nm). Thus it is proposed that excitation of the SPR of the nanoparticles, which enhances 
the electromagnetic field in the vicinity of the particle, deactivates the excited state of the 
Ir(III) complex by either energy transfer or electron transfer. 
 
Flow fields on the micron scale are generated within small blood vessels, which produce 
unsteady flow phenomena and govern the transport rates of oxygen, nutrients, waste and 
drugs. The flow dynamics determine the mechanical shear forces imparted on the vessel 
walls, and can influence pathophysiological mechanisms within the vascular bed.32 Thus, the 
continued study of blood flow dynamics will improve the understanding of the circulatory 
system function, and will also be important in the design of biomedical devices and drug-
delivery platforms.33-37 Not only are the flow dynamics and delivery of intravenous 
theranostic nanoparticles important but also their fate in vivo is of prime interest.38-40 
Furthermore, a drug platform which can be tracked, e.g. by luminescence, would be highly 
advantageous for studying pharmacokinetics and for targeting in nanomedicine.  
 
Further development of the iridium(III)-labelled gold nanoparticles has been explored to 
extend their imaging potential to gross tissue imaging, by designing multimodal imaging 
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nanoprobes with both MRI-active gadolinium(III) complexes and luminescent iridium(III) 
complexes to nanoparticles. Gadolinium(III) chelates are highly paramagnetic, with seven 
unpaired electrons, and give T1-contrast in proton MRI imaging by reducing the longitudinal 
relaxation time of nearby water protons, which enhances local contrast with respect to 
background tissue.41-43 The combination of multiple imaging probes onto a single nanoprobe 
can offer synergetic multifunctional nanomedical devices, with the possibility of multimodal 
imaging;44-46 every imaging technique has advantages and disadvantages, and the integration 
of two different imaging modality probes can optimise both the precision and the speed of 
diagnosis.  Such particles have the potential for locating gross tissue in vivo by MRI, and then 
subsequent pathological biopsy of the microvasculature could be performed optically to give 
higher resolution detail regarding disease progression. This, combined with a targeting 
moiety, has potential as a multimodal theranostic probe.47-49   
 
5.1.3	Chapter	Outline	
In this chapter the labelling-strategy of gold nanoparticles developed with ruthenium(II) 
polypyridyl complexes in Chapters Two and Three, has been extended by developing surface-
active iridium(III) polypyridyl complexes with superior photophysical properties, with the 
aim of achieving brighter nanoparticles which can be imaged in dynamic systems. Two 
luminescent surface-active iridium(III) complexes, IrBpySAc and IrPhenSAc,  have been 
synthesised and characterised. 13 nm and 100 nm citrate gold nanoparticles have been coated 
with IrBpySH and IrPhenSH, synthesised in situ from IrBpySAc and IrPhenSAc 
respectively, in a surfactant-mediated process using the fluorosurfactant Zonyl® 7950. The 
structures of IrBpySH and IrPhenSH are presented in Figure 5.6 and the labelled 
nanoparticles discussed in this chapter are shown in Figure 5.7. 
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Figure 5.6 Structures of IrBpySAc, IrBpySH, IrPhenSAc,and IrPhenSH complexes discussed in this 
chapter. 
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Figure 5.7 Schematics of IrBpy-Z•AuNP13, (b) IrBpy-Z•AuNP100, and (c) IrPhen-Z•AuNP100. 
 
 
The brightest nanoparticles, IrBpy-Z•AuNP100, were studied in flow, to see if they could be 
imaged flowing through microchannels, and thus be used as velocimetry tracers to analyse 
fluid mechanics. Flow studies were explored in blood in an in vitro channel model, and the 
biodistribution and detection of nanoparticles in biological tissue have been investigated in a 
murine model. 13 nm gold nanoparticles have also been co-coated with the gadolinium(III) 
pentetic acid derivative, GdQSH (Figure 5.8) and IrBpySH (Figure 5.6) to give IrBpy-
GdQ•AuNP13 (Figure 5.8), which can be detected by optical luminescence microscopy and 
by proton MRI using T1-weighted contrast. GdQ•AuNP13 nanoparticles were also 
synthesised for comparison (Figure 5.8). 
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Figure 5.8 Schematics of (a) GdQSH complex, (b) GdQ•AuNP13 nanoparticles made for 
comparative purposes and (c) IrBpy-GdQ•AuNP13, as discussed in Section 5.5. 
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5.2	Synthesis	and	Characterisation	of	IrBpySH	and	IrPhenSH	
IrBpySH and IrPhenSH were synthesised according to the schematic shown in Figure 5.9. 
 
Figure 5.9 Synthesis of the surface-binding Ir(III) complexes IrBpySH and IrPhenSH. 
 
 
The bis-cyclometallated μ-dichloro bridged complex, [Ir(ppy)2(μ-Cl)]2, was synthesised by 
Nonoyama reaction50 of 2-phenylpyridine with iridium(III) chloride hydrate, according to 
literature procedure,17 forming the kinetic product, i.e. the dimer with the N-coordinated 
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heterocycles in a trans-relationship, as this positions the sigma-donating C¯ atoms trans to the 
Cl¯ bridging ligands.12 The dimer was isolated, and a solution of the solid in d6-DMSO was 
characterised by NMR (1H and 13C{1H} PENDANT) spectroscopy and mass spectrometry. 
Each proton resonance of the phenylpyridyl ligand (Hb, Hc, Hd, He, Hh, Hi, Hj, Hk) is split into 
two different environments in a 50:50 ratio in the 1H NMR spectrum, due to the DMSO 
solvent breaking the dimer and forming [Ir(ppy)2(DMSO)Cl] monomers, and only the 
[Ir(ppy)2]+ fragment peak is observed by mass-spectometry, at m/z = 501.1. (Splitting is not 
seen if the dimer is dissolved in CD2Cl217).  
 
The ancillary ligands were synthesised by the Williamson reaction of 4,4’-dihydroxy-2,2’-
bipyridine or 4,7-dihydroxy-1,10-phenanthroline with bromohex-1-ene in the presence of base 
to give BpyHex1 (see Chapter 2, Section 2.2.1) and PhenHex (synthesised by Dr Shiva 
Farabi51) respectively. Facile replacement of the bridging chloride ligands in the dimer with 
the ancillary ligand was achieved by heating [Ir(ppy)2(μ-Cl)]2 with two equivalents of each 
ligand in the mixed solvent system CH2Cl2:CH3OH (2:1). IrPhenHex was isolated as a 
hexafluorophosphate salt by addition of 10-fold molar excess ammonium 
hexafluorophosphate, according to the literature procedure by Sun et al.,52 whereas IrBpyHex 
was isolated directly as the chloride salt. Purification of the resulting complexes by column 
chromatography afforded IrBpyHex and IrPhenHex, which were characterised by NMR 
spectroscopy (both 1H and 13C{1H} PENDANT) and mass spectrometry. Successful 
complexation of both IrBpyHex and IrPhenHex is evident from their eletrospray mass 
spectra, with peaks observed for each monocharged complex after loss of its counterion, at 
m/z 853.5 for IrBpyHex, corresponding to [M−Cl]+., and at m/z 877.4 for IrPhenHex, 
corresponding to [M−PF6]+.. The 1H NMR spectra of both IrBpyHex and IrPhenHex feature 
protons of the two phenylpyridyl ligands and the ancillary ligand (BpyHex or PhenHex) all 
integrating in the correct ratios with respect to one another. The protons of each ancillary 
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ligand exhibit quite striking chemical shifts upon complexation to Ir3+: H6 shifts upfield from 
8.45 ppm in the free BpyHex ligand to 7.59 ppm in IrBpyHex, whereas H3 and H5 shift 
downfield, from 7.94 ppm and 6.82 ppm in the free ligand, to 8.46 ppm and 7.28 ppm 
respectively in the complex. Similary in PhenHex, H2 shifts upfield from 8.89 ppm to 
7.93 ppm, and H3 and H7 shift downfield from 7.28 ppm and 8.15 ppm, to 7.56 ppm and 8.36 
ppm respectively, upon complexation. In each case, the CH proton adjacent to the donating 
nitrogen atom on the aromatic ring experiences electron shielding due to the proximity of the 
Ir(III) d-electrons, whereas the remaining protons, which face away from the metal centre, 
experience an overall deshielding effect upon complexation, due to the donation of electrons 
from the ligand towards the metal centre. The same effect is seen upon complexation with 
Ru2+.1,51 In addition, an upfield shift in Hb of the phenylpyridyl ligands, by ca. 2 ppm, 
corroborates the metathesis reaction.    
 
 The olefin groups of IrBpyHex and IrPhenHex were converted into thioester groups by the 
free-radical mediated nucleophilic addition reaction of thioacetic acid to give the oxidatively 
stable bis-thioacetyl groups, according to the previously reported reaction1,2 used to form 
RuSAc in Chapter Two. IrBpySAc and IrPhenSAc were both isolated as chloride salts and 
characterised by 1H and 13C{1H}PENDANT NMR spectroscopy and mass spectrometry. 
Elecrospray mass spectrometry of each complex revealed peaks for each monocharged 
complex after loss of its counterion, observed at m/z 1005.4 for IrBpySAc and at m/z 1029.3 
for IrPhenSAc, and it was possible to obtain high-resolution mass spectra within 5 ppm of 
the theoretical mass in each case. The carbonyl bond of each thioester is evident from the 
peak observed at 1682 cm−1 and 1684 cm−1 in the FT-IR absorption spectra of IrBpySAc and 
IrPhenSAc respectively, which are absent in the spectra of IrBpyHex and IrPhenHex. The 
successful thioesterification reaction was confirmed undoubtedly by 1H NMR spectra, with 
loss of the olefin protons at ca. 5.8 ppm and 5.0 ppm, and the appearance of the triplet at 2.83 
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ppm (H12 in IrBpySAc) and at 2.86 ppm (H13 in IrPhenSAc), as well as the appearance of 
the terminal methyl group of each thioester at ca. 2.3 ppm. In all cases, the relative peak areas 
by integration matched theory. The thiol groups were finally unmasked in situ by thioester 
hydrolysis with aqueous ammonia directly prior to addition to the nanoparticles, which was 
confirmed by MALDI mass spectrometry using a gentisic acid matrix; peaks were observed 
for each monocharged complex after loss of its counterion, at m/z 920.2 for IrBpySH and at 
m/z 944.2 for IrPhenSH. 
 
5.3	Photophysical	Characterisation	of	IrBpySAc	and	IrPhenSAc	
Often, iridium(III) complexes are studied in degassed solvents or in rigid films and/or glasses 
at 77 K, where they tend to phosphoresce brightly because the non-radiative decay paths are 
minimised. Whilst such studies may be suited for OLED applications where such formulation 
is appropriate, when considering complexes for imaging agents in biological environments, it 
is important to undertake studies in conditions which are relevant to the application. The 
photophysical properties of IrBpySAc and IrPhenSAc were, therefore, characterised in both 
aerated CH3CN and aerated 1% CH3CN, H2O, to emulate the solvent conditions within an 
aqueous colloidal dispersion, whilst facilitating solubility, as presented in Figure 5.10.  
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Figure 5.10 UV-Vis absorption spectra (solid lines) of 20 M (a) IrBpySAc and (b) IrPhenSAc 
solutions in CH3CN (black) and water, 1% CH3CN (blue). Steady-state luminescence spectra (dashed 
lines), exc = 355 nm. *  =scattering peak, i.e. second harmonic of 355 nm. Spectra corrected for 
instrument response.   
 
The UV-Vis absorption profiles of both IrBpySAc and IrPhenSAc exhibit intense spin-
allowed singlet LC (*) transitions of the (C^N) and (N^N) ligands in the far UV region 
(200–300 nm) with molar absorption coefficients in the order of 104 dm3 mol−1cm−1. The 
spectra of both complexes exhibit maxima at 255 nm, and a peak at 230 nm in the case of 
IrBpySAc, presumably due to the singlet LC state associated with the bipyridyl-ancillary 
ligand. The corresponding LC absorption associated with the ancillary (N^N) ligand in 
IrPhenSAc appears to overlap with the phenylpyridyl peak, red-shifted with respect to the 
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bipyridyl equivalent. The absorption profiles of both complexes show weaker absorptions 
extending from 300 nm into the near-visible, corresponding to direct absorptions into the 
spin-allowed singlet MLCT excited state, with molar absorption coefficients of the order of 
103 dm3 mol−1cm−1. These features are similar to the UV-Vis absorption spectral features 
observed for the parent compounds [Ir(ppy)2bpy]+53,54 and [Ir(ppy)phen]+.52 Excitation of both 
IrBpySAc and IrPhenSAc complexes at 355 nm, gives rise to a broad emission peak in the 
luminescence spectra from 450–800 nm. The steady-state luminescence spectrum of 
IrBpySAc in an aerated solution of CH3CN is structureless with max at 585 nm and a 
quantum yield of 3%, whereas the emission spectrum of IrPhenSAc peaks at 515 nm, with a 
smaller quantum yield of 1%, whilst exhibiting some vibronic structure, with a peak at 
480 nm and a shoulder at 545 nm (Figure 5.10).  Excitation spectra of both complexes can be 
found in Appendix 10. 
 
Solutions of both IrBpySAc and IrPhenSAc exhibit significant changes in their emission 
profiles as the polarity of the solvent changes from CH3CN to H2O (with 1 % CH3CN), as has 
been observed by Pope and co-workers25 and as is observed with the ruthenium(II) 
polypyridyl complexes described in Chapter Two, due to the charge-transfer nature of the 
excited states. The solution photophysical characterisations of each compound are 
summarised in Table 5.1, along with the corresponding data for the two parent compounds: 
[Ir(ppy)2bpy]+, taken from work by Constable55 and Watts;10 and [Ir(ppy)2phen]+, which was 
synthesised by the author as a control, and has been published in a separate study.29   
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Table 5.1 Summary of the solution photophysical properties of IrBpySAc and IrPhenSAc in CH3CN 
and 1% CH3CN, H2O.
 IrBpySAc IrPhenSAc [Ir(ppy)2bpy]+ [Ir(ppy)2phen]+
solvent 
system: 
 
CH3CN 
1% CH3CN, 
H2O 
 
CH3CN
1% CH3CN, 
H2O 
 
CH3CN 
 
CH3CN

max / nma 
 
585 
 
570 
 
515 
 
550 
 
585b 
 
595c 
 
obs / nsd 60
 
 
[325] 
75 (25%) 
300 (75%) 
 
- 
40
 
 
[2250] 
110 (6%)
325 (80%) 
745 (14%) 
- 
 
- 
 
 
[340]e 
60c
 
 
[780]c 
 
Φf 
 
0.03 
[0.09] 
 
0.05 
- 
0.01 
[0.28] 
 
0.04 
- 
 
- 
[0.14]b 
 
0.02c 
[0.20]c 
 
aestimated error = ±3 nm  
bdata taken from Constable and co-workers55 
c data measured by the author and published in a separate study.29 
d lifetimes measured in aerated solutions, deaerated measurements (systems degassed with nitrogen for 20 min), 
shown in square brackets. Multi-component lifetimes quoted with intensity weightings in parenthesis. Errors 
estimated as ±6% for measured data. 
e data taken from Watts and co-workers10 
f aerated Φ measurements, deaerated measurements (systems degassed with nitrogen for 20 min) shown in 
square brackets. Estimated error for Φ = ±25%.  
 
 
A 35 nm bathochromic shift in the emission max is observed when IrPhenSAc, is dissolved 
in an aqueous (1% CH3CN) solution, with respect to a 100% CH3CN solution, similar to the 
smaller 15 nm red shift that is observed with [Ir(ppy)2phen]+(see Appendix 12).29 In addition 
the emission peak broadens (FWHM increases by 40%) in the aqueous solution and the 
vibronic structure disappears. This effect is most likely due to the stabilisation of the MLCT 
state in the more polar environment, which increases the mixing between the MLCT and LC 
states, reducing the energy gap between the first excited state and ground state, whilst giving 
the state more MLCT character, as shown below in Figure 5.11. 
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Figure 5.11 Schematic of the energy levels of the lowest excited states of IrPhenSAc in (a) CH3CN 
and (b) H2O / 1% CH3CN. 
 
 
In contrast, a 15 nm hypsochromic shift in the emission maximum is observed in the aqueous 
solution of IrBpySAc, with respect to the CH3CN solution, which is an unusual observation 
for a MLCT excited state; usually increasing the polarity of the solvent system stabilises the 
polar charge-transfer state, lowering the energy of the transition.  A similar iridium(III) 
bis(phenylpyridyl) chloride salt, with a 4,4’-ethoxyamino-2,2’- bipyridine ancillary ligand29 
has a similar blue shift in water, from 575 nm to 550 nm (see Appendix 11). Chen and co-
workers53 recently investigated the relaxation dynamics of [Ir(ppy)2bpy]+ using time-resolved 
emission spectroscopy and proposed that there are, in fact, multiple emission bands that 
overlap in energy, as was first shown in by King and Watts in 1987.54 It is believed that 
emission is observed from three states; a triplet ligand-to-ligand(ppy* bpy) charge 
transfer (LLCT) band, an MLCT (dppy) band, and also an MLCT (dbpy) band, and 
thus solvation effects are far from trivial.53 It was not possible to tail-fit (i.e fit the decay 
beyond the time point where the excitation light pulse has disappeared) the observed lifetimes 
of either IrBpySAc or IrPhenSAc in aqueous environments with a monoexponential decay 
model; such fitting rendered unacceptable reduced chi-square fitting parameters and 
oscillating residual data. Therefore, the exponential order was increased until the residual plot 
presented random noise distributed about zero, with a reduced chi-square value between 1.0-
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1.3. (see Appendix 13). The reduced chi-square value estimates the predicted variation of the 
fitted data, divided by the actual variance of the parent dataset, which should be close to unity 
if the function is a good fit for the data. 
 
Solution studies of both IrBpySAc and IrPhenSAc in CH3CN show an increase in the 
steady-state luminescence and a lengthening of the observed lifetime upon de-aeration of the 
solution, due to quenching of the triplet excited state by ground-state molecular oxygen 
(O2 (3g-)), as described in Chapter Two, Section 2.1.2. Degassing the solutions removes these 
quenching pathways and reduces the non-radiative rate of decay. A three-fold increase in the 
quantum yield and a five-fold increase in the luminescence lifetime are observed upon 
deaeration of IrBpySAc in CH3CN, which equates to a six-fold decrease in the non-radiative 
rate of decay from the excited state, whereas a ca. 60-fold increase in the lifetime and a ca.30-
fold increase in the quantum yield (an 80-fold decrease in the non-radiative rate of decay) is 
observed for IrPhenSAc. Therefore, IrPhenSAc appears to be far more oxygen sensitive than 
IrBpySAc, which complements the significant LC character observed in the steady-state 
luminescence, as the excited-state also has more triplet character. Using the Stern-Volmer 
equation56 below (Equation 5.1), the bimolecular quenching rate constant, kq, can be 
calculated from the lifetime data measured in aerated and de-aerated solutions. 
ఛ
ఛబ ൌ 1 ൅ ݇௤߬ሾܳሿ              Equation 5.1 
= the quenched lifetime, = the unquenched lifetime, kq =  the bimolecular quenching rate 
constant, and [Q] = the concentration of the quenching species, i.e. [O2]. Assuming that the 
[O2] = 2.4 mM in air-saturated CH3CN,57 kq is 6 × 109 dm3 mol−1 s−1 for IrBpySAc, and 
10 × 109 dm3 mol−1 s−1 for IrPhenSAc, in CH3CN. 
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The ether functionalisation of the bipyridine ligand with the surface-active appendages in 
IrBpySAc has very little effect upon the photophysical properties of the lumiphore, with 
respect to the parent complex [Ir(ppy)2bpy]+; the max value and the degassed lifetime are the 
same within an experimental error of ± 5%. The quantum yield is reduced by 35 %, which 
may be due to the additional appendages opening up further non-radiate vibrational relaxation 
pathways from the excited state, which compete with the luminescence. For comparison, ether 
functionalisation of the bipyridine ligand a similar iridium(III) bis(phenylpyridyl) chloride 
salt, with a 4,4’-ethoxyamino-2,2’-bipyridine ancillary ligand, blue-shifts the max value by 
10 nm, and bi-exponential degassed lifetimes of 380 ns (32%) and 1325 ns (68%) (intensity 
weightings shown in parenthesis), and a similar quantum yield of 0.16 is observed.29 In this 
instance, 4,4’-ethoxyamino- groups appear to affect the excited state energies more so than 
the hexyl-ether appendages in IrBpySAc, which is expected due to the proximity of the 
electron-donating amine groups. A similar blue shift is observed by Pope25 with Ir(III) 
bis(cyclometallated) complexes in which the cyclometallating ligands are ethyl-2-
phenylquinoline-4-carboxylates, and the ancilliary ligand is bipyridine-based; upon 
esterification in the 4,4’-positions of the ancillary bipyridine ligand, a 7 nm blue-shift is 
observed in the steady-state emission.25  
 
The ether functionalisation of the phenanthroline unit in IrPhenSAc has a marked effect upon 
the excited state of the complex, with respect to [Ir(ppy)phen]Cl; the MLCT state of the 
complex appears to be destabilised  due to the electron-donating ether-group, which in turn 
reduces the MLCT–LC mixing, and increases the energy gap between the ground-state and 
the first-excited state, as represented in Figure 5.12 below: 
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Figure 5.12 Schematic of the energy levels of the lowest excited states of (a) [Ir(ppy)2phen]+ and (b) 
IrPhenSAc in CH3CN. 
 
 
The destabilisation of the MLCT state results in a blue-shifted max emission peak and more 
LC character and hence the appearance of vibronic structure, due to less mixing of the two 
states. In addition, the degassed lifetime of IrPhenSAc extends into the microsecond time 
range, unlike that of [Ir(ppy)2phen]+, which is again indicative of significant  triplet LC 
character. A similar blue-shift is observed upon methylation of the phenanthroline ligand in 
the 4 and 7 position, in a similar [Ir(ppy)2(N^N)]+ complex ((N^N = 4,7-dimethyl-1,10-
phenanthroline), in which a 17 nm blue-shift is observed.58  
 
To investigate the excited-state characteristics further, the steady-state luminescence spectra 
of each compound were measured in CH3CN at 77 K, as presented in Figure 5.13. 
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Figure 5.13 Steady-state luminescence spectra of 20 uM (a) IrBpySAc and (b) IrPhenSAc, exc = 
355 nm, in CH3CN at 298 K (solid) and 77 K (dashed). Insets – photograph of each complex in 
CH3CN at 77 K (left) and 298 K (right),exc = 370 nm .Spectra corrected for instrument response. 
 
 
The two complexes behave very differently upon reducing the temperature from 298 K to 
77 K in CH3CN; the steady-state spectrum of IrBpySAc exhibits a rigidochromic blue-shift 
of ca. 50 nm, which is indicative of a charge-transfer excited state. In fluid solution at room 
temperature, solvent reorganisation can stabilise the polar charge-transfer excited state, 
whereas at 77 K this stabilisation process is impeded in the rigid matrix, and thus the emissive 
excited state increases in energy. In addition, at 77 K, the rigidity of the complex itself 
increases, which prevents access to the excited vibrational states of the ground state, and 
subsequently blue-shifts the emission max as transitions can only occur to the low energy 
vibrational states of the ground electronic state. In contrast, no spectral shift is observed for 
IrPhenSAc, rather the vibronic fine structure sharpens upon cooling, which is indicative of 
LC character.  
 
In summary, the luminescence excited state of the IrBpySAc complex appears to have MLCT 
character, as the broad emission peak is structureless and blue-shifts upon cooling to 77 K, 
whereas that of the IrPhenSAc complex appears to have much more LC character when 
dissolved in CH3CN, indicated by the vibronic fine structure present, the weaker 
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luminescence quantum yield and the lack of rigidochromic effect. The emissive excited state 
of IrPhenSAc also appears to have significant triplet character, as it is incredibly oxygen 
sensitive; an 80-fold decrease in the quantum yield is observed upon oxygenation of 
acetontirile with air-saturated solvent, and a large bimolecular collisional quenching rate 
constant of 10 × 109 dm3 mol−1 s−1 is observed. However, in a predominantly aqueous 
environment, the MLCT excited state of IrPhenSAc appears to be stabilised in the higher 
polarity solvent, and thus reduces in energy and mixes into the LC state to give MLCT-
characteristics, i.e. higher quantum yield, and a structureless emission peak.  
 
5.4	Synthesis	of	Iridium(III)‐labelled	Gold	Nanoparticles	
Gold nanoparticles were labelled with IrBpySH and IrPhenSH (synthesised in situ from 
their oxidatively stable thioester analogues IrBpySAc and IrPhenSAc) using the surfactant-
mediated process developed and discussed in Chapter Two.1,2 Citrate-stabilised gold 
nanoparticles of 13 nm and 100 nm in diameter were synthesised according to the methods 
described in Chapter Two (Section 2.3)1 and Chapter Three (Section 3.2)1 respectively, and 
initially coated in the stabilising agent Zonyl® 7950. Subsequently, IrBpySH or IrPhenSH 
was added to the colloid, as presented in the schematic below, Figure 5.14. The coated 
particles were isolated by centrifugation, followed by decantation of the supernatant and 
resuspension of the pellet in deionised water. Neither complex could be added directly to the 
colloids without fluorosurfactant as this afforded aggregation and sedimentation of the 
particles out of suspension. 
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Figure 5.14 Schematic of surfactant-mediated co-coating procedure for iridium(III)/ zonyl® 7950-
coated gold nanoparticles, with IrBpySH as an example. 
 
 
Isolated IrBpy-Z•AuNP13, IrBpy-Z•AuNP100, and IrPhen-Z•AuNP100 have been 
characterised by UV-Vis absorption spectroscopy, DLS (Figure 5.15), TEM and 
electrophoretic mobility measurements to give zeta potential data.  
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Figure 5.15 DLS intensity distribution (a),(c) and number distribution (b),(d) of functionalised gold 
nanoparticles. (a) and (b): citrate 13 nm gold nanoparticles (black), isolated Z•AuNP13 (black 
dashed), and IrBpy-Z•AuNP13 (red). (c) and (d): 100 nm gold nanoparticles (black), isolated 
Z•AuNP100 (black dashed), IrBpy-Z•AuNP100 (red), and IrPhen-Z•AuNP100 (blue).   
 
 
The DLS average number distribution of IrBpy-Z•AuNP13 is the same, within error, as the 
fluorosurfactant-coated 13 nm gold nanoparticles, and thus there is no evidence of 
aggregation occurring upon addition of IrBpySH. A change in the zeta potential from 
−61±4 mV , for Z•AuNP13, to −35±3 mV for IrBpy-Z•AuNP13 indicates that some of the 
highly electronegative fluoropolymer has been displaced from the surface of the nanoparticles 
upon addition of the Ir(III) complex, as is presented in Table 5.2 below. A similar effect is 
seen when RuSH is added to the fluorosurfactant-coated nanoparticles, to give 
Ru-Z•AuNP13 with a zeta potential of −48±2 mV, in Chapter Two, Section 2.33.  
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Table 5.2 Summary of nanoparticle characterisation data for nanoparticles 
coated with Zonyl® 7950 and  IrBpySH or IrPhenSH complexes 
sample diameter (DLS 
average number 
distribution) / nm 
zeta potential 
(measured at 2 nM in 
water) / mV 
 
Z•AuNP13 
 
20±2 
 
−61±4 
IrBpy-Z•AuNP13 
 
19±5 −35±3 
Z•AuNP100 
 
92±21 −47±3 
IrBpy-Z•AuNP100 
 
71±19 −33±3 
IrPhen-Z•AuNP100 
 
70±24 −32±3 
All errors are quoted as ±1 standard deviation
 
Similarly, the DLS data for the 100 nm coated nanoparticles show no evidence of 
aggregation, and the same effect is observed with the zeta potentials; a change in the zeta 
potential from −47±3 mV to −33±3 mV and −32±3 mV is observed upon addition of 
IrBpySH  and IrPhenSH  to fluorosurfactant-coated gold nanoparticles respectively. This is 
very similar to the zeta potential observed for Ru-Z•AuNP100, discussed in Chapter Three, 
Section 3.3, of −35±3 mV. Transmission electron microscopy (TEM) was also performed on 
IrBpy-Z•AuNP13 and IrBpy-Z•AuNP100 samples, as shown in Figure 5.16, which confirms 
the size and uniformity of the resultant nanoparticles. 
 
 
Figure 5.16 TEM images of (a) IrBpy-Z•AuNP13 and (b) IrBpy-Z•AuNP100. 
 
  Chapter Five 
201 
 
IrBpy-Z•AuNP100 nanoparticles were also sized using NanoSight nanoparticle tracking 
analysis, as shown below in Fig 5.17. 
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Figure 5.17 NanoSight nanoparticle tracking analysis of IrBpy-Z•AuNP100 at 20 oC (solid line) 
with cumulative frequency distribution shown (dashed). 
 
 
NanoSight nanoparticle tracking analysis of IrBpy-Z•AuNP100 revealed a mean particle 
diameter of 80 nm and a modal diameter of 104 nm, in agreement with the sizing by DLS and 
TEM. 
 
The Ir(III)-loading of the isolated IrBpy-Z•AuNP13 nanoparticles was measured by 
ICP-OES, and the atomic Au:Ir ratio of 106:1 was observed. This corresponds to 940  
IrBpySH complexes per IrBpy-Z•AuNP13 (see Appendix 2.5), which is slightly lower than 
the loading observed with RuSH in Chapter Two (1600 complexes per 13 nm nanoparticle).  
 
5.4.1	Photophysical	Characterisation	of	Ir(III)‐labelled	Gold	Nanoparticles	
The photophysical properties of IrBpy-Z•AuNP13, IrBpy-Z•AuNP100, and 
IrPhen-Z•AuNP100 were investigated to determine whether the surface-grafting to gold 
nanoparticles had an effect upon the photophysical properties of each iridium(III) lumiphore. 
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The UV-Vis absorption spectra of all three types of nanoparticles were dominated by the SPR 
of the gold nanoparticles, with the LC peak of each Ir(III) complex superimposed at ca. 
260 nm, as shown in Figures 5.18 and 5.19 below. 
 
 
Figure 5.18 UV-Vis absorption spectrum (solid line), excitation spectrum, em = 550 nm (dashed line) 
and steady-state emission spectrum exc = 355 nm, (bold solid line) of (a) 1nM IrPhen-Z•AuNP13, 
and (b) 10 mM IrPhen-Z•AuNP100. Spectra corrected for instrument response.   
.   
 
The isolated IrBpyZ•AuNP13 and IrBpyZ•AuNP100 particles are highly emissive upon 
excitation at 355 nm, both with max at 570 nm, which is the same as the free IrBpySAc 
complex in water (with 1% CH3CN). However, the quantum yields of luminescence of the 
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nanoparticles were greater than the free complex in water (with 1% CH3CN), at 0.14 and 0.19 
for IrBpyZ•AuNP13 and IrBpyZ•AuNP100 respectively, compared with only 0.05 for the 
complex in a predominantly aqueous environment.  The excitation spectra, measured at 
550 nm, for both IrBpyZ•AuNP13 and IrBpyZ•AuNP100 are very similar, displaying the 
spectral features of the UV-Vis absorption spectrum of the IrBpySAc complex in solution. As 
a control experiment, 20 M IrBpySAc complex was dissolved in 1% CH3CN, water, with 
1 mM Zonyl® 7950 fluorosurfactant, and the steady-state emission was measured with 
excitation at 355 nm. Again, a max at 570 nm was observed under these conditions, and a 
140% increase in the quantum yield to 0.12 was observed, with respect to the free complex in 
water (1% CH3CN). This is very similar to the quantum yields measured for the coated 13 nm 
and 100 nm gold particles, for which the error is relatively high as the difference in the 
absorbance between uncoated and coated nanoparticles at 355 nm is such a small component 
of the absolute absorbances.  
 
IrPhen-Z•AuNP100 behave somewhat differently to the free complex in water; upon 
excitation at 355 nm the nanoparticles exhibit broad emission with evidence of some vibronic  
fine-structure, with shoulders at 490 nm and 530 nm, and a max at 555 nm. In 1% CH3CN, 
water, the emission has a max at 550 nm, with no obvious shoulders in the broad peak (Figure 
5.19). The steady-state emission of 20 M IrPhenSAc complex dissolved in 1% CH3CN, 
water, with 1 mM Zonyl® 7950 fluorosurfactant, exhibits emission with clear vibronic fine-
structure and a max at 515 nm, when excited at 355 nm, which is similar to the complex 
dissolved in CH3CN (Section 5.2, Figures 5.10 and 5.13b), and very different to the 
nanoparticles co-coated with both the complex and fluorosurfactant.  The quantum yield of 
IrPhen-Z•AuNP100 could not be measured due to the low signal intensity at such low 
concentration of lumiphore; low colloidal concentrations (7 pM) are used to minimise the 
scattering, and thus bright signal is required for measuring quantum yields on nanoparticles.   
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Figure 5.19 UV-Vis absorption spectrum (solid line), excitation spectrum, em = 550 nm (dashed line) 
and steady-state emission spectrum exc = 355 nm, (bold solid line) of 10 pM IrPhen-Z•AuNP100. * = 
scattering peak (second harmonic of 355 nm excitation). Spectra corrected for instrument response.   
 
 
The photophysical properties of IrBpy-Z•AuNP13, IrBpy-Z•AuNP100, 
IrPhen-Z•AuNP100 and the control studies of each IrBpySAc and IrPhenSAc complexes 
mixed with the Zonyl® 7950 fluorosurfactant in solution are summarised below in Table 5.3: 
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Table 5.3 Summary of the photophysical properties of IrBpy-Z•AuNP13, IrBpy-Z•AuNP100 and 
IrPhen-Z•AuNP100 nanoparticles, and control studies of aqueous free complexes mixed with 
fluorosurfactant in solution. 
 IrBpy-Z•AuNP13a IrBpy-Z•AuNP100b IrPhen-Z•AuNP100b 
 
IrBpySAc 
(aq) with 
Zonyl 7950c 
 
IrPhenSAc 
(aq) with 
Zonyl 7950c 

max  
/ nmd 
 
570 
 
570 555 
 
570 
 
515 

obs 
/ nse 
 
80 (7%) 
380 (93%) 
 
[75 (6%)] 
[435 (94%)] 
 
 
90 (10%) 
400 (90%) 
 
[85 (11%)] 
[420 (89%)] 
 
50 (25%) 
335 (75%) 
 
[300 (15%)] 
[1570 (85%)] 
 
 
140 (32%) 
380 (68%) 
 
[165 (18%)] 
[625 (82%)] 
 
145 (31%) 
375 (69%) 
 
[150(5%)] 
[1605 (95%)] 
 
 
Φ f  
 
0.19 
 
0.14 
 
-g 
 
 
0.12 
 
0.02 
a nanoparticle measurements at 2 nM in aqueous solution 
b nanoparticle measurements at 7 pM in aqueous solution 
c20 M Ir complex dissolved in 1% CH3CN, H2O, with 1.2 mM Zonyl® 7950 
d error estimated as ±3 nm 
e lifetimes measured in aerated solutions, dearated measurements (systems degassed with nitrogen for 20 min) 
shown in square brackets. Multi-exponential fits shown with intensity weightings shown in parenthesis. Errors 
estimated as ±6% for solution data, and ±10%  for nanoparticle samples.  
f aerated Φ s measured using an integrating sphere, using un-coated nanoparticles as the reference. Errors 
estimated as ±25%. 
g signal intensity too weak to at pM concentrations of particles to measure Φ with integrating sphere 
 
The observed luminescence lifetimes of IrBpy-Z•AuNP13 and IrBpy-Z•AuNP100 are very 
similar to one another, and relatively insensitive to molecular oxygen quenching; upon 
degassing, neither the short component nor the long component of the biexponential lifetime 
changes by more than 15%, whereas this is not observed in the control experiment of 
IrBpySAc complex mixed with fluorosurfactant. In contrast, IrPhen-Z•AuNP100 are very 
sensitive to molecular oxygen quenching, and a ca. five-fold increase in both the short and the 
long components of the observed lifetimes is observed. The absence of oxygen quenching is 
highly desirable for biological imaging applications for two reasons: firstly, blood and 
biological tissue have significant triplet oxygen present, and quenching would reduce the 
brightness of luminescent probes in situ; secondly, the quenching process of triplet O2 with a 
triplet excited state usually produces singlet oxygen, which is highly reactive and has 
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associated toxicity.59 However, the production of toxic singlet oxygen by 
IrPhen-Z•AuNP100 has the potential to be applied as a means of photodynamic therapy.  
 
There is no evidence of luminescence quenching of the IrBpySH complex upon attachment to 
gold nanoparticles, as the quantum yield does not decrease upon attachment to gold 
nanoparticles, whereas this is difficult to assess for the IrPhenSH because the quantum yield 
could not be measured on nanoparticles. However, the luminescence lifetime of the 
IrPhenSH complex does not shorten upon addition to the 100 nm gold nanoparticles, and 
thus these data support a lack of quenching by the gold nanoparticles in IrPhen-Z•AuNP100 
also. Notably, the IrBpy-Z•AuNP100 nanoparticles are a lot brighter than IrPhen-
Z•AuNP100, with a measurable quantum yield within the integrating sphere setup. 
5.5	Imaging	Ir(III)‐labelled	Gold	Nanoparticles	in	Flow	Systems	
Bright luminescent nanoparticles have the potential to be used as flow tracers in microfluidic 
systems; the particles have to be bright enough to capture images many times per second so 
that velocities can be mapped with high temporal resolution and thus IrBpy-Z•AuNP100 
have been chosen as potential candidates for flow tracers; the IrBpySH complex offers 
advantageous photophysical properties for optical imaging over the IrPhenSH complex, as 
discussed in Section 5.2, and the larger nanoparticles have been chosen as they offer brighter 
(i.e. more lumiphore labels per probe) tracers to track by luminescence. 
 
There are two different approaches to particle imaging, both of which give velocity profiles 
within a given system, but with resolution in different dimensions. Particle tracking 
velocimetry (PTV) is a technique used to measure the velocity of particles by means of 
tracking individual particles as they move through space, through several time frames of a 
video sequence.60 The resolution of the particle position is limited by the particle size, and 
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thus can be measured with sub-micrometer accuracy, but the velocity measurement is 
calculated by averaging the change in position of the particle across several frames in time. 
Therefore there is high spatial resolution of individual particles, but the velocity is averaged 
over a significant period of time and temporal flow information within the time scale of the 
averaged tracks is lost. On the other hand, particle imaging velocimetry (PIV) extracts 
velocity fields with high temporal resolution by dividing a flow domain into windows of 
interrogation and using pairs of images to produce a displacement vector from a cross-
correlation routine, whilst averaging out the correlation over a significant interrogation area in 
space.61,62  
 
PIV is the preferred technique if studying velocity fields in systems where the flow in not 
continuous, so that the temporal variation in the velocity fields can be resolved. PIV requires 
many seeding particles within each frame to ensure high spatial resolution with sub-pixel 
accuracy, and relies on the seeding particles to faithfully follow the flow of the fluid.  
Traditional macroscopic PIV methods use glass beads or oil droplets as seeding tracers, and 
image their movement from their scattering of laser light, and more recently, fluorescent 
particles with scales between 1 and 10 μm have been used.60 However, the advent of micro-
PIV (μ-PIV)63 requires smaller seeding particles to analyse microchannel flow dynamics. 
Nanoparticles present a unique opportunity to exploit a bottom-up approach to materials 
fabrication to produce tracers for PIV, and luminescence imaging significantly improves 
image quality over scattering measurements as scattering artifacts from channel walls and 
obstacles are removed and signal to noise ratio is significantly increased.63  
 
μ-PIV studies were attempted by flowing IrBpy-Z•AuNP100 particles through a 
microchannel and capturing images for processing at UCL, but it was not possible to achieve 
high enough seeding densities in the channel for good image correlation. In addition, the 
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significant Brownian motion of the 100 nm particles was difficult to filter out of the flow 
velocities. Therefore, 500 nm silica nanoparticles were synthesised and labelled with a similar 
surface-active Ir(III) complex, and these were deemed suitable for PIV measurements. This 
has been published as a separate study by the author.29 
5.6	Imaging	Blood	Flow	in	Biological	Tissue	with	IrBpy‐Z•AuNP100	
Particle tracking velocimetry studies have been performed with IrBpy-Z•AuNP100 in 
microchannels, and for the application of measuring blood flow dynamics in microvessels in 
the body, the study of IrBpy-Z•AuNP100 in blood flow has been explored. 
 
5.6.1	Blood	Flow	Introduction	
The cardiovascular system is a circulatory pressure system in which the heart pumps blood, 
which is a concentrated suspension of cells in plasma, around the body.  Studies of transport 
phenomena in the microvasculature using optical techniques are extremely challenging due to 
the high absorption of visible light by haemoglobin, and the scattering produced by red blood 
cells (RBC). Goldsmith and co-workers have investigated tracer-particle flows in dispersions 
of ghost RBC (i.e. RBC which have had the haemoglobin removed)64,65 but this type of model 
does not replicate the correct viscosity ratios of RBC relative to the extra-cellular fluid. More 
recently, work has been carried out by tracking fluorescently-labelled blood cells in vitro66,67 
and by tracking cells with confocal scanning laser microscopy (CLSM) in reflection mode in 
vivo,68 but these methods limit the spatial resolution to the cell size (ca. 8 μm), which is 
problematic for the narrow vessels and when tracking flow-rates near to the channel walls. 
Studies have also been executed by co-flowing luminescent tracer microparticles (as small 
as 0.4 μm) with blood in vitro69 and in vivo,70-72 but nano-scale particles are required to 
investigate narrow microchannels and to provide flow information on a scale relevant to the 
transport of drugs. The flow dynamics of nanoparticles are also incredibly important when 
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considering the intravenous administration of the evergrowing research field of nanomedical 
devices.73-75  
5.6.2	In	Vitro	Blood	Flow	Tracking	
To determine whether IrBpy-Z•AuNP100 particles could be used as tracers to measure flow 
dynamics in the microvasculature, they were initially studied in vitro by seeding RBC 
suspensions with IrBpy-Z●AuNP100, as shown in Figure 5.20. The RBC were spiked with 
ca. 1% RBC that had been fluorescently-labelled with a fluorescein dye, cell tracker® green 
5-chloromethylfluorescein diacetate, to give CMFDA-labelled RBC. These labelled RBC 
could be excited between 450–500 nm, and detected between 500–600 nm (max = 517 nm) in 
order to facilitate independent tracking of the RBC for comparative purposes.  
 
 
Figure 5.20 Schematic of RBC (red) flowing through a100 m deep rectangular microchannel, spiked 
with 1% CMFDA-labelled RBC (green) and IrBpy-Z●AuNP100nanoparticles (yellow). 
 
The nanoparticles and the labelled RBC were imaged by epiluminescence microscopy, in the 
centre of the channel. The two luminescence channels (of IrBpy-Z•AuNP100 and CMFDA-
labelled RBC) were separated by excitation wavelength: IrBpy-Z•AuNP100 were imaged 
with λexc = 355 nm,  λem > 510 nm, and the labelled RBC were imaged with λexc = 475 nm, λem 
> 510 nm. An example video sequence of the two channels is presented as a two-dimensional 
image in Figure 5.21, with the sequences projected onto the time axis. The blood model in 
this example is 10% haematocrit, i.e. the volume percentage of RBC in the system is 10%.
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Figure 5.21 Overlay of time frames of consecutive luminescence images of IrBpy-Z•AuNP100 (left, 
λexc = 355 nm, λem nm > 510 nm) and luminescence images of stained RBC (right,  λexc = 475 nm, λem 
nm > 510 nm) flowing in 10% haematocrit at 12 µm channel depth, 5 µL min−1 flow rate. Imaging at 
30 fps. 
 
There were noticeable differences between the appearances of the IrBpy-Z•AuNP100 and the 
labelled RBC tracks (Figure 5.21): the former appeared as smaller spots of luminescence and 
showed more variance in the x-direction. This is unsurprising because it has been reported that 
the when blood flows though vessels, the flow fields enhance substance diffusion to a greater 
degree than simple Brownian motion76 and in vitro models of micron tracer particles within 
RBC suspensions have also shown significant radial dispersions within the flow.77 It was 
possible to image the particles and the labelled RBC up to a depth of ca. 25 µm into the 10–
30% haematocrit suspensions by luminescence microscopy; beyond this, visualisation was 
impaired by the opacity of the suspension at the visible wavelengths used. Although these 
findings indicate that as blood tracers, the  IrBpy-Z•AuNP100 particles may only be suitable 
for the measurement of flow rates across very narrow vessels or close to the vessel wall, their 
performance was no worse than that of the labelled RBC, which are ca. 70 times larger in 
diameter. Moreover, it is blood flow within the narrow channels of the vascular tree (as small 
as 8 μm diameter) which is the least understood. Video sequences of IrBpy-Z•AuNP100 and 
labelled RBC were recorded at 64 fps, at varying depths into the channel, and were tracked 
manually to gain vy data, Figure 5.22.  For IrBpy-Z•AuNP100 suspended in 0% haematocrit 
(i.e. PBS), the particles could be tracked throughout the whole channel, and the expected 
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parabolic flow profile was observed, with a  flow maximum of ca. 1100 µm s−1. This is 
comparable to the simple model maximum flow value of 1250 µm  s−1 (see Appendix 14), 
assuming a Poiseuille flow between infinitely wide parallel plates (Figure 4.22). This not only 
substantiated the suitability of IrBpy-Z•AuNP100 for determining flow rates but also 
facilitated calibration of the starting depth for the image sequences by fitting the data with a 
second-order polynomial and setting the turning-point as the centre of the channel (i,e.  
channel depth of 50 µm).  Due to the large size difference between IrBpy-Z•AuNP100 and 
RBC, it was hypothesised that the RBC concentration (the percentage haematocrit) might 
affect the ability of the nanoparticle tracers to follow the flow paths faithfully in the 
suspension. Indeed, blood rheology can significantly affect the flow characteristics of smaller 
haematopoietic cells in vivo; for example, the margination of platelets to the walls of blood 
vessels is dependent upon the rheology, which  is a crucial phenomenon for clotting 
processes.78,79 The percentage haematocrit was varied from 0–30% to assess the effect of this, 
as presented in Figure 5.22b. However, the percentage haematocrit did not affect the vy of 
either the particles or the labelled RBC at any of the depths studied. 
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Figure 5.22 a) Measured vy of IrBpy-Z•AuNP100 suspended in 0% haematocrit solution (PBS) at 
depths up to 72 m from the wall of a cuboidal channel (depth 100 m) when perfused at rate 5 L 
min−1, () data point, (—) median vy.  IrBpy-Z•AuNP100 were visualised by their luminescence (λem > 
510 nm). b) Median vy of IrBpy-Z•AuNP100 (filled bars) and CMFDA-labelled RBC (open bars) 
suspended in RBC suspensions between 0 and 30%, at depths up to 25 m from the channel wall when 
perfused at 5 L min−1 through a cuboidal channel (depth 100 m).  IrBpy-Z•AuNP100 and labelled 
RBC were tracked sequentially at each depth from their emission (λem > 510 nm) by switching the 
excitation wavelength between λexc = 355 nm (IrBpy-Z•AuNP100) and λexc = 475 nm (labelled-RBC). 
c) Median vy of IrBpy-Z•AuNP100 and RBC, plotted in (b), expressed as relative vy 
(IrBpy-Z•AuNP100/RBC). 
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Normalization of the IrBpy-Z•AuNP100 vy to the RBC vy (Figure 5.22c) showed that the 
particles followed the flow speeds of the RBC in all cases.  
 
The presence of fibrinogen and other macromolecules within blood often supports the 
assembly of RBC into tube-like aggregates, known as ‘rouleaux’, and plug-flow dynamics can 
arise, which tend to blunt the flow profile and alter the degree of margination of certain 
species within particulate flow.80 RBC aggregation can be artificially manipulated in vitro 
using dextrans of different molecular weights.79 Therefore, in order to investigate whether 
aggregation conditions may alter the velocity of the nanoparticles in flow, 30% haematocrit 
was prepared in 1% Dextran500 (aggregating) and 2% Dextran40 (non-aggregating viscosity 
control), and IrBpy-Z•AuNP100 and RBC were tracked up to a depth of 25 µm (Figure 
5.24). RBC aggregation was verified by bright-field microscopy using a static sample, as 
shown in Figure 5.23 below. 
 
Figure 5.23 Brightfield microscopy images of 30% haematocrit prepared in 2% Dextran40 (viscosity 
control) (a) and 1% Dextran500 (b), both containing IrBpy-Z●AuNP100 at 2pM. Aggregated RBC 
are observed in (b). 
 
However, under flow conditions, the aggregation did not appear to alter the vy of either the 
IrBpy-Z•AuNP100 or the RBC, as presented in Figure 5.24. 
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Figure 5.24 Measured vy of IrBpy-Z●AuNP100 (filled bars) and CMFDA-labelled RBC (open bars) 
suspended in 30% haematocrit solution prepared in PBS, 2%Dextran40 (Dx40) or 1%Dextran500 
(Dx500) at depths up to 25 m from the wall of a cuboidal channel (depth 100 m) when perfused at 
rate 5 L min−1.  
 
 
These results are noteworthy in terms of the ability of nanoparticles to act as faithful flow 
tracers regardless of their position within the channel and, perhaps regardless of the 
architecture of the vasculature being examined.  This may be significant for the study of blood 
vasculature in vivo in the early diagnosis of conditions where abnormal changes in flow are 
indicative of the pathological state.  
 
Current methods to explore such pathological states are based on Doppler ultrasound, or the 
injection of contrast agents, and are inherently macroscopic low-resolution techniques, which 
are limited in their ability to study the microvasculature. IrBpy-Z•AuNP100 nanoparticles, 
therefore, present a unique opportunity to explore the microvasculature, in terms of resolution 
and size, and when combined with their ability to track blood flow faithfully under a range of 
blood rheologies, they represent a highly suitable tool for imaging.   
 
5.6.3 Imaging Nanoparticles in Biological Tissue 
In order to investigate the suitability of the IrBpy-Z•AuNP100 for blood flow studies in vivo, 
nanoparticle suspensions in PBS were injected into mice, and excised tissue sections of the 
lungs, mesentery and extensor hallucis proprius skeletal leg muscle were imaged using 
6 12 19 25 6 12 19 25 6 12 19 25
0
200
400
600
800
1000 Dx500PBS Dx40
Depth into channel (m)
v y
 (
m
 s
-1
)
  Chapter Five 
215 
 
epiluminescence microscopy following wet mounting of the tissue onto coverslips. 
IrBpy-Z•AuNP100 particles were observed in all tissues investigated, and images of particles 
in the mesentery tissue and skeletal muscle are shown below, in Figure 5.25. 
 
  
Figure 5.25 Bright field (a and c) image and luminescence images (λexc = 405 nm, λem > 510  (b and d) 
of a small blood vessel in the mesentery tissue (a and b), with the white arrow indicating the 
endothelial cells lining the vessel (adipocytes, i.e. fat cells, are evident as spherical objects beneath 
the vasculature), and in the skeletal muscle (c and d) of a mouse injected with IrBpy-Z•AuNP100, 
with the black arrow indicating the striated muscle fibres. The steady-state emission spectrum 
obtained from the field of view in image d is shown, corrected for instrument response (inset). 
 
Under bright-field illumination, a ca. 100 μm diameter blood vessel was located within the 
mesentery tissue. RBC filling the vessel and endothelial cells lining the vessel, were visible 
(Figure 5.25a) and spots of luminescence were clearly visible in the luminescence image 
(Figure 5.25b). Characteristic skeletal muscle fibres were visible in the extensor hallucis 
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proprius which gave it a striated appearance by bright-field microscopy (Figure 5.25c) and 
the point-source luminescence of the nanoparticles was observed under epiluminescence 
detection. Steady-state emission spectra taken for the fields of view displayed the 
characteristic peak expected for IrBpy-Z•AuNP100 (Figure 5.25d inset), which together with 
luminescence lifetimes (measured from image with a 375 nm laser at 550 nm to be 86 ns 
(15%) and 320 ns (85%)), confirmed that the observed signal is from the nanoparticles, not 
autofluorescence. These results confirm that IrBpy-Z•AuNP100 had reached the small 
capillaries within this tissue. The nanoparticles were similarly detected in the lungs (Appendix 
15).   
 
Preliminary biodistribution data of the IrBpy-Z•AuNP100 in mice have been collected by 
analysing the gold content of excised organs in four different specimens by inductively-
coupled plasma mass spectrometry (ICP-MS). The data are presented below in Figure 5.26.  
 
Figure 5.26 Biodistrubution of gold in four specimen mice, administered with 100 L (80 pM)(M2) or 
200 L(M3) IrBpy-Z•AuNP10 by intracardial injection, or with 500L (80 pM) IrBpy-Z•AuNP100 
by carotid artery cannulation (M5). M6 is a control, with a saline intracardial injection. 
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These pilot data show a zero background with negative controls (saline injection), and a dose-
dependent effect with injected particle number. Carotid artery cannulation to deliver 
nanoparticles to the heart (in the left ventricle, thus avoiding the lung perfusion on first pass) 
confirmed good clearance in the liver and spleen, but not the lungs. It is of interest that 
clearance of nanoparticles (unlike microparticles) may be greater in the viscera (with 
sinusoidal, fenestrated endothelium) rather than the lung (with continuous endothelium). This 
may prove to be important for future targeting studies. 
 
5.7	Developing	 Luminescent	 Ir(III)‐labelled	 Gold	Nanoparticles	with	
T1	MRI	Contrast	
Due to the success of the IrBpySH complex in labelling gold nanoparticles to form bright 
enough nanoconstructs to image in flow, an attempt has been made at designing multimodal 
imaging nanoprobes by incorporating the supplied GdQSH complex (synthesised by Dr D. J. 
Lewis) and IrBpySH onto the same nanoparticles, thus rendering an imaging agent that can 
be visualised optically and imaged using nuclear magnetic resonance. 
 
Magnetic resonance can be exploited for imaging purposes by exciting nuclei which possess 
spin with a radio frequency pulse, within a strong magnetic field (analogous to NMR), whilst 
using magnetic gradients to spatially encode the signal of each voxel to produce an image. 
Conventional clinical MRI studies resonate the water protons within a sample, and the 
intensity of each voxel (i.e. the contrast of the image) can be weighted with various 
parameters, including proton density, longitudinal relaxation times (T1), and transverse 
relaxation times (T2). As discussed in the introduction to this chapter (Section 5.2.1), 
gadolinium(III) chelates are often used as MRI contrast agents for imaging, because the 
tricationic lanthanide centres are highly paramagnetic, with seven unpaired electrons. Such 
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paramagnetic centres give T1-contrast in proton MRI imaging by reducing the longitudinal 
relaxation time of nearby water protons, which enhances local contrast with respect to 
background tissue.41-43 In brief, T1 is the time taken for the macroscopic magnetisation vector 
to reurn to thermal equilibrium, following excitation by a 90o radio frequency pulse. T1 
relaxation depends upon magnetic fluctuations in the transverse plane (relative to the static 
magnetic field), which stimulate transitions from the excited spin state back to the ground 
spin state, if the fluctuations occur at the correct frequency (i.e. that of the energy gap 
between the two states). Therefore the relative molecular motion between water protons and 
highly paramagnetic Gd(III) metal centres rapidly increases the 1/T1 relaxation rates. 
 
13 nm gold nanoparticles were chosen for this pilot study, rather than 100 nm particles, to 
maximise the surface area:volume ratio of the colloid, and thus enhance the sensitivity of the 
probes by maximising the area available for surface-grafted complexes. The GdQSH 
complex has two functions in the 13 nm citrate nanoparticle coating process; both to give T1 
contrast in proton MRI imaging, and to stabilise the particles with respect to aggregation, in a 
similar fashion to the neutral surfactant molecules investigated in Chapter Two. The 
nanoparticles (9 nM) are initially coated in excess GdQSH complex, i.e. beyond the 
saturation in the shift of the SPR band of the nanoparticles upon adding the complex, as has 
been previously reported by Dr A. C. Savage.81 Once the neutral GdQSH has displaced the 
citrate anions from the surface, and surrounds each nanoparticle with a bulky neutral group, 
IrBpySH can be added without aggregation of the nanoparticles occurring, as shown below in 
Figure 5.27. Upon titration of GdQSH (0–100 L ,1mM) into 13 nm gold nanoparticles 
(1 mL, 9 nM), a 6 nm red-shift in the SPR of the nanoparticles is observed, as has previously 
been reported in the group.81  
 
  Chapter Five 
219 
 
 
Figure 5.27 (a)UV-Vis absorption spectra of citrate gold nanoparticles(1 mL, 9 nM) (solid line), and 
upon addition of GdQSH (100 L, 1 mM in CH3OH) (bold solid line) and subsequent addition of 
IrBpySH (6L, 3.5 mM in 1:1 (30 % w/v NH4OH(aq):CH3CN) (dashed line). (b) Plot of SPR max 
vs.[GdQSH] upon titration 0–100 into 9 nM 13 nm gold nanoparticles. 
 
Excess GdQSH, was added to ensure that the particles were fully coated with a neutral 
complex and to try to maximise their stability before addition of a cationic complex. Upon 
addition of IrBpySH (made in situ from IrBpySAc), no further shift in the SPR was 
observed, and there was no evidence of nanoparticle aggregation by inspection of the UV-Vis 
absorption spectrum. Notably, if the same concentration of IrBpySH is added directly to 
13 nm citrate-coated gold nanoparticles, the nanoparticles immediately aggregate; the solution 
turns steel blue and eventually the aggregates sediment out of suspension.  
 
The resultant nanoparticles were isolated by centrifugation, decantation of the supernatant and 
resuspension of the pellet in deionised water to give IrBpy-GdQ•AuNP13. These 
nanoparticles were characterised by UV-Vis spectroscopy, ICP-OES, TEM and DLS, and 
their photophysical properties have been analysed, as presented in Figure 5.28.  
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Figure 5.28 UV-Vis absorption spectrum (solid line), excitation spectrum, em = 550 nm (dashed line) 
and steady-state emission spectrum exc = 355 nm, (bold solid line) of  1nM IrBpy-GdQ•AuNP13 
Spectra corrected for instrument response.   
 
 
The UV-Vis absorption spectrum of the isolated IrBpy-GdQ•AuNP13 is dominated by the 
SPR of the gold nanoparticles, with a max maintained at 526 nm, following isolation from the 
excess gadolinium(III) and iridium(III) complexes. Upon excitation at 355 nm, the 
nanoparticles emit bright yellow luminescence, with max = 580 nm, and time-resolved 
luminescence measurements taken at em = 550 nm, after excitation with a 375 nm laser, 
reveal observed luminescence lifetimes of 90 ns (29%) and 285 ns (71%) for aerated 
nanoparticles, with intensity weightings in parenthesis. The steady-state max red-shifts 10 nm 
in comparison to the IrBpy-Z•AuNP13, which indicates, as expected, that the Zonyl®7950 
fluoropolymer and the GdQSH co-coating moieties affect the photophysical properties of the 
surface-bound IrBpySH complex. The time-resolved emission decay in aerated aqueous 
systems follows biexponential law for the IrBpy-GdQ•AuNP13 nanoparticles ( = 90 ns 
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(29%) and 285 ns (71%) ), with a similar short component to that of IrBpy-Z•AuNP13 ( = 
80 ns (7%), 380 ns (93%)). The long component is, however, 25% shorter.  
 
The nanoparticle sizing data is shown below in Figure 5.29. The nanoparticles do not appear 
to aggregate, as the DLS number distribution has a mean value of 11±3 nm, and the TEM 
displays individual spherical nanoparticles. 
 
Figure 5.29 DLS number distribution of IrBpy-GdQ•AuNP13. Inset: TEM image of 
IrBpy-GdQ•AuNP13. 
 
 
To calculate the number of Gd(III) and Ir(III) complexes per nanoparticle, samples were 
analysed by ICP-OES to give atomic ratios of Au:Gd of 98:1 for GdQ•AuNP13 particles, and 
of 73:1 for IrBpy-GdQ•AuNP13 particles. Assuming that the gold nanoparticles are 13 nm in 
diameter, this equates to 1020 and 1370 gadolinium(III) complexes per nanoparticles for 
GdQ•AuNP13 and IrBpy-GdQ•AuNP13 respectively (see appendices 2.6 and 2.7 
respectively). The atomic ratio of Au:Ir for IrBpy-GdQ•AuNP13 particles = 300:1, which 
equates to 330 complexes per nanoparticle (Appendix 2.7).  
 
To investigate the r1 relaxivity of IrBpy-GdQ•AuNP13, i.e. the change in rate of the 
longitudinal relaxation rate of solvent water protons (1/T1), per concentration of contrast 
agent,41 a concentration series of the free complex, GdQSH, IrBpy-GdQ•AuNP13 and a 
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control study of GdQ•AuNP13 (i.e. particles made analogous to IrBpy-GdQ•AuNP13, but 
with omission of the addition of IrBpySH), was analysed. To increase the concentration of 
the samples beyond 9 nM (i.e. the concentration at which the 13 nm citrate nanoparticles are 
synthesised), the final volume of water that the pellet was dispersed in was altered 
accordingly. The samples were imaged in a 3T clinical MRI instrument by Ms Lindsey van 
Gemeren, and T1 relaxation times were analysed. These values are used to calculate the r1 
relaxivities of the nanoparticles, using the ICP-OES data to calculate r1 relaxivities with 
respect to Gd(III) concentration. T1 relaxation times were collected by Ms Lindsey van 
Gemeren at 5 different concentrations of free complex (10–90 M) or coated-nanoparticles 
(1–40 nM), and a linear regression of 1/T1 vs. [Gd(III)] was fitted to the data to calculate the 
r1 relaxivities. The r1 relaxivity of the free GdQSH complex in water (with 10% CH3OH for 
solubility) was measured as 5.1 s−1mM−1, which is very similar to that of Gadidiamide (sold 
under the name of Omniscan™), for r1= 4.8 s−1mM−1, measured in a 3T field..82 (Gadidiamide 
is a similar pentetic acid gadolinium(III) chelate, in which two of the carboxyl groups are 
methyl amides.) A 40–60% increase in the r1 relaxivity per unit Gd(III) is observed when the 
complex is attached to nanoparticles, with r1 relaxivities measured as 7.1 s−1mM−1 and 8.4 
s−1mM−1 for GdQ•AuNP13 and IrBpy-GdQ•AuNP13 respectively. Relaxivity increases are 
often observed when molecular contrast agents are attached to nanomaterials, because this 
dramatically alters the diffusion dynamics of the complex, which affects the ability of the 
gadolinium(III) centres to influence the T1 longitudinal relaxation rate of surrounding water 
protons.42,83  
 
As a preliminary study, to verify whether the nanoparticles were optically tracable in cells, 
A549 human lung cancer cells were incubated with 1 nM IrBpy-GdQ•AuNP13 for 24 hr, 
and imaged by confocal microscopy, as shown in Figure 5.30. 
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Figure 5.30 Confocal micrographs of A549 cancer cells dosed with (a,b) no nanoparticles, (c,d) 
GdQ•AuNP13, and (e,f) IrBpy-GdQ•AuNP13. (a,c,e = brightfield transmission channel, b,d,f = 
luminescence channel: exc = 405nm,em = 500–750 nm). 
  
 
The IrBpy-GdQ•AuNP13 nanoparticles are optically bright enough to image in cells, as can 
be seen in the yellow channel, Figure 5.30(f). Control studies with blank A549 cells (a,b) and 
cell dosed with the same concentration of GdQ•AuNP13 confirm that the luminescence in the 
yellow channel is due to the presence of the IrBpySH complex bound to the 
IrBpy-GdQ•AuNP13  nanoarticles.  
 
Solution studies of IrBpy-GdQ•AuNP13 nanoparticles demonstrate that they are promising 
candidates for multimodal imaging probes, and preliminary in vitro studies suggest that the 
particles can be visualised optically in cells. In vitro studies of these particles are ongoing by 
Ms Lindsey van Gemeren, to verify whether the MRI-contrast is applicable at particle 
concentrations that can be achieved in living cells. 
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5.8	Conclusion	
Two luminescent Ir(III) complexes have been evaluated in this Chapter, IrBpySAc, and 
IrPhenSAc. The photophysical properties of IrBpySAc were found to be more suitable for 
luminescent imaging applications, due to the larger quantum yield and reduced sensitivity to 
molecular oxygen quenching of the luminescent state, with respect to IrPhenSAc. Both 
complexes have been attached to 100 nm gold nanoparticles, using a fluorosurfactant-
mediated strategy, and the resulting nanoparticles were all emissive and maintained their 
colloidal stability. The 100 nm particles coated in IrPhenSAc were emissive, but the aerated 
particles were not bright enough to measure a quantum yield in an integrating sphere. 
Similarly to the free complex, the coated particles were very sensitive to quenching by 
molecular oxygen.  IrBpySAc was attached to 13 nm and 100 nm gold nanoparticles, and 
both sizes of labelled nanoparticles have very similar photophysical properties; the quantum 
yields of the particles were higher than the free complex in an aqueous environment, and the 
enhancement is expected to be mainly due to the presence of the Zonyl® 7950 surfactant. 
Importantly neither size of IrBpySH-labelled nanoparticle is sensitive to luminescence 
quenching by molecular oxygen, and  no luminescence quenching of the IrBpySH complex 
was observed, upon attachment to gold nanoparticles.  
 
IrBpy-Z•AuNP100 nanoparticles were studied in dynamic blood flow systems to assess their 
ability as tracking velocimetry tracers. It was possible to measure the particles by 
epiluminescence microscopy to depths of 25 m in 30% haematocrit, and the particles appear 
to follow the flow velocities of the RBCs, even when RBC aggregation is induced in the 
system by macromolecular Dextran500. Ex-vivo imaging of particles in tissue from mice 
injected intravenously with IrBpy-Z•AuNP100 was performed successfully, and 
biodistribution studies of the gold in surgically excised organs was investigated.  
 
  Chapter Five 
225 
 
In addition, 13 nm gold nanoparticles have been successfully co-coated with IrBpySH and 
GdQSH, with the aim to develop luminescent nanoparticles with additional T1-contrast for 
imaging by optical microscopy and MRI. The resultant nanoparticles are emissive, and do 
give T1-weighted contrast, with a r1 relaxivity of 8.4 s−1 mM−1 ([Gd]) in a 3T field, which is 
60% enhanced with respect to the free gadolinium(III) complex in solution. 
 
In summary, the iridium complex IrBpySH is a valuable luminescent label which can be 
attached to gold nanoparticles to produce imaging probes with much-improved quantum 
yields over the analogous ruthenium(II)-labelled nanoparticles in Chapter Two. This chapter 
demonstrates that nanoparticles coated in IrBpySH can be optimised for a variety of 
appicaltions.  
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5.10	Experimental	
5.10.1	General	Synthesis	
Zonyl® 7950 was purchased from Sigma Aldrich and used without further purification. 
13 nm gold nanoparticles were synthesised by the citrate reduction method,84 as described in 
Section 2.12.1, and 100 nm gold nanoparticles were synthesised according to the growth 
method described in Section 3.7.1, adapted from the published procedure by Ziegler and 
Eychmüller.85 The BpyHex ligand was synthesised according to the method described in 
Section 2.12.12 and the PhenHex ligand provided by Dr Shiva Farabi.51 GdQSH was 
provided by Dr D. J. Lewis, synthesised by the reported method.86  
  
Characterisation of 4,7-bis(hex-5-en-1yloxy)-1,10-phenanthroline  (PhenHex ligand)  
The PhenHex ligand was synthesised by Dr Shiva Farabi51  and characterised by NMR. Data 
agree with previously reported work and thus no further characterisation is reported.1H NMR 
(300 MHz, d6-DMSO): δH = 8.89 (d, 2H, 3JH3 = 5.3 Hz, H2), 8.15 (s, 2H, H7), 7.28 (d, 2H, 
3JH2 = 5.3 Hz, H3), 5.94–5.74 (m, 2H, H12), 5.12–4.96 (m, 4H, H13/H14), 4.31 (t, 4H, 3JH9 = 6.3 
Hz, H8), 2.22–2.12 (m, 4H, H11), 1.98–1.86 (m, 4H, H9), 1.670–1.57 (m, 4H, H10).      
 
Synthesis of tetrakis(2-phenylpyridine-C2,N’)(-dichloro)diiridium ([Ir(ppy)2(μ-Cl)2])   
 
Synthesis was performed according to the method of Sprouse, and is detailed herein.87 A 
solution of iridium(III) trichloride hydrate (805 mg, 2.70 mmol) and 2-phenylpyridine 
(1.593 g, 10.3 mmol) in 2-methoxyethanol (60 mL) was refluxed at 130 ºC overnight to give a 
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yellow/brown suspension. This was left to cool and was filtered under suction to render a 
yellow powder. The residue was washed with ethanol (100 mL) and dissolved in CH2Cl2 (150 
mL). The solution was filtered and hexane (20 mL) and toluene (50 mL) were added. The 
volume was reduced in vacuo to 100 mL and cooled on ice to crystallise. The product was 
retrieved by filtration as yellow crystalline solid (0.7369 g, 0.687 mmol, 51 % yield). Rf = 
0.81 (CH2Cl2:CH3OH 10:1). 1H NMR (300 MHz, d6-DMSO): δH = 9.81 / 9.53 (d, 4H, 3JHc = 
5.8 Hz, Hb), 8.27 / 8.19 (d, 4H, 3JHd = 7.9 Hz, He), 8.10 / 8.01 (m (apparent t, 3JHe  3JHc = 
7.6 Hz) 4H, Hd), 7.79 / 7.74 (d, 4H, 3JHi = 7.9 Hz, Hh), 7.57 / 7.46 (m (apparent t, 3JHd  3JHb = 
6.6 Hz) 4H, Hc), 6.94–6.68 (m, 8H, Hi, Hj), 6.25 / 5.66 (d, 4H, 3JHj = 7.3 Hz, Hk). 13C NMR 
(100 MHz, d6-DMSO): δC = 166.9 / 152.0 / 145.4 / 143.7 / 143.1 (quaternary C), 152.1 / 150.6 
(Cb), 139.2 / 138.1 (Cd), 131.2 / 129.6 (Ck), 129.9 / 128.9 / 122.2 / 121.9 (Ci/Cj), 124.8 / 123.8 
(Ch), 123.5 / 122.8 (Cc), 120.0 / 119.4 (Ce). TOF ES-MS(+): 501.1 [Ir(ppy)2]+. IR υmax (cm−1): 
3040 (C–H), 1605 (C–Cring,/C–Nring), 1581(C–Cring,/C–Nring), 1561, 1476, 1414, 1030, 754. 
UV-Vis (CH3CN) λmax [nm] = 259, 350 (shoulder), 390 (shoulder), 430 (shoulder). Emission 
(CH3CN, λexc = 355 nm) λmax [nm] = 510. 
 
Synthesis of [Ir(ppy)2BpyHex]Cl (IrBpyHex complex)  
 
The cyclometalled iridium(III) dimer [Ir(ppy)2(μ -Cl)]2 ( 634 mg, 0.591 mmol) and BpyHex 
(310 mg, 0.876 mmol, 1.5 eq) were dissolved in CH2Cl2/CH3OH (45 mL, 2:1) and refluxed 
overnight at 60 ºC under nitrogen. Following cooling, the solvent was removed in vacuo to 
render a yellow residue. The residue was purified by chromatography on silica eluting 
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CH2Cl2:CH3OH 10:1 (Rf = 0.44) to give IrBpyHex as a yellow powder (0.602 g, 0.677 mmol, 
77% yield). Rf = 0.44 (CH2Cl2:CH3OH 10:1). 1H NMR (400 MHz, d6-DMSO): δH = 8.46 (s, 
2H, H3), 8.25 (d, 2H, 3JHd = 8.2 Hz, He), 7.98–7.88 (m, 4H, Hd/Hh), 7.69 (d, 2H, 3JHc = 5.6 Hz, 
Hb), 7.59 (d, 2H, 3JH5 = 6.6 Hz, H6), 7.28 (dd, 2H, 3JH6 = 6.6 Hz, 4JH3 = 2.5 Hz, H5), 7.19 (m 
(apparent t, 3JHd  3JHb = 5.7 Hz) 2H, Hc), 7.00 (m (apparent t, 3JHh  3JHj = 7.5 Hz) 2H, Hi), 
6.88 (m (apparent t, 3JHk  3JHi = 7.5 Hz) 2H, Hj), 6.19 (d, 2H, 3JHj = 7.5 Hz, Hk), 5.90–5.76 
(m, 2H, H11), 5.09–4.95 (m, 4H, H12/H13), 4.24 (t, 4H, 3JH8 = 6.3 Hz, H7), 2.16–2.06 (m, 4H, 
H10), 1.85–1.73 (m, 4H, H8), 1.59–1.46 (m, 4H, H9). 13C NMR (100 MHz, d6-DMSO): δC = 
150.5 (C6), 148.7 (Cb), 138.5 / 138.3 (Cd/C11), 131.1 (Ck), 130.1 (Cj), 125.9 (Ch), 125.0 (Cc), 
123.8 (Ci), 121.9 (Ce), 115.1 (C12), 114.5 (C5), 111.9 (C3), 69.1 (C7), 32.6 (C10), 27.6 (C8), 
24.5 (C9). TOF ES-MS(+): m/z 853.5 [M−Cl]+. IR υmax (cm–1): 3045 (C–H), 2940 (C–H), 
1606 (C–Cring / C–Nring), 1472, 1436, 1341, 1284, 1226, 1031, 994, 756.  
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Synthesis of [Ir(ppy)2BpySAc]Cl (IrBpySAc complex)  
 
Thioacetic acid (564 μL, 7.890 mmol) and 1,1’-azobiscyclohexane carbonitrile (ABCN,  756 
mg, 3.093 mmol) in anhydrous THF (10 mL) were heated at 60 ºC under N2 (g) for 30 min. 
IrBpyHex (600 mg, 0.675 mmol) in anhydrous THF (40 mL) was added dropwise to the 
mixture, which was then stirred at 60 ºC under N2(g). The progress of the reaction was 
monitored by the disappearance of the terminal olefins by 1H NMR. Thioacetic acid (100 μL, 
1.399 mmol) and ABCN (125 mg, 0.512 mmol) were added after 18 hr, another portion of 
thioacetic acid (120 mL, 1.679 mmol) and ABCN (150 mg, 0.614 mmol) was added after 22 
hr. After a total of 45 hr, the reaction was pushed to completion and the ABCN was quenched 
with saturated NaHCO3 (aq) (150 mL). The solution was extracted with CH2Cl2/H2O, dried 
over MgSO4, and filtered. The solvent was removed in vacuo to render a dark brown viscous 
residue which was purified by column chromatography on silica, eluting CH2Cl2:CH3OH 10:1 
to give IrBpySAc as a bright yellow solid (459 mg, 0.441 mmol, 65% yield). Rf = 0.56 
(CH2Cl2:CH3OH 10:1). 1H NMR (300 MHz, d6-DMSO) : δH = 8.44 (d, 2H, 4JH5 = 2.5 Hz, 
H3), 8.25 (d, 2H, 3JHd = 8.1 Hz, He), 7.96–7.86 (m, 4H, Hd/Hh), 7.68 (d, 2H, 3JHc = 5.1 Hz, 
Hb), 7.58 (d, 2H, 3JH5 = 6.4 Hz, H6), 7.27 (dd, 2H, 3JH6 = 6.4 Hz, 4JH3 = 2.4 Hz, H5), 7.18 (m 
(apparent t,  3JHd  3JHb = 5.7 Hz) 2H,  Hc ), 6.99 (m (apparent t, 3JHj  3JHh = 7.5 Hz) 2H , Hi ), 
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6.85 (m (apparent t,  3JHk  3JHi = 7.4 Hz) 2H, Hj ), 6.18 (d, 2H, 3JHj = 6.6 Hz, Hk ), 4.21 (t, 
4H, 3JH8 = 6.1 Hz, H7), 2.83 (t, 4H, 3JH11 = 7.2 Hz, H12), 2.30 (s, 6H, H15),1.80–1.71 (m, 4H, 
H10), 1.56–1.48 (m, 4H, H8), 1.46–1.34 (m, 8H, H9/H11). 13C NMR (100 MHz, d6-DMSO): δC 
= 166.9  / 166.8 / 156.9 / 151.1 / 143.9 (quaternary C), 150.5 (C6), 148.7 (Cb), 138.5 / 125.0 
(Cd/Ch), 131.1 (Ck), 130.1 (Cj), 123.8 (Cc), 121.9 (Ci), 119.9 (Ce), 114.5 (C5), 111.9 (C3), 69.2 
(C7), 30.6 (C15), 29.0 (C8), 28.2 (C12), 28.0 (C10), 27.7 / 24.8 (C9/C11). TOF ES-MS(+): m/z 
1006.2 [M−Cl]+. HRMS (ES+): Calc. for C48H52193IrN4O4S2 1005.3060, found 1005.3046 
Anal. calcd for C48H52ClIrN4O4S2 : C 55.4, H 5.0, N 5.4. Found: C 55.1, H 4.9, N 5.2. IR, υmax 
(cm-1): 3043 (C–H), 2930 (C–H), 2857 (C–H), 1682(C=O), 1605 (C–Cring / C–Nring), 1476, 
1417, 1337, 1269, 1225, 1063, 1030, 952, 757.  UV-Vis (CH3CN) λmax [nm, (log ε)] = 228 
(4.7), 256 (4.8), 295 (4.5), 346 (4.0), 420 (3.6). Emission (CH3CN, λexc = 355 nm) λmax [nm] = 
585. Lifetime (CH3CN, λexc = 375 nm, λem = 550 nm) = 60 ns (aerated), =325 ns (degassed). 
Φ (CH3CN, λexc = 355 nm) = 0.03 (aerated), = 0.09 (degassed).   
 
Synthesis of [Ir(ppy)2BpySH]Cl (IrBpySH complex)   
 
To IrBpySAc (50 μL, 7.0 mM in MeCN, 350 nmol) was added NH4OH(aq) solution (50 μL, 
30% w/w). The mixture was stirred for 10 min in a sealed vial to render IrBpySH (3.5 mM) 
directly prior to titration into the colloid. TOF MALDI-MS(+): 920.15 [M−Cl]+.  
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Synthesis of [Ir(ppy)2PhenHex]PF6 (IrPhenHex complex)  
 
The cyclometalled iridium(III) dimer [Ir(ppy)2(μ -Cl)]2 ( 290 mg, 0.271 mmol) and PhenHex 
(177 mg, 0.470 mmol, 1.7 eq) were dissolved in CH2Cl2:CH3OH (45 mL, 2:1) and refluxed 
overnight at 60 ºC under nitrogen. The reaction was cooled to room temperature and a 10-fold 
excess of NH4PF6 was added. The suspension was stirred for 15 min and filtered to remove 
any insoluble inorganic salts. The solvent was removed in vacuo to render an orange solid, 
which was purified by chromatography on silica eluting CH2Cl2:CH3OH 10:1 (Rf = 0.36) to 
give IrPhenHex as an orange powder (0.291 g, 0.285 mmol, 53% yield). Rf = 0.36 
(CH2Cl2:CH3OH 10:1). 1H NMR (400 MHz, d6-DMSO): δH = 8.36 (s, 2H, H7), 8.24 (d, 2H, 
3JHd = 8.1 Hz, He), 7.96–7.91 (m, 4H, H2/Hh), 7.87 (t, 2H, 3JHc  3JHe  7.9 Hz, Hd), 7.58–7.54 
(m, 4H, H3/Hb), 7.07–6.97 (m, 4H, Hc/Hi), 6.92 (t, 2H, 3JHi  3JHk  7.3 Hz, Hj), 6.30 (d, 2H, 
3JHj = 7.5 Hz, Hk), 5.91–5.79 (m, 2H, H12), 5.09–5.02 (m, 2H, H13), 5.01–4.96 (m, 2H, H14), 
4.36 (t, 4H, 3JH9 = 6.4 Hz, H8), 2.18–2.10 (m, 4H, H11), 1.95–1.86 (m, 4H, H9), 1.66–1.57 (m, 
4H, H10).  13C NMR (100 MHz, d6-DMSO): δC = 167.0, 162.5, 150.6, 146.7, 144.1 (Cquaternary), 
151.6 (C2), 148.9 (Cb), 138.4 (Cd/C12), 131.3 (Ck), 130.0 (Cj), 124.9 (Ch), 123.7/122.0 (Cc/Ci), 
121.0 (C7), 119.8 (Ce), 115.1 (C13), 107.9 (C3), 69.8 (C8), 32.7 (C11), 27.5 (C9), 24.6 (C10). 
TOF ES-MS(+): m/z 877.4 [M−PF6]+. IR υmax (cm−1): 3043 (C–H), 2927 (C–H), 2858 (C–H), 
1605 (C–Cring / C–Nring), 1577, 1524, 1504, 1477, 1416, 1353, 1299, 1267, 1227, 1188, 1163, 
1062, 1031, 998, 914, 835, 756, 730. 
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Synthesis of [Ir(ppy)2PhenSAc]PF6  
 
Thioacetic acid (200 μL, 2.798 mmol) and 1,1’-azobiscyclohexane carbonitrile (ABCN,  400 
mg, 1.637 mmol) in anhydrous THF (10 mL) were heated at 60 ºC under N2 (g) for 30 min. 
IrPhenHex (197 mg, 0.193 mmol) in anhydrous THF (10 mL) was added dropwise to the 
mixture, which was then stirred at 60 ºC under N2(g). The progress of the reaction was 
monitored by the disappearance of the terminal olefins by 1H NMR. Thioacetic acid (100 μL, 
1.399 mmol) and ABCN (125 mg, 0.512 mmol) were added after 18 hr, another portion of 
thioacetic acid (120 mL, 1.679 mmol) and ABCN (150 mg, 0.614 mmol) was added after 22 
hr. After a total of 45 hr, the reaction was pushed to completion and the ABCN was quenched 
with saturated NaHCO3 (aq) (80 mL). The solid residue was stirred in excess hexane (50 mL) 
for 30 min and filtered and washed with more hexane (20 mL), and dried under vacuum to 
give [Ir(ppy)2PhenSAc]PF6 as an orange solid (158 mg, 0.135 mmol, 70% yield). 1H NMR 
(400 MHz, d6-DMSO): δH = 8.36 (s, 2H, H7), 8.25 (d, 2H, 3JHd = 8.2 Hz, He), 7.96–7.91 (m, 
4H, H2/Hh), 7.87 (t, 2H, 3JHc  3JHe  7.7 Hz, Hd), 7.59–7.54 (m, 4H, H3/Hb), 7.08–6.98 (m, 
4H, Hc/Hi), 6.93 (t, 2H, 3JHi  3JHk  7.6 Hz, Hj), 6.31 (d, 2H, 3JHj = 7.4 Hz, Hk), 4.34 (t, 4H, 
3JH9 = 6.2 Hz, H8), 2.86 (t, 4H, 3JH12 = 7.2 Hz, H13), 2.31 (s, 6H, H16), 1.95–1.84 (m, 4H, H9), 
1.61–1.49 (m, 4H, H10/H12), 1.48–1.39 (m, 4H, H11).  13C NMR (100 MHz, d6-DMSO): δC = 
162.0, 150.6, 146.7, 144.2 (Cquaternary), 151.7 (C2), 148.9 (Cb), 138.4 (Cd), 131.3 (Ck), 130.0 
  Chapter Five 
233 
 
(Cj), 124.9 (Ch), 123.7/122.0 (Cc/Ci), 121.0 (C7), 119.8 (Ce), 107.9 (C3), 69.9 (C8), 30.5 (C16), 
29.0/27.9 (C11/C12), 28.2 (C13), 27.7 (C9), 24.9 (C10). TOF ES-MS(+): m/z 1030.2 [M−PF6]+. 
HRMS (ES+): Calcd for C50H52193IrN4O4S2: 1029.3060, found: 1029.3018.  Anal. calcd for 
C50H52F6IrN4O4PS2 : C 51.1, H 4.5, N 4.8. Found: C 51.0, H 5.0, N 5.5. IR υmax (cm−1): 3041 
(C–H), 2931 (C–H), 2856 (C–H), 1684 (C=O), 1605 (C–Cring / C–Nring), 1577, 1525, 1504, 
1477, 1417, 1354, 1299, 1269, 1227, 1188, 1164, 1134, 1110, 1062, 1031, 989, 956, 835, 759, 
730.  
 
Synthesis of  [Ir(ppy)2PhenSAc]Cl (IrPhenSAc) 
 
 [Ir(ppy)2PhenSAc]PF6 (20 mg, 0.017 mmol) was dissolved in ethanol (1mL) and passed 
through a Dowex 1x8, 50–100 mesh ion exchange column, eluting with ethanol. The solvent 
was removed in vacuo to afford the chloride salt, IrPhenSAc (11 mg, 61 % yield). 1H NMR 
(400 MHz, d6-DMSO): δH = 8.36 (s, 2H, H7), 8.25 (d, 2H, 3JHd = 8.3 Hz, He), 7.96–7.91 (m, 
4H, H2/Hh), 7.87 (t, 2H, 3JHc  3JHe  7.7 Hz, Hd), 7.59–7.54 (m, 4H, H3/Hb), 7.08–6.98 (m, 
4H, Hc/Hi), 6.93 (t, 2H, 3JHi  3JHk  7.6 Hz, Hj), 6.31 (d, 2H, 3JHj = 7.5 Hz, Hk), 4.35 (t, 4H, 
3JH9 = 6.2 Hz, H8), 2.86 (t, 4H, 3JH12 = 7.2 Hz, H13), 2.31 (s, 6H, H16), 1.95–1.84 (m, 4H, H9), 
1.61–1.49 (m, 4H, H10/H12), 1.48–1.39 (m, 4H, H11).  TOF ES-MS(+): m/z 1029.3 [M−Cl]+. 
HRMS (ES+): Calcd for C50H52193IrN4O4S2: 1029.3059, found: 1029.3077. UV-VIS (CH3CN) 
λmax [nm(log ε)] = 254 (4.7), 322 (4.1), 343 (4.1), 390 (3.7), 420 (3.5). Emission (CH3CN, λexc 
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= 355 nm) λmax [nm] = 515. Lifetime (CH3CN, λexc = 375 nm, λem = 550 nm) = 40 ns 
(aerated), =2250 ns (degassed). Φ (CH3CN, λexc = 355 nm) = 0.01 (aerated), = 0.28 
(degassed).   
 
Synthesis of IrPhenSH    
 
To IrPhenSAc (50 μL, 7.0 mM in CH3CN, 350 nmol) was added NH4OH(aq) solution (50 μL, 
30% w/w). The mixture was stirred for ten minutes in a sealed vial to render IrPhenSH (3.5 
mM) directly prior to titration into the colloid. TOF MALDI-MS(+): 944.16 [M−Cl]+.  
 
 
Synthesis of [Ir(ppy)2phen]Cl  
 
Method as published by author.29 The cyclometalled iridium(III) dimer, [Ir(ppy)2(μ-Cl)]2 
(0.103 g, 0.096 mmol, 1.0 eq) and 1, 10-phenanthroline (0.037 g, 0.187 mmol, 1.9 eq.) were 
suspended in a mixture of dichloromethane (8 mL) and methanol (4 mL) and heated to 60 ºC 
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for 7 hours.  The solvent was then reduced to ca.1 mL and the product was purified by 
column chromatography on silica gel eluting dichloromethane : methanol (20 : 1) (Rf = 0.14) 
to give [Ir(ppy)2phen]Cl as an orange solid (0.086 g, 63 %). 1H NMR (300 MHz, CDCl3) δ 
ppm: 8.93 (dd, 2H, 3JH3 = 8.2 Hz, 4JH2 = 1.0 Hz, H4), 8.41 (s, 2H, H5), 8.28 (d, 2H, 3JHd = 8.1 
Hz, He), 8.21 (dd, 2H, 3JH3 = 5.0 Hz, 4JH4 = 1.0 Hz, H2),  8.07 (dd, 2H, 3JH4 = 8.2 Hz, 3JH2 = 
5.0 Hz, H3), 7.97 (d, 2H, 3JHi = 7.9 Hz, Hh), 7.92–7.85 (m, 2H, Hd), 7.47 (d, 2H, 3JHc = 5.2 Hz, 
Hb), 7.16 – 6.90 (m, 6H, Hc/Hi/Hj), 6.30 (d, 2H, 3JHj = 6.7 Hz, Hk). 13C NMR (100 MHz, 
CDCl3) δ ppm: 166.8/149.8/146.1/144.0/131.1 (Cquaternery), 150.6 (C2), 149.1 (Ca), 138.8 / 
138.7 (Cc / C4 ), 131.2 (Ch), 130.2 / 123.8 / 122.3 (Cb / Cf / Cg), 128.3 (Cc), 127.1 (C3), 125.0 
(Ce), 120.0 (Cd). TOF ES-MS(+) m/z: 681 [M−Cl]+.  HRMS (ES+) calc. for C34H24191IrN4: 
679.1607.  Found: 679.1635. Emission (CH3CN, λexc = 355 nm) λmax [nm] = 595. Lifetime 
(CH3CN, λexc = 375 nm, λem = 550 nm) = 60 ns (aerated), =780 ns (degassed). Φ (CH3CN, λexc 
= 355 nm) = 0.02 (aerated), = 0.20 (degassed).   
 
Synthesis of IrBpy-Z●AuNP13 
 Zonyl® 7950 (CH2–C(CH3)COOC2H4(CF2)nF), MW ca. 500, 1 μl, 1.15 g mL−1) was added 
to 13 nm citrate gold nanoparticles (1 mL, 9 nM nanoparticles, zeta potential at 2 nM in 
deionised water = −40±5 mV,  diameter = 13±4 nm (DLS number distribution), = 29±12 nm 
(86%), 998±624 nm (14%) (DLS intensity distribution)) to give fluorosurfactant coated 
nanoparticles (9 nM nanoparticles), with a final fluorosurfactant concentration of ca. 1mL. 
(Isolated Z●AuNP13, by three rounds of centrifugation, decantation of the supernatant and 
resuspension of the pellet have a zeta potential of −61±4 mV (2 nM in deionised water) and 
diameter of 20±2 nm (DLS number distribution), and of 32±15 nm (DLS intensity 
distribution)). A solution of IrBpySH (20 μl, 3.5 mM, (made in situ, NH4OH(aq) 30 % 
w/w:CH3CN (1:1) solution)) was added to the fluorosurfactant / nanoparticle mixture (not 
isolated), and was stirred for 20 min. The particles were centrifuged at 12,000 g for 15 min, 
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and the supernatant was decanted from each pellet to remove unbound material. The 
nanoparticles were resuspended in deionised water, and this was repeated twice to give 
IrBpy-Z●AuNP13. UV-Vis (H2O) λmax [nm] = 522 (SPR). Diameter = 19±5 nm (DLS 
number distribution), = 340±166 nm (60%), 33±1 nm (38%), 4567±844 nm (2%) (DLS 
intensity distribution), zeta potential = −35±3 mV (isolated, 2 nM in deionised water diluent). 
Emission (H2O, λexc = 355 nm) λmax [nm] = 570. Lifetime (H2O, λexc = 375 nm, λem = 550 nm) 
= 80 ns (7%), 380 ns (93%) (aerated), = 75 ns (6%), 435 ns (94%)  (degassed). Φ (H2O, λexc = 
355 nm) = 0.19 (aerated). ICP-OES Au:Ir atomic ratio = 106:1. 
 
Synthesis of IrBpy-Z●AuNP100 and IrPhen-Z•AuNP100 
Zonyl® 7950 (CH2–C(CH3)COOC2H4(CF2)nF), MW ca. 500, 1 μl, 1.15 g mL−1,) was added to 
100 nm citrate gold nanoparticles (1 mL, 40 pM nanoparticles, zeta potential at 4 pM in 
deionised water = −33 ± 3 mV, diameter = 98 ± 27 nm (DLS number distribution), = 136 ± 62 
nm (DLS intensity distribution)) to give fluorosurfactant coated nanoparticles (40 pM 
nanoparticles), with a final fluorosurfactant concentration of ca. 1mL. (Isolated Z●AuNP100, 
by three rounds of centrifugation, decantation of the supernatant and resuspension of the 
pellet have a zeta potential of −47±3 mV (4 pM in deionised water) and diameter of 
92±21 nm (DLS number distribution), 131±62 nm (DLS intensity distribution).) A solution of 
IrBpySH or IrPhenSH (20 μl, 3.5 mM (made in situ, NH4OH(aq) 30 % w/w:CH3CN (1:1) 
solution)) was added to the fluorosurfactant / nanoparticle mixture (not isolated), and was 
stirred for 20 min. The particles were centrifuged at 12,000 g for 15 min, and the supernatant 
was decanted from each pellet to remove unbound material. The nanoparticles were 
resuspended in deionised water, and this was repeated twice to give IrBpy-Z●AuNP100 and 
IrPhen-Z•AuNP100. IrBpy-Z●AuNP100: UV-Vis max [nm] = 568(SPR). Diameter = 71 
± 19 nm (DLS number distribution) =169 ± 84 nm (DLS intensity distribution), zeta 
potential= −33±3 mV (isolated, 4 pM in deionised water). Emission (H2O, λexc = 355 nm) λmax 
  Chapter Five 
237 
 
[nm] = 570. Lifetime (H2O, λexc = 375 nm, λem = 550 nm) = 90 ns (10%), 400 ns (90%) 
(aerated), = 85 ns (11%), 420 ns (89%)  (degassed). Φ (H2O, λexc = 355 nm) = 0.14 (aerated). 
ICP-OES Au:Ir atomic ratio = 1974:1.  IrPhen-Z●AuNP100: UV-Vis max (H2O) λmax [nm] 
= 569 (SPR). Diameter = 70±24 nm (DLS number distribution) = 114±40 nm (DLS intensity 
distribution), zeta potential (isolated, 4 pM in deionised water) = −32±3 mV. Emission (H2O, 
λexc = 355 nm) λmax [nm] = 555. Lifetime (H2O, λexc = 375 nm, λem = 550 nm) = 50 ns (25%), 
335 ns (75%) (aerated), = 300 ns (15%), 1570 ns (85%)  (degassed).  
 
Synthesis of GdQ●AuNP13 
GdQSH (20–100 L, 1 mM, CH3OH) was titrated into 13 nm gold nanoparticles (1 mL, 9 
nM), to a final complex concentration of 100 M, and the SPR was monitored by UV-Vis 
absorption spectroscopy. The nanoparticles were isolated from unbound material by 
centrifugation at 12,000 g for 15 min; the supernatant was decanted from each pellet to 
remove unbound material and the nanoparticles were resuspended in deionised water. This 
was repeated twice to give GdQ●AuNP13. UV-Vis (H2O) λmax [nm] = 526 (SPR), T1 
relaxivity = 7.1 s−1 mM−1 ([Gd]), at 3T. ICP-OES Au:Gd atomic ratio = 98:1.  
 
Synthesis of IrBpy-GdQ●AuNP13 
GdQSH (20–100 L, 1 mM, CH3OH) was titrated into 13 nm gold nanoparticles (1 mL, 9 
nM), to a final complex concentration of 100 M. Subsequently, IrBpySH, (1–6 M, 3.4 
mM, (made in situ, NH4OH(aq) 30 % w/w:CH3CN (1:1) solution)) was added. The SPR was 
monitored by UV-Vis absorption spectroscopy throughout the titration. The nanoparticles 
were isolated from unbound material by centrifugation at 12,000 g for 15 min; the supernatant 
was decanted from each pellet to remove unbound material and the nanoparticles were 
resuspended in deionised water. This was repeated twice to give IrBpy-GdQ●AuNP13. UV-
Vis (H2O) λmax [nm] = 526 (SPR), diameter = 11±3 nm (DLS number distribution) = 128±135 
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nm (DLS intensity distribution).  Emission (H2O, λexc = 355 nm) λmax [nm] = 580. Lifetime 
(H2O, λexc = 375 nm, λem = 550 nm) = 90 ns (29%), 285 ns (71%) (aerated). r1 relaxivity  = 7.1 
s−1 mM−1 ([Gd]), at 3T. ICP-OES Au:Gd atomic ratio = 73:1, Au:Ir ratio = 300:1. 
	
5.10.2	Flow	Imaging	in	Blood	
Isolation of RBC and preparation of defined percentage haematocrit suspensions   
Isolation was performed by Dr Hannah Jeffery in the laboratory of Professor G. Nash. Venous 
blood from healthy individuals was added to citrate phosphate dextrose adenine (CPDA) 
solution (Sigma Aldrich) in sterile 15 mL round bottom polystyrene tubes (Sterilin, Appleton 
Woods, Birmingham, UK) at ratio of 9:1 following informed consent and with approval from 
the University of Birmingham Local Ethical Review Committee. RBC were isolated by 
centrifugation (2500 rpm, 10 min) and washed twice with 10 mL phosphate buffered saline 
(PBS) (3000 rpm, 10 min). RBC pellets from 27 mL venous blood were pooled and 
centrifuged (3000 rpm, 5 min) to pack cells. The supernatant was removed and the packed 
RBC diluted 1:1 with PBS. RBC density was determined using a Coulter Particle Count and 
Size Analyser (Beckman Coulter). Percentage haematocrit of the RBC suspension was also 
measured using the microhaematocrit method; RBC suspension was drawn into glass 
capillary tubes under capillary action and one end of the tube sealed by melting the glass. The 
capillary tube was centrifuged (15,000 g, 5 min) to separate the RBC from the liquid phase. 
Percentage haematocrit was calculated by dividing the length of the RBC column into the 
total length of the RBC suspension column. No corrections were made for small volumes of 
solution trapped within the tightly packed RBC. 2.5 mL suspensions of known percentage 
haematocrit were prepared by dilution with PBS. In order to allow tracking of the RBC, the 
preparations were spiked with 2.8 x 107 CellTracker GreenTM/5-Chloromethylfluorescein 
Diacetate (CMFDA) (Molecular probes, Life Technologies)-labelled RBC per 2.5 mL RBC 
suspension. The number of labelled RBC added was negligible compared to the total present 
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(0.27–0.79%) and was kept constant, irrespective of the percent haematocrit, in order that the 
frequency of labelled cells passing the field of view under flow conditions was uniform across 
test conditions. To investigate effects of RBC aggregation on the dynamics of nanoparticles 
under flow conditions, 62.5% of the fluid phase was replaced with solutions of different 
molecular weight dextrans: 1.6% high molecular weight 500kDa dextran (Dextran500) to 
induce aggregation and 3.25% low molecular weight 40kDa dextran (Dextran40) as a 
viscosity control.  
 
Fluorescent labelling of RBC    
Labelling was performed by Dr Hannah Jeffery. 90 × 106 washed RBC were suspended in 
15 mL CMFDA (10µM) diluted in non-supplemented medium M199 (Gibco, Invitrogen, 
Paisley, Scotland) and incubated (37 °C, 5% CO2) for 40min. Cells were pelleted by 
centrifugation (1500 rpm, 5 min) then resuspended in 15 mL medium M199 supplemented 
with 10% Foetal Calf Serum and incubated (37 °C, 5% CO2) for 40 min. Cells were pelleted 
by centrifugation (1500 rpm, 5 min), washed in 15 mL PBS (1500 rpm, 5 min) and 
resuspended in 800 µl PBS. 250 µl volumes were added per 2.5 mL preparation of each 
percent haematocrit suspension as a component of the total diluent volume.   
 
Flow Imaging  
Imaging was performed by the author, Dr David J. Lewis and Dr Hannah Jeffery. Assays 
were performed using a set-up described previously.88 Briefly, prefabricated channel slides of 
rectangular cross-section (µ-slide VI0.1(non-coated, ibidi GmbH, Martisnsried Germany)), 
channel dimensions 1 mm (x-axis) × 17 mm (y-axis, parallel to the flow) × 0.1 mm (z-axis)) 
17 mm length (y-axis) x 1 mm width (x-axis), were pre-treated with 4% bovine serum 
albumin solution in PBS for 3 hr, rinsed with PBS and mounted on the stage of an inverted 
microscope (Olympus IX-71) fitted with an LUCPLFLN 40× objective lens, numerical 
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aperture 0.6, field number 22 and a variable focus collar with a working distance 2.7 – 4 mm. 
The barrel of a 5 mL syringe was fitted into the luer port at one end of the channel to act as a 
sample reservoir and 1.5 mm diameter plastic tubing fitted via a luer adaptor into the port at 
the opposite end of the channel. A three-way tap was fitted to the other end of the tubing and 
connected to both a Harvard withdrawal syringe pump and a 10 mL syringe. These syringes 
respectively facilitated the controlled perfusion of sample during imaging at a flow rate of 
5µL min−1 and the removal of wash buffer (PBS) that was perfused to rinse the channel 
between samples. The observation plane was located in the centre of the channel with respect 
to the x-axis. Two image sets each containing 500 16-bit images taken with 4 x 4 binning 
(128 x 128 pixels) were acquired at 64 frames per second (fps) at each depth. The microscope 
was focussed on the channel wall for the first image sequence (the channel wall was identified 
by focussing on occasional nanoparticles that had become stuck on the wall) and then, the 
focal point was varied by increments of 5m through the z-axis and image sequences captured 
at each depth across the channel. 2 pM nanoparticles in PBS with 0% to 30% haematocrit, 
were perfused through the model vessel  at a volumetric flow rate of 5 µm min−1.To monitor 
the velocities of IrBpy-Z•AuNP10 and RBC at the same depth, image sets were collected 
under both 355 nm excitation (IrBpy-Z•AuNP10) and 475 nm excitation (labelled RBC). 
Image sets were converted to audio video interleave (AVI) files for offline analysis of particle 
velocity. 
 
Calculation of particle velocity from AVIs   
AVIs were processed in the open source ImageJ64 software as 3D projections of the x-axis/y-
axis/time stacks, by the author and Hannah Jeffery, and were projected onto the x-axis. 
Background was subtracted from the images using a sliding paraboloid with 1.0 pixel rolling 
ball radius. Flowing luminescent nanoparticles or stained RBC appeared as diagonal tracks 
within the y-axis vs time projection. The angles of 20–30 track lines were measured manually 
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at each depth and the velocities of the particles, with respect to the flow axis (vy), were 
calculated. To avoid bias, every line encountered on movement left to right across the y-axis 
vs time projection was measured. 
 
5.10.3	Murine	Tissue	Studies	
Murine studies were conducted by Professor S. Egginton, under licence PPL 30/2789, and  
C57/Bl6 mice were obtained from Charles River (UK). Mice were anaesthetised using 
isoflurane (3%, balance oxygen) and intracardial or tail-vein injections of 100–200 μL sterile 
80 pM nanoparticle samples suspended in PBS were performed. Animals were sacrificed at 
5 min by cervical dislocation. The author, Dr Hannah Jeffery, and  Dr David J. Lewis 
performed tests on post-mortem tissue. 
 
Microscopy  
Tissues including the mesentery, lung and extensor hallucis proprius skeletal muscle were 
excised and immersed in 4% paraformaldehyde in PBS for 15 min, washed with 3 x PBS, and 
mounted onto glass coverslips with Vectashield (Vector Labs) mounting medium. Tissues 
were imaged within 5 hours of euthanasia using an inverted microscope (Olympus IX-71) 
fitted with an LUCPLFLN 40X objective lens, numerical aperture 0.6, field number 22 and a 
variable focus collar with a working distance 2.7 – 4 mm.  
 
Biodistribution Studies  
The following organ samples were excised for digestion  and ICP-MS was employed to 
calculate gold content: lung, spleen, gut, kidney, liver, brain. The tissue was frozen 
immediately post-excision, and then later defrosted for analysis. Glass vials were cleaned 
thoroughly with ultrapure aqua regia (HCl:HNO3, 3:1, using ultrapure grade acids) before use. 
The organs were weighed, and then digested in sealed vials in aqua regia (3 mL,), and heated  
  Chapter Five 
242 
 
to 100 oC for 10 hr. Samples were cooled and filtered (to remove and insoluble material) into 
falcon tubes, and diluted to 10 mL. The samples were then analysed for gold concentration by 
ICP-MS.  
	
5.10.4	MRI	Studies	of	IrBpy‐GdQ•AuNP13	Nanoparticles	
T1 relaxation time analysis 
Analysis was performed by Ms Lindsey van Gemeren, under the supervision of Dr Nigel 
Davies. Imaging was performed on a 3T Siemens MAGNETOM Verio clinical imaging 
machine at Birmingham Women’s Hospital. T1 mapping was executed using a 16 channel 
head coil with a saturation recovery pulse sequence. 
 
Preliminary in vitro studies in A549 cells 
A549 tissue culture was performed by Mr Sunil Claire in the School of Biosciences. Cells 
were incubated with 0.9 nM GdQ•AuNP13 and IrBpy-GdQ•AuNP13for 24 hr in complete 
media.  Cell media was removed and the cells washed twice in PBS and subsequently fixed 
with paraformaldehyde for 5 min, followed by two further washes with PBS. Coverslips were 
removed and mounted on a droplet of Hydromount media (national diagnostics) on glass 
slides, sealed with clear nail varnish and stored for 24 hours at 4°C before imaging. Confocal 
imaging was performed by the author. 
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6.1	Materials		
Solvents were purchased from Fisher or Sigma Aldrich and anhydrous solvents were dried 
over 3Å molecular sieves under N2(g) for 1 hr, or by PureSolv-EN solvent purification 
system. Deuterated solvents for NMR were also purchased from Sigma Aldrich. HPLC grade 
solvents were used in photophysical studies and water was deionised using an Elga Option 3 
water purifier. All compounds were synthesised under N2(g) unless otherwise indicated, using 
standard Schlenk techniques. 
 
6.2	General	Experimental	Details	for	Synthesis	
1H and 13C{1H} PENDANT NMR spectra were recorded using a Bruker AC 300, AV 300, 
AMX 400 or AV 400 spectrometer, and Si(CH3)4 was used as the external reference. 
Electrospray mass spectra were recorded on a Waters Micromass LCT time of flight mass 
spectrometer, using a nitrogen laser, and matrix assisted laser desorption ionisation time of 
flight (MALDI-TOF) mass spectrometry was performed on a Bruker Diflex IV mass 
spectrometer, using gentisic acid (CH3CN solution with 0.1% TFA) as the matrix. 
	
Elemental analysis was performed on either a Carlo Erba EA1110 Simultaneous CHN 
elemental analyser (University of Birmingham), or at the London School of Pharmacy, UCL, 
on an Elemental Analyser, Model 1108 (Carlo-Erba, Milan, Italy) with PC based data system, 
Eager 200 for WindowsTM and a Sartorious Ultra Micro Balance, 4504MP8. 
 
Fourier transform infra red (FT-IR) spectroscopy was performed on powder samples, using a 
Perkin Elmer Spectrum 100 FT-IR, with a universal attenuated total reflectance attachment. 
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6.3	Photophysical	Characterisation	Techniques	
UV-Vis absorption spectroscopy measurements were performed on a Varian Cary 5000 
spectrometer at a 300 nm min−1 acquisition rate. Samples were prepared in either 1 cm or 
0.4 cm path length low volume quartz cuvettes. 
 
Steady-state and time-resolved luminescence measurements were executed on an Edinburgh 
Instruments FLS920 spectrometer, with a 450 W xenon arc lamp illumination source. The 
detection system uses a Hamamatsu R928 photomultiplier tube (PMT), and an emission 
monochromator blazed at 500 nm. Samples were prepared in quartz cuvettes with four 
transparent faces, and appropriate long-pass filters were employed to eliminate second-order 
photon scattering. 77 K studies were measured in an in-house built sample holder within a 
nitrogen cryostat (Oxford Instruments), using the Edinburgh Instruments FLS920 
spectrophotometer. 
 
Luminescence lifetimes () were measured with a 375 nm or a 445 nm picosecond pulse 
length diode laser excitation source, using the time-correlated single-photon counting module 
of the FLS920 spectrometer set-up, with the Hamamatsu R928 photomultiplier tube (PMT). 
Lifetimes were tail-fitted using the Edinburgh Instruments F900 or FAST PC software, i.e. 
fitted beyond the time point where the excitation light has disappeared, and thus in a region 
where there is no further sample signal generation. The quality of the fit results was evaluated 
by analysing the reduced chi-square parameter, and the residual data. The exponential order 
was increased until the residual plot presented random noise distributed about zero, with a 
reduced chi-square value between 1.0–1.3. All lifetimes were fitted using a Marquardt-
Levenberg algorithm. 
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Quantum yield (Φ) measurements were performed on the spectrometer using an integrating 
sphere. Solution measurements were referenced to the solvent used, and nanoparticles were 
referenced to un-labelled gold nanoparticles. Low intensity signal (for low Φ solutions or low 
concentration nanoparticle samples) were measured using a calibrated neutral density filter. 
6.4	Nanoparticle	Characterisation	Techniques	
Zeta potential and dynamic light scattering measurements were performed using either a 
Zetasizer Nano ZS, (Malvern Instruments), or a Beckmann Coulter Delsa Nano C instrument, 
calibrated with a zeta potential transfer standard (Malvern Instruments). DLS size 
distributions are calculated by analysis of the scattered light autocorrelation function with the 
CONTIN algorithm (i.e. an inverse Laplace transform).  
 
Nanoparticle Tracking Analysis (NTA) was performed using a Nanosight LM-10 (Nanosight, 
UK) system equipped with a 488 nm laser in scattering mode, using the analysis of at least 
2000 tracks. 
 
Transmission electron microscopy (TEM) was performed using a JEOL JEM-1200EX and a 
JEOL JEM-2100 electron microscope fitted with a Gatan camera by drying colloid onto 
formvar-coated copper grids (Agar Scientific). Images were acquired using Digital 
Micrograph 1.8 software (Gatan, CA, USA). Scanning electron microscopy (SEM) imaging 
was performed at the Centre for Electron Microscopy with the help of Theresa Morris, on a 
Jeol JSM 7000F Microscope fitted with an Oxford Inca Energy Dispersive X-Ray 
Spectrometer. 
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Inductively coupled plasma optical emission spectroscopy was performed using a 5300DV 
ICP-OES system (Perkin-Elmer) at the University of Warwick. Inductively coupled plasma 
optical mass spectrometry (ICP-MS) measurements were performed on a 7500cx IPC-MS 
with an integrated auto-sampler (Agilent). Metal concentrations were determined using 
PlasmaCal calibration standards (QMX laboratories), with R2 > 0.999 linear calibration 
curves in all cases. For these experiments, colloidal suspensions were digested in ultrapure 
aqua regia (Sigma Aldrich) and then diluted ten-fold in deionised water. 
6.5	Luminescence	Microscopy	
Epiluminescence images were acquired with the Edinburgh Instruments FLSP920 
Spectrometer appended to an Olympus IX71 Inverted Microscope, with a LUCPLFLN 
40×0.60 NA objective. Samples were excited with a 450 W xenon arc lamp, using the double 
monochromator in the excitation arm to select the excitation wavelength, and images were 
acquired with a Hamamatsu EM CCD C9100-13 camera. Confocal laser scanning microscopy 
was performed using a Leica TCS SP2 confocal microscope (Leica Microsystems). 
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Appendix	1:	Nanoparticle	Size	and	Concentration	Calculations	
‐1.1	Concentration	of	13	nm	Gold	Nanoparticles	
Mass of HAuCl4 (49 % Au by assay) = 0.09889 g 
Mass of Au = 0.49 × 0.09889 = 0.04846 g 
Moles of Au = 0.04846 / 197 = 2.4597 × 10-4 moles 
Concentration of Au = 2.4597 × 10-4 moles / 0.275 dm3 =  8.944 × 10-4 M. 
 
Estimated atomic radius of gold = 140 pm 
Number of gold atoms per 13 nm nanoparticle = (6.5 × 10-9)3 / (140 × 10-12)3 = 100,000 
(assuming that the particles are perfectly spherical). 
Concentration of 13 nm gold nanoparticles = 8.944 × 10-4 M / 100,000 = 9 nM. 
 
‐1.2	Concentration	of	the	100	nm	Gold	Nanoparticles	
During growth step one, 6 mL of the 13 nm gold nanoparticle seeds (9 nM) are diluted in 
80 mL. Assuming no new seeds are formed, the concentration of the 25 nm particles formed = 
0.7 nM. 
 
In the second growth step 9 mL of the 25 nm gold nanoparticle seeds (0.7 nM) are diluted to 
80 mL. Again, assuming no new seeds are formed, the concentration of the 50 nm particles 
formed = 80 pM. 
 
In the final growth step, 40 mL of the 50 nm gold nanoparticles (80 pM) are diluted to 80 mL, 
rendering 100 nm gold nanoparticles at 40 pM.  
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Appendix	2:	Nanoparticle	Lumiphore‐loading	Calculations	
Estimated atomic radius of gold = 140 pm 
Number of gold atoms per 13 nm nanoparticle = (6.5 × 10-9)3 / (140 × 10-12)3 = 100,000 
Number of gold atoms per 100 nm gold nanoparticle = (50 × 10-9)3 / (140 × 10-12)3 = 46×106 
 
‐2.1	Ru‐T20•AuNP13	
Au:Ru measured by ICPOES = 72:1 (atoms). 
Assuming 100,000 gold atoms per 13 nm gold nanoparticle: 
72/100,000 = 7.2 × 10-4 particles per Ru(II) complex 
1/ 7.2 × 10-4 = 1390 RuSH complexes per gold nanoparticle. 
Surface area of the 13 nm gold nanoparticle = 4 (6.5 × 10-9)2 = 5.31 × 10-16 m2 Surface area 
per RuSH complex = 5.31 × 10−16 / 1390 = 3.82 × 10−19 m2 (0.6 nm × 0.6 nm). 
 
‐2.2	Ru‐Z•AuNP13	
Au:Ru measured by ICPOES = 63:1 (atoms). 
Assuming 100,000 gold atoms per 13 nm gold nanoparticle: 
63/100,000 = 6.3 × 10−4 particles per Ru(II) complex 
1/ 6.3 × 10−4 = 1590 RuSH complexes per gold nanoparticle. 
Surface area of the 13 nm gold nanoparticle = 4 (6.5 × 10−9)2 = 5.31 × 10−16 m2 (assuming 
particle is spherical). 
Surface area per RuSH complex = 5.31 × 10−16 / 1590 = 3.34 × 10−19 m2 (0.6 nm × 0.6 nm). 
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‐2.3	Ru‐Z•AuNP100	
 
Figure A1 UV-Vis absorption spectra of 100 nm gold nanoparticles in water (40 pM) (-o-), gold 
nanoparticles +fluorosurfactant (1.15 µg mL−1, ca. 1 mM) (--), gold nanoparticles (40 pM) 
+fluorosurfactant ( 1.15  µg mL−1) +RuSH (40 µM) (--), 40 pM centrifuged Ru-ZAu100NP(- -), 
supernatant from first wash of Ru-ZAu100NP (-+-). 
 
 
Concentration of RuSH, left on the nanoparticles, estimated from absorbance at 460 nm: 
Abs (460) by the 40 µM RuSH in the uncentrifuged sample = Abs (460) of (--) − abs (460) 
of (-o-), = 1.06−0.705 = 0.355. Abs (460) in the supernatant of first wash = 0.317. 
Concentration of RuSH in the supernatant = 0.317/0.355 × 40 µM  = 35.7 µM. 
Concentration of RuSH on the nanoparticles = 40 – 35.7 µM = 4.3 µM. 
This assumes that the Beer-Lambert law applies, assuming that all RuSH complexes on each 
nanoparticles have the same absorbance. 
Ratio of RuSH complexes : 100 nm gold nanoparticles  = 4.3 µM / 40 pM = 107,500. 
Surface area of AuNP100 = 4π (50 × 10−9)2 = 3.14 × 10−14 m2 (assuming particles are 
spherical). 
Surface area per complex  = 3.14 × 10−14 / 107500 = 2.92 × 10−19 m2. (0.5 nm × 0.5 nm). 
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‐2.4	Ru‐pHLIP•AuNP13	
Au:Ru measured by ICPOES = 48:1 (atoms). Assuming 100,000 gold atoms per 13 nm gold 
nanoparticle: 48/100,000 = 4.8 × 10−4 particles per Ru(II) complex. 
1/ 4.8 × 10−4 = 2080 RuSH complexes per gold nanoparticle. 
Surface area of the 13 nm gold nanoparticle = 4 (6.5 × 10−9)2 = 5.31 × 10−16 m2 (assuming 
particle is spherical). 
Surface area per RuSH complex = 5.31 × 10−16 / 2080 = 2.55 × 10−19 m2 (0.5 nm × 0.5 nm). 
 
‐2.5	IrBpy‐Z•AuNP13	
Au:Ir measured by ICPOES = 106:1 (atoms). Assuming 100,000 gold atoms per 13 nm gold 
nanoparticle: 106/100,000 = 1.06 × 10−3 particles per Ir(III) complex. 
1/ 1.06 × 10−3 = 940 IrBpySH complexes per gold nanoparticle. 
Surface area of the 13 nm gold nanoparticle = 4 (6.5 × 10−9)2 = 5.31 × 10−16 m2 (assuming 
particle is spherical). 
Surface area per IrBpySH complex = 5.31 × 10−16 / 940 = 5.65 × 10−19 m2 (0.8 nm × 
0.8 nm). 
 
‐2.6	IrBpy‐Z•AuNP100	
Au:Ir measured by ICPOES = 1974:1 (atoms). Assuming 46 × 106 gold atoms per 100 nm 
gold nanoparticle: 2000/46 × 106 = 4.35 × 10−5 particles per Ir(III) complex 
1/ 4.35 × 10−5 = 23,000 IrBpySH complexes per gold nanoparticle. 
Surface area of the 13 nm gold nanoparticle = 4 (50 × 10−9)2 = 3.14 × 10−14 m2. 
Surface area per RuSH complex = 3.14 × 10−14 / 23,000 = 1.37 × 10−20 m2 (1 nm × 1 nm). 
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‐2.7	GdQ•AuNP13	
Au:Gd measured by ICPOES = 98:1 (atoms). Assuming 100,000 gold atoms per 13 nm gold 
nanoparticle: 98/100,000 = 9.8 × 10−4 particles per Gd(III) complex 
1/ 9.8 × 10−4 = 1020 GdQSH complexes per gold nanoparticle. 
Surface area of the 13 nm gold nanoparticle = 4 (6.5 × 10−9)2 = 5.31 × 10−16 m2 (assuming 
particle is spherical). 
Surface area per GdQSH complex = 5.31 × 10−16 / 1020 = 5.21 × 10−19 m2 (0.7 nm × 0.7 
nm). 
 
‐2.8	IrBpy‐GdQ•AuNP13	
73:1 Gd (1300), 300:1 Ir (330) 
Au:Gd measured by ICPOES = 73:1 (atoms). 
Assuming 100,000 gold atoms per 13 nm gold nanoparticle: 73/100,000 = 7.3 × 10−4 particles 
per Gd(III) complex 
1/ 97.3 × 10−4 = 1370 GdQSH complexes per gold nanoparticle. 
Au:Ir measured by ICPOES = 300:1 (atoms). 
Assuming 100,000 gold atoms per 13 nm gold nanoparticle: 
300/100,000 = 3.0 × 10−3 particles per Ir(III) complex 
1/ 3.0 × 10−3 = 330 IrBpySH complexes per gold nanoparticle. 
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Appendix	3:	Size‐exclusion	Chromatography	Study	with	Zonyl®	7950	
The following samples (Table A1) were loaded onto a size-exclusion column, using 
Sephadex® G-25, and the elution volumes and elution times were observed. 
 
Column = 3 cm in diameter, and 8 cm in length; 60 mL in total volume 
The dead space in the column (according to Sephadex®-G25 superfine high-trap column 
manual) = 60 x 1.5/5 = 18 mL  
Thus, the nanoparticles should elute in 18 mL.  
Fractioning range of Sephadex®-G25 = 1000-5000, i.e. anything in this range should interact 
with the beads and be retarded. 
 
Table A1 Elution times and volumes using Sephadex® G-25 Column Chromatography. 
Sample Elution volume 
/ mL
Elution time / 
min
Sample in void volume of 
column? 
RuSAca >210
 
> 20 NO – sample stuck to the 
sephadex 
RuSAc+ Zonyl® 7950b 10–17 1.5–2.5 YES 
Z•Au13 10–15 1.5–3.0 YES 
Ru-Z•AuNP13 10–15 1.5–2.5 YES 
a dissolved in 1% CH3CN, H2O. 
bdissolved in 1% CH3CN, H2O, with 1 mM Zonyl® 7950. 
 
The fluorosurfactant transports the unbound RuSAc complex through the void volume of the 
stationary phase with the functionalised nanoparticles, presumably due to the formation of 
micelles, and thus separation of the particles from unbound material does not occur. 
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Appendix	4:	XPS	Survey	Scan	of	Ru‐Z•AuNP13	
 
Figure A2 XPS Survey scan of 13 nm citrate gold nanoparticles (red), isolated Z•AuNP13 (brown), 
and isolated Ru-Z•AuNP13 (purple). 
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Appendix	5:	Control	Steady‐state	Luminescence	Spectra	of	 the	RuSAc	
Complex	
‐5.1	Aqueous	Emission	of	RuSAc,	in	the	presence	of	TWEEN®	20	Surfactant	
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Figure A3 Steady-state luminescence spectrum of 9 M RuSAc, with 1 mM TWEEN® 20 in 1% 
CH3CN/H2O. Spectrum corrected for instrument response. 
 
 
‐5.2	Aqueous	Emission	of	RuSAc,	in	the	presence	of	Zonyl®	7950	Surfactant	
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Figure A4 Steady-state luminescence spectrum of 9 M RuSAc, with 1 mM Zonyl® 7950 in 1% 
CH3CN/H2O. Spectrum corrected for instrument response. 
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Appendix	 6:	 Luminescence	 Lifetimes	 of	 the	 RuSAc	 Complex	 and	
Ru(II)‐functionalised	Nanoparticles	
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 fits
Equation y = A1*exp(-x/t1) + y0
Adj. R-Square 0.99973 0.99841
Value Standard Error
-- y0 0.00118 2.99759E-4
-- A1 4.77578 0.02568
-- t1 127.73855 0.31886
-- y0 0.00337 4.27638E-4
-- A1 1.22158 0.0027
-- t1 776.37626 2.23139
	
Figure A5 Luminescence lifetime data of aerated (black) and deaerated (blue) RuSAc measured in 
CH3CN solution, exc = 445 nm, em = 630 nm Monoexponential fits shown in red.  
 
 
0 1000 2000 3000 4000 5000
0.0
0.2
0.4
0.6
0.8
1.0
S
ig
na
l I
nt
en
si
ty
 a
t 6
30
 n
m
Time / ns
 aerated RuSAc, 1% CH3CN, H2O
 deaerated aerated RuSAc, 1% CH3CN, H2O
 fits
Equation y = A1*exp(-x/t1) + y0
Adj. R-Square 0.99928 0.99947
Value Standard Error
Normalized Y1 y0 0.00353 2.08965E-4
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Normalized Y1 t1 262.71503 0.6134
Normalized Y 2 y0 0.00279 3.16301E-4
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Normalized Y 2 t1 323.37337 0.77017
 
Figure A6 Luminescence lifetime data of aerated (black) and deaerated (blue) RuSAc measured in 
1% CH3CN, H2O (predominantly aqueous solution), exc = 445 nm, em = 630 nm. Monoexponential 
fits shown in red. 
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Figure A7 Luminescence lifetime data of degassed (blue) and aerated (black) 9 M RuSAc, with 1 mM 
TWEEN® 20 in 1% CH3CN/H2O.  exc = 445 nm, em = 630 nm. Monoexponential fits shown in red. 
 
 
Figure A8 Luminescence lifetime data of degassed (blue) and aerated (black) 9 M RuSAc, with 1 
mM Zonyl® 7950 in 1% CH3CN/H2O.  exc = 445 nm, em = 630 nm. Monoexponential fits shown in 
red. 
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Figure A9 Luminescence lifetime data of aerated (black) and deaerated (blue) Ru-T20•AuNP13 
(0.3 nM) in water, exc = 445 nm, em = 630 nm. Monoexponential fits shown in red. Residuals shown 
in insets.  
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Figure A10 Luminescence lifetime data of aerated Ru-Z•AuNP13 (1 nM) in water, exc = 445 nm, em 
= 630 nm. Monoexponential fit shown in red. Residual shown in inset. 
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Figure A11 Luminescence lifetime data of degassed Ru-Z•AuNP13 (1 nM) in water, exc = 445 nm, 
em = 630 nm. Monoexponential fit shown in red. Residual shown in inset. 
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Figure A12 Luminescence lifetime data of aerated Ru-Z•AuNP100 (10 pM) in water, exc = 445 nm, 
em = 630 nm. Monoexponential fit shown in red. Residual shown in inset. 
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Figure A13 Luminescence lifetime data of deaerated Ru-Z•AuNP100 (10 pM) in water, exc = 
445 nm, em = 630 nm. Monoexponential fit shown in red. Residual shown in inset. 
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Figure A14 Luminescence lifetime data of aerated (black) and deaerated (grey) Ru-CALNN•AuNP13 
(1 nM) in water, exc = 445 nm, em = 630 nm. Monoexponential fits shown in red. 
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Figure A15 Luminescence lifetime data of aerated (black) and deaerated (grey) Ru-pHLIP•AuNP13 
(1 nM) in water, exc = 445 nm, em = 630 nm. Monoexponential fits shown in red. 
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Figure A16 Luminescence lifetimes of pHLIP (1–120 mM) titrated into RuSAc (20 mM), in 1% 
CH3CN, H2O. exc = 445 nm, em = 630 nm. Monoexponential fits shown in red. 
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Figure A17 Luminescence lifetime data of aerated (black) and deaerated (grey) 
Ru-C105Y-Z•AuNP13 (1 nM) in water, exc = 445 nm, em = 630 nm. Monoexponential fits shown in 
red. 
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Appendix	7:	Confocal	Microscopy	of	Undosed	Control	A549	Cells	
 
 
 
Figure A18 Confocal Micrographs of control A549 cells incubated without nanoparticles, and stained 
with Hoechst 33258 in (a) the transmission micrograph (λexc = 488 nm), (b) confocal reflectance (λexc 
= 488 nm, λem = 478–498 nm), (c) the blue channel(nuclear stain) (λexc = 405 nm, λem = 410–455 nm)  
and (d) the red channel (λexc = 453 nm, λem = 550–800 nm). 
 	
  Appendix 
[A18] 
 
Appendix	8:	Structures	and	Abbreviations	of	Amino	Acids	
 
 
 
 
 
 Figure A19 Structures and abbreviations of amino acids discussed in chapter Four. 
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Appendix	9:	Data	for	Synthesis	of	Ru(II)	and	Ir(III)	Compounds	
‐9.1	NMR	and	FT‐IR	of	Spectra	BpyHex	Ligand	
 
Figure A20 1H NMR spectrum of BpyHex in CDCl3. 
	
	
 
Figure A21 1H-1H COSY NMR spectrum of BpyHex ligand, in CDCl3. 
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Figure A22 1H,13C-HSQC NMR spectrum of BpyHex ligand, in CDCl3. 
 
 
 
Figure A23 FT-IR spectrum of BpyHex solid powder. 
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‐9.2	NMR	and	FT‐IR	Spectra	of	RuHex	
  
Figure A24 1H NMR spectrum of RuHex in CD3CN. 
 
  
Figure A25 1H-1H COSY NMR spectrum of RuHex, in CD3CN. 
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Figure A26 1H,13C-HSQC NMR spectrum of RuHex, in CD3CN. 
 
 
Figure A27 FT-IR spectrum of RuHex solid powder. 
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‐9.3	NMR	and	FT‐IR	Spectra	of	RuSAc	
 
Figure A28 1H NMR spectrum of RuSAc in CD3CN. 
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Figure A29 1H-1H COSY NMR spectrum of RuSAc, in CD3CN. 
 
 
Figure A30 1H,13C-HSQC NMR spectrum of RuSAc, in CD3CN. 
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Figure A31 FT-IR spectrum of RuSAc solid powder. 
 
‐9.4	NMR	and	FT‐IR	Spectra	of	IrBpyHex	
 
Figure A32 1H NMR spectrum of IrBpyHex in d6-DMSO. 
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Figure A33 1H-1H COSY NMR spectrum of IrBpyHex, in d6-DMSO. 
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Figure A34 FT-IR spectrum of IrBpyHex solid powder. 
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‐9.5	NMR,	HRMS	and	FT‐IR	Spectra	of	IrBpySAc	
	
Figure A35 1H NMR spectrum of IrBpySAc in d6-DMSO, zoom of aromatic region (top), zoom of 
aliphatic region (middle) and full spectrum (bottom). 
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Figure A36 1H-1H COSY NMR spectrum of IrBpySAc, in d6-DMSO. 
 
	
	
Figure A37 1H,13C-HSQC NMR spectrum of IrBpySAc, in d6-DMSO. 
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Figure A38 High resolution ES-TOF+ mass spectrum of IrBpySAc parent peak (bottom), calculated 
spectrum (top). 
 
	
 
Figure A39 FT-IR spectrum of IrBpySAc solid powder. 
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‐9.6	NMR	and	FT‐IT	Spectra	of	IrPhenHex	
 
Figure A40 1H NMR spectrum of IrPhenHex in d6-DMSO 
 
 
Figure A41 1H-1H COSY NMR spectrum of IrPhenHex, in d6-DMSO. 
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Figure A42 1H,13C-HSQC NMR spectrum of IrPhenHex, in d6-DMSO. 
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Figure A43 FT-IR spectrum of IrPhenHex solid powder. 
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‐9.7	NMR,	HRMS	and	FT‐IR	Spectra		of	IrPhenSAc	
	
Figure A44 1H NMR spectrum of [IrPhenSAc]Cl in d6-DMSO, zoom of aliphatic region (top), zoom of 
aromatic region (middle) and full spectrum (bottom).  
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Figure A45 1H-1H COSY NMR spectrum of [IrPhenSAc]PF6 in d6-DMSO. 
 
 
	
Figure A46 1H,13C-HSQC NMR spectrum of [IrPhenSAc]PF6, in d6-DMSO. 
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Figure A47 High resolution ES-TOF+ mass spectrum of [IrPhenSAc]PF6 parent peak (bottom), 
calculated spectrum (top). 
 
	
 
Figure A48 FT-IR spectrum of [IrPhenSAc]PF6 solid powder 
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Appendix	 10:	 Luminescence	 Excitation	 Spectra	 of	 IrBpySAc	 and	
IrPhenSAc		
‐10.1	Luminescence	Excitation	Spectra	of	IrBpySAc	in	CH3CN	and	1%	CH3CN,	
H2O.	
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Figure A49 Luminescence excitation spectra of 9 M IrPhenSAc in CH3CN and in 1% CH3CN, H2O, 
em = 550 nm. Spectra corrected for instrument response. 
 
 
‐10.2	 Luminescence	 Excitation	 Spectra	 of	 IrPhenSAc	 in	 CH3CN	 and	 1%	
CH3CN,	H2O.	
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Figure A50 Luminescence excitation spectra of 9 M IrPhenSAc in CH3CN and in 1% CH3CN, 
H2Oem = 550 nm. Spectra corrected for instrument response. 	
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Appendix	11:	Control	Steady‐state	Luminescence	Spectra	of	IrBpySAc	
and	IrPhenSAc	
‐11.1	 Aqueous	 Emission	 of	 IrBpySAc,	 in	 the	 presence	 of	 Zonyl®	 7950	
Surfactant	
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Figure A51 Steady-state luminescence spectrum of 20 M IrBpySAc, with 1 mM Zonyl® 7950 in 1% 
CH3CN/H2O. Spectrum corrected for instrument response.  
 
 
‐11.2	 Aqueous	 Emission	 of	 IrPhenSAc	 in	 the	 presence	 of	 Zonyl®	 7950	
Surfactant	
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Figure A52 Steady-state luminescence spectrum of 20 M IrPhenSAc, with 1 mM Zonyl® 7950 in 1% 
CH3CN/H2O. Spectrum corrected for instrument response.  
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Appendix	 12:	 Control	 Steady‐state	 Luminescence	 Spectra	 of	 Similar	
Ir(III)	Cyclometallated	Complexes1	
‐12.	1	Emission	of	[Ir(ppy)2(phen)]Cl	in	CH3CN	and	in	1%	CH3CN,	H2O.	
 
Figure A53 Steady-state luminescence spectrum of 20 M [Ir(ppy)2(phen)]Cl (structure shown in 
Figure inset) in CH3CN (black) and in 1% CH3CN/H2O (blue). Spectrum corrected for instrument 
response.  
 
‐12.	2	Emission	of	[Ir(ppy)2(bpy‐et‐NH2)]Cl	in	CH3CN	and	in	1%	CH3CN,	H2O.	
 
Figure A54 Steady-state luminescence spectrum of 20 M [Ir(ppy)2(bpy-et-NH2)]Cl (structure shown 
in Figure inset) in CH3CN (black) and in 1% CH3CN/H2O (blue). Spectrum corrected for instrument 
response.  	
                                                 
1 Lewis, D. J.; Dore, V.; Rogers, N. J.; Mole, T. K.; Nash, G. B.; Angeli, P.; Pikramenou, Z. Langmuir 2013, 29, 14701. 
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Appendix	13:	Luminescence	Lifetimes	of	the	IrBpySAc	and	IrPhenSAc	
Complexes,	and	Ir(III)‐functionalised	Nanoparticles	
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Figure A55 Luminescence lifetime data of aerated IrBpySAc measured in CH3CN solution, exc = 
375 nm, em = 550 nm Monoexponential fit shown in red. Residual shown in inset.  
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Figure A56 Luminescence lifetime data of deaerated IrBpySAc measured in CH3CN solution, exc = 
375 nm, em = 550 nm Monoexponential fit shown in red. Residual shown in inset. 
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Figure A57 Luminescence lifetime data of aerated IrBpySAc measured in 1% CH3CN, H2O solution, 
exc = 375 nm, em = 550 nm. Biexponential fit shown in blue, residual shown in red.  
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Figure A58 Luminescence lifetime data of aerated IrPhenSAc measured in CH3CN solution, exc = 
375 nm, em = 550 nm. Monoexponential fit shown in red, residual shown in inset.  
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Figure A59 Luminescence lifetime data of deaerated IrPhenSAc measured in CH3CN solution, exc = 
375 nm, em = 550 nm. Monoexponential fit shown in red, residual shown in inset  
 
 
 
 
 
Figure A60 Luminescence lifetime data of aerated IrPhenSAc measured in 1% CH3CN, H2O solution, 
exc = 375 nm, em = 550 nm. Triexponential fit shown in blue, residual shown in red. 
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Figure A61 Luminescence lifetime data of aerated 20 M IrBpySAc, with 1 mM Zonyl® 7950 in 1% 
CH3CN/H2O.exc = 375 nm, em = 550 nm. Biexponential fit shown in blue, residual shown in red. 
 
 
Figure A62 Luminescence lifetime data of deaerated 20 M IrBpySAc, with 1 mM Zonyl® 7950 in 
1% CH3CN/H2O.exc = 375 nm, em = 550 nm. Biexponential fit shown in blue, residual shown in red. 
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Figure A63 Luminescence lifetime data of aerated 1 nM IrBpy-Z•AuNP13 in deionised water, exc = 
375 nm, em = 550 nm. Biexponential fit shown in blue, residual shown in red. 
 
 Figure A64 Luminescence lifetime data of deaerated 1 nM IrBpy-Z•AuNP13 in deionised water, exc 
= 375 nm, em = 550 nm. Biexponential fit shown in blue, residual shown in red. 
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Figure A65 Luminescence lifetime data of aerated 10 pM IrBpy-Z•AuNP100 in deionised water, exc 
= 375 nm, em = 550 nm. Biexponential fit shown in blue, residual shown in red. 
 
 
Figure A66 Luminescence lifetime data of deaerated 10 pM IrBpy-Z•AuNP100 in deionised water, 
exc = 375 nm, em = 550 nm. Biexponential fit shown in blue, residual shown in red. 
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Figure A67 Luminescence lifetime data of aerated 10 pM IrPhen-Z•AuNP100 in deionised water, 
exc = 375 nm, em = 550 nm. Biexponential fit shown in blue, residual shown in red. 
 
 
Figure A68 Luminescence lifetime data of deaerated 10 pM IrPhen-Z•AuNP100 in deionised water, 
exc = 375 nm, em = 550 nm. Biexponential fit shown in blue, residual shown in red. 
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Figure A69 Luminescence lifetime data of aerated 1 nM IrBpy-GdQ•AuNP13 in deionised water, exc 
= 375 nm, em = 550 nm. Biexponential fit shown in blue, residual shown in red. 
 
 
Fitting: lifetime = 65 ns (15%), 320 ns (85%), reduced chi-square = 1.028. 
Figure A70 Luminescence lifetime data taken from field of view in epiluminescence image shown in 
Figure 5.25d (Chapter Five, Section 5.6.3) and in inset, of IrBpy-Z•AuNP100 in the skeletal leg 
muscle of murine tissue. 	
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Appendix	 14:	 Fluid	 Calculation	 for	 Flow	 in	 a	 Rectangular	 Capillary	
Tube	
 
An adaptation of Poiseuille flow for vessels of rectangular cross section can be used to predict 
the flow velocities, assuming that the width of the channel is much greater than the height, 
and thus the flow is considered as between infinitely wide, parallel plates: 
 
ܸ ൌ 6ܳݓ݄ଷ ቆ
݄ଶ
4 െ ݔ
ଶቇ																																																																																																	 
	
Q = volumetric flow rate, = 5 L min−1, w = channel width, = 1 mm,	h = channel height, = 0.1 
mm,	x = displacement from the centre of the channel.  
 
ܸ ൌ 6 ൈ 5 ൈ 10
ିଽ/60
1 ൈ 10ିଷ ൈ ሺ1 ൈ 10ିସሻଷ ቆ
ሺ1 ൈ 10ିସሻଶ
4 െ 0
ଶቇ ൌ 1.25 ൈ 10ିଷ	m	sିଵ 
            = 1250m s−1 
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Appendix	15:	Additional	Epiluminescence	Images	of	IrBpy‐Z•AuNP100	
Particles	in	Ex‐vivo	Murine	Tissue	
(a)             (b) 
 
(c)            (d) 
 
 
Figure A71 Bright field (a and c) image and epiluminescence images (λexc = 405 nm, λem > 510  (b 
and d) of blood capillaries in lung tissue (a and b), and in the mesentery tissue (c and d) of a mouse 
injected with IrBpyS●AuNP100. White scale bar represents 40 m. 
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High coating of Ru(II) complexes on gold
nanoparticles for single particle luminescence
imaging in cells†
Nicola J. Rogers,‡a Sunil Claire,‡b Robert M. Harris,c Shiva Farabi,a Gerald Zikeli,a
Iain B. Styles,d Nikolas J. Hodges*c and Zoe Pikramenou*a
Gold nanoparticles are eﬃciently labelled with a luminescent ruthe-
nium complex, producing 13 and 100 nm diameter, monodisperse
red-emissive imaging probes with luminescence lifetimes prolonged
over the molecular unit. Single, 100 nm particles are observed in
whole cell luminescence imaging which reveals their biomolecular
association with chromatin in the nucleus of cancer cells.
The design of coordination metal complexes as cellular probes
has attracted much research interest based on their distinctive/
unique photophysical and electrochemical properties.1–3 How-
ever, nanoscale probes are more ideal for detecting spatially
localised cellular probes in luminescence imaging. Indeed,
gold nanoparticles and quantum dots have been used for a
plethora of biochemical and therapeutic applications.4–7 We
have combined these approaches, and demonstrated labelling
gold nanoparticles (AuNPs) with luminescent metal complexes,
so that the nanoprobes bear the distinct optical signature of the
luminescent agent, independent of the particle properties.8,9
Such designed probes offer multimodal detection taking advan-
tage of gold’s high electron density, and also lack the blinking
effect observed in quantum dots. We demonstrated 13 nm
AuNP coated with neutral (uncharged) lanthanide lumo-
phores and different modalities to image them in cells.10 When
co-coated with a pH sensitive peptide, selective cell uptake
could be achieved.11
To explore metal lumophores with still more eﬃcient light
excitation in the visible region, we have now chosen highly photo-
stable ruthenium(II) polypyridyl complexes. However, a new strategy
is required for the coating of AuNPs since the positive charge of the
ruthenium complex leads to flocculation of the AuNPs in aqueous
solutions; this challenge is addressed herein. Association of ruthe-
nium complexes with AuNPs has previously been studied using
electrostatic interactions,12 thiol exchange methods using Brust-
type13 nanoparticles,14–17 or by direct reduction of Au3+ by
NaBH4.
18–20 All of these methods lead to nanoparticles with sizes
smaller than 10 nm that are relatively polydisperse, with limited
control over the coating of the ruthenium probe. To increase
sensitivity and spatial resolution in imaging,21 nanoparticles with
large Au cores and high number of labels are desirable.
In this communication, we now report an eﬃcient coating
method for water soluble gold nanoparticles, 13 (AuNP13) and
100 (AuNP100) nm in diameter, with a ruthenium complex that
allows luminescence imaging of non-aggregated, single nano-
particles in cells, revealing interesting biomolecular interactions.
The preparation of RuSAuNP13 and RuSAuNP100 was achieved by
controlling the coating of the nanoparticle surface with a non-ionic
fluorinated surfactant, Zonyl 7950 (Scheme 1) prior to the addition
of the surface-active ruthenium complex, RuSH (ESI†). RuSH has
two thiol groups for attachment to gold nanoparticles and a hexyl
spacer group to distance the ruthenium centre from the surface.22
Scheme 1 Controlling nanoparticle labelling with metal complexes to avoid
flocculation. Method for preparation of RuSAuNP13 and RuSAuNP100.
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Zonyls 7950 was chosen to stabilize nanoparticles and inhibit
flocculation induced from the positively charged ruthenium
complex. It bears a hydrophilic polar head group and a hydro-
phobic chain and its interaction with gold surfaces has been
demonstrated.23–25 We isolated and characterised the ZAuNP13
and ZAuNP100 and then added the RuSH complex to yield
RuSAuNP13 and RuSAuNP100 (ESI†). The surface environment
of the nanoparticle changes with the addition of the cationic
complex and partial displacement of the surfactant as confirmed
using zeta potential studies and X-ray photoelectron spectroscopy
analysis of the Au 4f region. Analysis of the inductively-coupled
plasma optical emission spectroscopy (ICP-OES) results, based on
the Au :Ru ratio, gives 103 ruthenium complexes per AuNP13
(ESI†). For the case of RuSAuNP100, the number of RuS com-
plexes per AuNP, was estimated to be 105 based on calculations
from the 1MLCT UV-Vis absorption of the supernatant from
centrifugation due to their insufficient digestion for ICP-OES.
The Zonyl enables a very high loading on the nanoparticles and
the extent of loading per surface area is similar in both sizes,
allowing for an estimated surface area of B0.5  0.5 nm per
ruthenium complex. The TEM images and dynamic light scatter-
ing studies confirm the uniformity of the nanoparticles. The
RuSAuNP100 can also be tracked as single particles by NanoSight
analysis (ESI†).
It is striking that isolatedRuSAuNP13 and RuSAuNP100 display
luminescence lifetimes of 340 ns and 360 ns (10%), indicating not
only no quenching from the gold surface but indeed an enhance-
ment compared to the free molecular RuSH complex 260  6% ns
in water with 1% CH3CN. The larger particles can also be imaged as
a single RuSAuNP100 in flow in a microchannel using lumines-
cence microscopy (Fig. 1a). A luminescence spectrum, collected
from the image, confirms the characteristic 3MLCT profile centred
at 640 nm with a blue shift from the free RuSH complex emission
(650 nm), attributed to the influence of the Zonyl hydrophobic
environment. To further examine the eﬀect of the addition of
ZAuNP to RuSH, the luminescence lifetime of RuSHwasmonitored
during addition of a solution of ZAuNP to RuSH (Fig. 1b). A 50%
increase of the luminescence lifetime is observed upon binding of
RuSH to ZAuNP100 or ZAuNP13 (Fig. 1b and ESI†). These titra-
tion results are consistent with the isolated RuSAuNP13 and
RuSAuNP100 lifetimes. The saturation point in Fig. 1b is consistent
with the 105 loading estimated above from UV-Vis absorption. The
luminescence lifetime of RuSH mixed with Zonyl 7950 is 400 ns
(3%), indicating that the eﬀect of the Zonyl is the dominant cause
of the extended lifetime of the nanoparticles.
To study the potential of RuSAuNP13 and RuSAuNP100 in
cellular imaging, they were incubated with A549 human lung cancer
cells. Cytotoxicity assays using both MTT (mitochondrial function)
and adenylate kinase release (cell membrane integrity) showed that
there was no statistically significant toxicity of the nanoparticles when
compared to a water matched control, at concentrations of up to
5 times the concentration used for imaging studies (ESI†). To
monitor the uptake and accumulation of particles in cells over
time we performed a pulse-chase experiment (ESI†) using con-
focal fluorescence microscopy for detection. Interestingly, even
after 3 days of the chase experiment, which we estimate as
representing approximately three cell divisions based on the
number of nuclei per field of view, many cells still contained
labelled RuSAuNP13 particles, demonstrating the stability, long
half-life and poor clearance of RuSAuNP13 particles. Although
nuclear localisation could not be excluded, there was little or no
evidence of RuSAuNP13 within the nucleus at any of the time
points investigated. However, when the larger nanoparticles
were used, more detailed information could be extracted. Cells
incubated with RuSAuNP100 displayed clear visualisation of
individual RuSAuNP100 nanoparticles as evidenced by both con-
focal luminescence and confocal reflection microscopy (Fig. 2).
Fig. 1 (a) Luminescence image and spectrum (inset) of a solution of
RuSAuNP100 in flow within a 100 mm deep, 1 mm wide ibidi micro-
channel, using epiluminescence microscopy. lexc = 450 nm, lem > 510 nm.
The emission spectrum (inset) is taken from the field of view in the image.
(b) Eﬀect of nanoparticle addition to the lifetime of RuSH (0.17 mM, 1%
CH3CN in H2O) by monitoring the luminescence at 630 nm upon titration
of ZAuNP100 0–400 ml (40 pM), lexc = 450 nm.
Fig. 2 Confocal images of single RuSAuNP100 nanoparticles in A549
cells. (a) Reflection microscopy image lexc = 488 nm, lem = 478–498 nm and
(b) ruthenium luminescence image lexc = 453 nm, lem = 555–800 nm.
Respective comparisons of the measured point-spread function of the micro-
scope convolved with a model of the nanoparticle sphere (solid-line), and the
experimental intensity profile of a nanoparticle from the inset (dashed-line) are
shown on the right. Scale bar 10 mm, inset scale-bar 1 mm, acquisition time 70 s.
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Gold nanoparticles appear as bright spots in the confocal
reflection images based on the strong scattering signal of the gold.
The confocal luminescence signal confirms the ruthenium red
luminescence of the particles (Fig. 2). Co-localisation of signals in
the red and the reflection images confirm the stability of the
nanoprobe after 24 h incubation. To further analyse the results,
we used a convolution of the measured point-spread function from
the confocal luminescence measurements using a simple model of
the nanoparticle sphere (Fig. 2). The model predicts the estimated
observable particle width in the luminescence images to be
250–300 nm (due to light diffraction effects) and is consistent with
actual measurements performed. In complementary cell studies, the
RuSAuNP13 are observed only as accumulations of nanoparticles,
due to their smaller diameter and limited resolution (ESI†).
Analysis of the confocal luminescence images of the cells
treated with RuSAuNP100 reveal co-localisation of red particles
and Hoechst 33258 emission in some cells, confirming that few of
these nanoparticles can localise in the nucleus (Fig. 3). This is in
contrast to RuSAuNP13 which were absent from the nucleus,
although this could be attributed to low spatial resolution as
accumulations of the 13 nm AuNPs are required for their visua-
lisation. Still more revealing is that some of the single nano-
particles appear to be localized to a condensed area of Hoechst
staining, indicative of nuclear chromatin material containing
genomic DNA (Fig. 3). The confocal luminescence images are
further supported by TEM studies (Fig. 3). In the TEM images of
the A549 cells treated with RuSAuNP100, particles can be seen in
close proximity to optically dense regions of the nucleus, which
are attributed to condensed chromatin. These results indicate an
interaction of the nanoparticles with chromatin that is visualised
using the aforementioned microscopy techniques.
In conclusion, by employing the Zonyl 7950 surfactant we have
achieved a very high loading of a luminescent transition metal
complex on AuNPs of diﬀerent sizes. This has enabled the design
of nanoprobes that can be imaged at single nanoparticle resolu-
tion in cells by conventional and widely available optical micro-
scopy methods. These nanoparticles do not present any
significant cytotoxicity in cells and are stable in cells without
losing their coating. Their strong luminescence allows imaging of
particle association with DNA condensed material in the nucleus.
These nanoprobes therefore present great potential in the detec-
tion and monitoring of biomolecular interactions at the level of a
single nanoprobe. Applications may also be envisaged in the
development of new nanomaterials with properties encoded by
the grafted transition metal complex.
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funding from the European Regional Development Fund (ERDF).
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Fig. 3 Imaging nuclear localisation of RuSAuNP100 in A549 cells.
(a) Orthogonal view of the central z-stack slice (xz plane below, yz
plane-right) from a single cell, illustrating ruthenium luminescence from
within the central z-planes containing the Hoechst luminescence. (Scale
bar 10 mm; acquisition time 75 s). (b) Ruthenium luminescence image and
(c) corresponding overlay with Hoechst nuclear stain; acquisition time =
60 s, showing association of chromatin with RuSAuNP100 particles inside
the nucleus (Scale bar 1 mm; acquisition time = 60 s). (d) Transmission
electron micrographs (70–90 nm slice width) of A549 cell dosed with
RuSAuNP100; magnified inset shows interaction of nanoparticles with
condensed chromatin (red dashed-line). Scale bars 5 mm, 2 mm and 100 nm.
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ABSTRACT: To establish highly luminescent nanoparticles for monitoring ﬂuid ﬂows,
we examined the preparation of silica nanoparticles based on immobilization of a
cyclometalated iridium(III) complex and an examination of the photophysical studies
provided a good insight into the Ir(III) microenvironment in order to reveal the most
suitable silica nanoparticles for micro particle imaging velocimetry (μ-PIV) studies. Iridium
complexes covalently incorporated at the surface of preformed silica nanoparticles, [Ir-4]@
Si500-Z, using a ﬂuorinated polymer during their preparation, demonstrated better
stability than those without the polymer, [Ir-4]@Si500, as well as an increase in steady
state photoluminescence intensity (and therefore particle brightness) and lifetimes which are increased by 7-fold compared with
nanoparticles with the same metal complex attached covalently throughout their core, [Ir-4]⊂Si500. Screening of the
nanoparticles in ﬂuid ﬂows using epi-luminescence microscopy also conﬁrm that the brightest, and therefore most suitable
particles for microparticle imaging velocimetry (μ-PIV) measurements are those with the Ir(III) complex immobilized at the
surface with ﬂuorosurfactant, that is [Ir-4]@Si500-Z. μ-PIV studies demonstrate the suitability of these nanoparticles as
nanotracers in microchannels.
■ INTRODUCTION
The miniaturization of chemical systems oﬀers many
advantages including continuous processing, improved yields
or purity, and reduction of side-products and of waste.1−3
Microﬂuidic devices incorporating novel channel architectures
encourage mixing in a passive manner.4,5 The increased surface
to volume ratio means that interfacial phenomena such as
Marangoni and Taylor ﬂows become signiﬁcant.6 Such
microchannels can also be used as high-throughput analytical
platforms for a range of interesting targets7−9 or as devices to
extract certain molecules from solution.10 Particle imaging
velocimetry (PIV) is a popular image analysis technique used to
extract Eulerian velocity ﬁelds by dividing a ﬂow domain into
windows of interrogation and using pairs of images to produce
a displacement vector from a cross-correlation routine.11,12
With the advent of micro-PIV (μ-PIV),13 smaller particles are
required to investigate microchannels. Nanoparticles present a
unique opportunity to exploit a bottom-up approach to
materials fabrication to produce tracers for μ-PIV. We have
been interested in strategies for attaching luminescent probes in
nanoparticles, using 13 nm gold nanoparticles as a scaﬀold on
which to assemble metal complexes,14 for their delivery and
imaging into cells both selectively15 and nonselectively.16 We
recently employed luminescent silica nanoparticles17 based on
their wider availability in sizes that can be tracked with high
accuracy. Metal complexes incorporated into silica nano-
particles display far superior stability to that of organic dyes
as ﬂuorophores in μ-PIV experiments,18 thus conferring the
beneﬁt of an increased shelf life and solution recycling.
Iridium(III) polypyridyl complexes, especially cyclometalated
complexes, have excellent photophysical properties within the
set of d6 metals and often display high quantum yields.19 The
bright luminescence from iridium(III) complexes has been
exploited for in vitro imaging applications20 as well as
incorporation into materials for organic light-emitting diodes
(OLEDS).21,22 While the incorporation of ruthenium(II)
complexes into silica is fairly well explored,23−29 reports of
the incorporation of cyclometalated iridium(III) species, which
in general are more hydrophobic, into silica are relatively few,
by either covalent18,30 or noncovalent means,31−33 although
supramolecular switches have been used to both entrap and
release an iridium(III) complex in mesoporous silica using
redox, light, pH changes, or electrochemical stimuli.34−37
To develop brightly luminescent nanoparticles with metal
complexes for μ-PIV applications an evaluation of the
photophysical properties with the mode of metal complex
attachment is highly desirable, to avoid issues with leakage of
the lumophore that are unavoidable in simple adsorption-based
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